"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"AOU_NOVARAGALLIATE",2000,3,6.66666666666667,2.66666666666667,0.666666666666667,0.666666666666667,0.666666666666667,1,0.666666666666667,0.666666666666667,0.666666666666667,0,0,1,0,0,1,0.33,0,0,0.33,68.67,1.51478459699631,NA,0,1,0.09,0,0,0,"FILIPTSEV PIA;S. BORLANDELLI;DANIELA GASPAROTTO;BARBARA PIVETTA;VALLÌ DE RE;C NAVINO;PALACIOS MARTINEZ DAVID;STEFANO PILERI;F. FARINETTI;PAOLO ALUFFI;G VERZETTI;GIANFRANCO FERRACCIOLI;M. BRUGNANI;SERGIO RISO;COFANO MF;FRANCESCO D’ANDREA;SALVATORE DE VITA;MARCO BALLARÈ;MAURO BOIOCCHI;A MONTEVERDE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","S. BORLANDELLI;C NAVINO;PALACIOS MARTINEZ DAVID;G VERZETTI;COFANO MF;FILIPTSEV PIA;F. FARINETTI;PAOLO ALUFFI;M. BRUGNANI;SERGIO RISO;FRANCESCO D’ANDREA;DANIELA GASPAROTTO;BARBARA PIVETTA;VALLÌ DE RE;STEFANO PILERI;GIANFRANCO FERRACCIOLI;SALVATORE DE VITA;MARCO BALLARÈ;MAURO BOIOCCHI;A MONTEVERDE","0.2;0.2;0.2;0.2;0.2;0.17;0.17;0.17;0.17;0.17;0.17;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11","FILIPTSEV PIA;C NAVINO;PAOLO ALUFFI;M. BRUGNANI;SERGIO RISO;FRANCESCO D’ANDREA;MARCO BALLARÈ;A MONTEVERDE","1;1;1;1;1;1;1;1","C NAVINO;FILIPTSEV PIA;PAOLO ALUFFI;M. BRUGNANI;SERGIO RISO;FRANCESCO D’ANDREA;MARCO BALLARÈ;A MONTEVERDE","0.2;0.17;0.17;0.17;0.17;0.17;0.11;0.11","A MONTEVERDE;BARBARA PIVETTA;DANIELA GASPAROTTO;GIANFRANCO FERRACCIOLI;MARCO BALLARÈ;MAURO BOIOCCHI;SALVATORE DE VITA;STEFANO PILERI;VALLÌ DE RE;F. FARINETTI;FILIPTSEV PIA;FRANCESCO D’ANDREA;M. BRUGNANI;PAOLO ALUFFI;SERGIO RISO;C NAVINO;COFANO MF;G VERZETTI;PALACIOS MARTINEZ DAVID;S. BORLANDELLI","109;109;109;109;109;109;109;109;109;97;97;97;97;97;97;0;0;0;0;0","A MONTEVERDE;MARCO BALLARÈ;FILIPTSEV PIA;FRANCESCO D’ANDREA;M. BRUGNANI;PAOLO ALUFFI;SERGIO RISO;C NAVINO","109;109;97;97;97;97;97;0","A MONTEVERDE;FILIPTSEV PIA;FRANCESCO D’ANDREA;M. BRUGNANI;MARCO BALLARÈ;PAOLO ALUFFI;SERGIO RISO;C NAVINO","1;1;1;1;1;1;1;0","MEDICINE","3","GASTROENTEROLOGY;IMMUNOLOGY;INTERNAL MEDICINE;SURGERY;INTENSIVE CARE MEDICINE;PATHOLOGY","2;2;2;2;1;1","ANEMIA;ANTIBODY;BIOPSY;BONE MARROW;CANCER;ERYTHROPOIETIN;FERRITIN;HEMODIALYSIS;IMMUNE SYSTEM;LYMPHOMA;PARENTERAL NUTRITION;PHARMACOECONOMICS;TRANSFERRIN;TRANSTHYRETIN;VIRUS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","B CELL;CD8;ENTERAL ADMINISTRATION;HEAD AND NECK CANCER;HEPATITIS C VIRUS;MONOCLONAL ANTIBODY;SERUM FERRITIN;SERUM IRON","1;1;1;1;1;1;1;1","CRYOGLOBULINEMIA;MONOCLONAL","1;1","HEAD AND NECK NEOPLASMS;ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE;ARGININE;B-LYMPHOCYTES;BONE MARROW CELLS;CRYOGLOBULINEMIA;FEMALE;HUMANS;LYMPHOCYTES;LYMPHOMA, B-CELL;MALE;MIDDLE AGED;NUTRITION DISORDERS;CELL DIVISION;ERYTHROPOIETIN;IRON;POSTOPERATIVE COMPLICATIONS;RENAL DIALYSIS;ADULT;AGED","5;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;1;1","GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;ROLE OF ERYTHROPOIETIN IN DISEASE TREATMENT AND MANAGEMENT","1;1;1","B-CELL RECEPTOR SIGNALING;ENTERAL ADMINISTRATION;ENTERAL NUTRITION;ERYTHROPOIESIS-STIMULATING AGENTS;HOME PARENTERAL NUTRITION;IMMUNONUTRITION;NUTRITION SUPPORT THERAPY;NUTRITIONAL STATUS;PHARMACOECONOMICS","1;1;1;1;1;1;1;1;1","BONE MARROW;CANCER PATIENTS;CELL EXPANSION;CELL LYMPHOMA;CRYOGLOBULINEMIA CLINICAL;ENTERAL IMMUNONUTRITION;HEMODIALYSIS ROLE;II MIXED;KEY FEATURE;MARROW PATHOLOGIC;MIXED CRYOGLOBULINEMIA;MOLECULAR FINDINGS;NECK CANCER;OLIGOCLONAL NON-NEOPLASTIC;PATHOLOGIC DIAGNOSIS;POSTOPERATIVE ENTERAL;TYPE II","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2001,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,5.5,418.5,0,0,0,88.5,0,0,1,0,3,0,0,0,0,4,0,0,0,0,0,0,0,4,0,0,4,0,0,0,0,0,0,0,0,0,"Belgium;Italy;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;UROLOGIC DISEASES;CARDIOVASCULAR;COLO-RECTAL CANCER;DIGESTIVE DISEASES;HEART DISEASE;ORPHAN DRUG;PATIENT SAFETY;PREVENTION;RARE DISEASES","4;4;3;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;1","6.1 PHARMACEUTICALS","4","BLADDER CANCER;COLON AND RECTAL CANCER","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2002,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,5,699,0,0,0,52.67,0,0,0,0,1,0,1,1,0,2,1,0,0,0,0,0,0,2,0,1,3,0,0,0,0,0,0,0,0,0,"Belgium;Germany","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","3;2;2","CLINICAL RESEARCH;AGING;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEMATOLOGY;HYPERTENSION;ORPHAN DRUG;PROSTATE CANCER;RARE DISEASES;UROLOGIC DISEASES","3;2;2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","3;1","LEUKEMIA / LEUKAEMIA;PROSTATE CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2003,5,6.2,2.6,0.8,0.4,0.8,1,0.8,0.666666666666667,0.8,0.2,0,2,1,0,2,0.4,0.2,0,0.4,2.6,0.049123428585391,NA,0,1,0.218,0,0,0,"PORTA ANDREA;IRENE ALABISO;FABIO LUNATI;ERALDO OCCHETTA;A RAVIELE;LAURA FORTI;ROBOTTI STEFANIA;SIMONA CARNIO;SEYMANDI PL;OSCAR ALABISO;STEFANO ASTOLFI;SANDRA MARIA MIRAGLIA;GIOSUÈ MASCIOLI;GIORGIO LEIGHEB;MICHELE MASSIMO GULIZIA;S BIGHIANI;GIUSEPPINA MAURA FRANCESE;G. GASPARINI;G BUSSI;ADDOLORATA CORRADO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FABIO LUNATI;GIANLUCA AIROLDI;MAURO CAMPANINI;SEYMANDI PL;G BUSSI;ESTHER MERLINI;BETTA PG;PORTA ANDREA;IRENE ALABISO;LAURA FORTI;ROBOTTI STEFANIA;SIMONA CARNIO;OSCAR ALABISO;STEFANO ASTOLFI;SANDRA MARIA MIRAGLIA;GIORGIO LEIGHEB;S BIGHIANI;MASSIMILIANO CAMETTI;BOGGIO PAOLO;ERALDO OCCHETTA","0.33;0.33;0.33;0.25;0.25;0.25;0.25;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.08","PORTA ANDREA;FABIO LUNATI;ERALDO OCCHETTA;LAURA FORTI;ROBOTTI STEFANIA;STEFANO ASTOLFI;GIORGIO LEIGHEB;MASSIMILIANO CAMETTI;GIANLUCA AIROLDI;ESTHER MERLINI;MIRIAM BORTNIK;BOGGIO PAOLO;MAURO CAMPANINI","1;1;1;1;1;1;1;1;1;1;1;1;1","FABIO LUNATI;GIANLUCA AIROLDI;MAURO CAMPANINI;ESTHER MERLINI;PORTA ANDREA;LAURA FORTI;ROBOTTI STEFANIA;STEFANO ASTOLFI;GIORGIO LEIGHEB;MASSIMILIANO CAMETTI;BOGGIO PAOLO;ERALDO OCCHETTA;MIRIAM BORTNIK","0.33;0.33;0.33;0.25;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.08;0.08","BETTA PG;ESTHER MERLINI;G BUSSI;SEYMANDI PL;A RAVIELE;A. BARBETTA;ADDOLORATA CORRADO;ANTONIO CURNIS;BOGGIO PAOLO;ERALDO OCCHETTA;F. DI GREGORIO;FABIO LUNATI;G. GASPARINI;GIANLUCA AIROLDI;GIORGIO LEIGHEB;GIOSUÈ MASCIOLI;GIUSEPPINA MAURA FRANCESE;LUCA BONTEMPI;MASSIMILIANO CAMETTI;MAURO CAMPANINI","10;10;10;10;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ESTHER MERLINI;BOGGIO PAOLO;ERALDO OCCHETTA;FABIO LUNATI;GIANLUCA AIROLDI;GIORGIO LEIGHEB;MASSIMILIANO CAMETTI;MAURO CAMPANINI;MIRIAM BORTNIK;PORTA ANDREA;ROBOTTI STEFANIA;STEFANO ASTOLFI;LAURA FORTI","10;1;1;1;1;1;1;1;1;1;1;1;0","BOGGIO PAOLO;ERALDO OCCHETTA;ESTHER MERLINI;FABIO LUNATI;GIANLUCA AIROLDI;GIORGIO LEIGHEB;MASSIMILIANO CAMETTI;MAURO CAMPANINI;MIRIAM BORTNIK;PORTA ANDREA;ROBOTTI STEFANIA;STEFANO ASTOLFI;LAURA FORTI","1;1;1;1;1;1;1;1;1;1;1;1;0","MEDICINE;GEOLOGY;BIOLOGY;PHYSICS","5;2;1;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;ANATOMY;CLASSICAL MECHANICS;ENDOCRINOLOGY;GASTROENTEROLOGY;GENERAL SURGERY;GENETICS;GEOMORPHOLOGY;PALEONTOLOGY;PATHOLOGY","4;2;2;1;1;1;1;1;1;1;1;1","BLOOD PRESSURE;CANCER;CELL CULTURE;DIABETES MELLITUS;DISEASE;ENUCLEATION;FIBROUS JOINT;GYNECOMASTIA;HEMODYNAMICS;HORMONE;LESION;MOMENT (PHYSICS);ORCHIECTOMY;STAGE (STRATIGRAPHY);STROMAL CELL;SUTURE LINE;TRACTION (GEOLOGY)","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;HEART RATE;LUTEINIZING HORMONE;NEUROBLASTOMA;POSTPRANDIAL;PRECOCIOUS PUBERTY;TENSION (GEOLOGY)","1;1;1;1;1;1;1","AUTONOMIC NERVOUS SYSTEM;AUTONOMIC NEUROPATHY;LEYDIG CELL;OXALIPLATIN","1;1;1;1","ADENOCARCINOMA;LEYDIG CELL TUMOR;TESTICULAR NEOPLASMS;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PACLITAXEL;STOMACH NEOPLASMS;CISPLATIN;FLUOROURACIL;HUMANS;LEUCOVORIN;LIVER NEOPLASMS;STOMACH ULCER;CHILD;FEMALE;GASTRECTOMY;GASTRIC STUMP;MALE;NEOPLASM STAGING;ORGANOPLATINUM COMPOUNDS","4;4;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;TESTICULAR GERM CELL TUMORS AND TREATMENT","1;1;1;1;1","AUTONOMIC NEUROPATHY;CANCER REGISTRY DATA;CANCER SURVIVORSHIP;FOLFOX;GYNECOMASTIA;HYPERTENSION;LEYDIG CELL TUMOR;ORCHIECTOMY;ORTHOSTATIC HYPOTENSION;PACEMAKER THERAPY;POSTURAL TACHYCARDIA SYNDROME;SOFT TISSUE AUGMENTATION;SUTURE LINE;TENSION (GEOLOGY);TESTICULAR CANCER","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIABETES MELLITUS;ELDERLY WOMAN;GASTRIC CANCER;HEMODYNAMIC RATE-RESPONSIVE;IMPEDANCE DETECTION;IV GASTRIC;LEYDIG-CELL TUMOUR;MODIFIED S-PLASTY;NERVOUS SYSTEM;P- HEMODYNAMIC;POSTPRANDIAL HYPOTENSION;RATE-RESPONSIVE PACING;SPARING ENUCLEATION;STAGE IV;SYSTEM IMPAIRMENT;TESTIS SPARING;TRANS-VALVULAR IMPEDANCE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","VENTRICULAR LEADS;ACTIVE IIXATION;ATRIAL VENTRICULAR;AUTOCAPTURE COMPATIBILITYTHE;CENTERSPOST IMPLANTATION;COMPARED PATIENTS;COMPATIBILITYTHE IMPLANTING;DETERMINED INTRAOPERATIVELY;EFFUSION PE;ELECTRICAL MEASUREMENTS;ELECTRICAL PERFORMANCE;ER SENSITIVITY;EUROPEAN CENTERSPOST;HANDLING CHARACTERISTICS;HOSPITAL DISCHARGE;IIXATION VENTRICULAR;IMPEDANCE IMP;IMPLANTATIONPERICARDIAL EFFUSION;IMPLANTING PHYSICIANS;INTRAOPERATIVELY PRE;LEADS ATRIAL;LEADS IMPLANTED;LEADTHE ELECTRICAL;MONTHSBY ECHOCARDIOGRAPHY;OKT VOLTAGE;PACING IMPEDANCE;PHYSICIANS JAN;PRE HOSPITAL;R-WAVE POTENTIAL;SENSITIVITY TESTTHEM","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,13,1093,7.69,0,0,52,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Italy","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","CANCER;CLINICAL RESEARCH;HEMATOLOGY;LYMPHOMA;RARE DISEASES","1;1;1;1;1",NA,NA,"4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1","NON-HODGKIN'S LYMPHOMA","1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2004,7,5.28571428571429,1,0.714285714285714,0,0.714285714285714,1,0.833333333333333,0,0.833333333333333,0.142857142857143,1,0,5,1,0,0,0.71,0.14,0,27.71,0.588993786358296,NA,0.142857142857143,1,0.444,0.133,0,0.133,"M. BALLARÈ;G. FASOLIS;FILOMENA SFORZA;C. GIACOSA;MARCO QUAGLIA;F. MONTINO;M. DEL PIANO;L CALDARA;ROBERTO MARIO SCARPA;I. MANFREDDA;FERNANDO FERRERO;ENRICA LUPO;MASSIMILIANO PANELLA;LUIGI ROLLE;PAOLO ALUFFI;MARIZA FERRO;BRUNO FREA;R ALBIERO;S SILBER;MARCO KRENGLI","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","M. BALLARÈ;L CALDARA;FERNANDO FERRERO;ENRICA LUPO;R ALBIERO;S SILBER;C DI MARIOET AL;C. GIACOSA;MARCO QUAGLIA;MARIZA FERRO;G MARTINA;GIUSEPPE PICCOLI;GIUSEPPE SEGOLONI;I. MANFREDDA;MASSIMILIANO PANELLA;PAOLO ALUFFI;MARCO KRENGLI;GIUSEPPINA GAMBARO;MARIO POLICARPO;FRANCESCO PIA","1.11;0.33;0.33;0.33;0.33;0.33;0.33;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.14","M. BALLARÈ;MARCO QUAGLIA;M. DEL PIANO;FERNANDO FERRERO;BRUNO FREA;R ALBIERO;MARCO KRENGLI","2;1;1;1;1;1;1","M. BALLARÈ;FERNANDO FERRERO;R ALBIERO;MARCO QUAGLIA;MARCO KRENGLI;BRUNO FREA;M. DEL PIANO","1.11;0.33;0.33;0.17;0.14;0.12;0.11","FRANCESCO PIA;GIUSEPPINA GAMBARO;I. MANFREDDA;MARCO KRENGLI;MARIO POLICARPO;MASSIMILIANO PANELLA;PAOLO ALUFFI;BRUNO FREA;DARIO FONTANA;G. FASOLIS;LUIGI ROLLE;M. BELLINA;M. MARI;P. DESTEFANIS;ROBERTO MARIO SCARPA;M. BALLARÈ;CINZIA MASINI;E. GARELLO;F. MONTINO;FILOMENA SFORZA","103;103;103;103;103;103;103;60;60;60;60;60;60;60;60;28;26;26;26;26","MARCO KRENGLI;BRUNO FREA;M. DEL PIANO;MARCO QUAGLIA;M. BALLARÈ;FERNANDO FERRERO;R ALBIERO","103;60;26;3;2;0;0","BRUNO FREA;M. BALLARÈ;M. DEL PIANO;MARCO KRENGLI;MARCO QUAGLIA;FERNANDO FERRERO;R ALBIERO","1;1;1;1;1;0;0","MEDICINE;BIOLOGY;PHILOSOPHY;PHYSICS","7;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ENVIRONMENTAL HEALTH;ANESTHESIA;FOOD SCIENCE;GASTROENTEROLOGY;GENERAL SURGERY;INTENSIVE CARE MEDICINE;LINGUISTICS;MICROBIOLOGY;NUCLEAR MEDICINE;OPTICS;RADIOLOGY;UROLOGY","5;3;2;2;1;1;1;1;1;1;1;1;1;1;1","MYOCARDIAL INFARCTION;POPULATION;ANALGESIC;ANGIOGRAPHY;ANGIOPLASTY;ANTIBIOTICS;AREA UNDER THE CURVE;BALLOON;CARCINOMA;CLONIDINE;CORONARY ARTERY DISEASE;DIALYSIS;DIARRHEA;FECES;FENTANYL;FERMENTATION;HEART FAILURE;INTENSIVE CARE;KETAMINE;LASER;MECHANICAL VENTILATION;NEUROMUSCULAR BLOCKING AGENTS;OBESITY;PARENTERAL NUTRITION;PERFUSION;PROPOFOL;PROSPECTIVE COHORT STUDY;RADIATION THERAPY;RECEIVER OPERATING CHARACTERISTIC;SEDATION;SEDATIVE;STENOSIS;STENT;TRANSPLANTATION;VOICE ANALYSIS","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BALLOON DILATATION;CLOSTRIDIUM DIFFICILE;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CORONARY ANGIOGRAPHY;DEXMEDETOMIDINE;EJECTION FRACTION;ENTERAL ADMINISTRATION;HEAD AND NECK CANCER;KIDNEY TRANSPLANTATION;LACTOBACILLUS;LASER SURGERY;MIDAZOLAM;PERFUSION SCANNING;RESTENOSIS;REVASCULARIZATION;WEIGHT LOSS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTIBIOTIC-ASSOCIATED DIARRHEA;BIFIDOBACTERIUM;CORDECTOMY;FRACTIONAL FLOW RESERVE;MORBID OBESITY","1;1;1;1;1","HUMANS;FEMALE;MALE;CARCINOMA;KIDNEY TRANSPLANTATION;LARYNGEAL NEOPLASMS;MIDDLE AGED;;AGED;ANALGESIA;ANASTOMOSIS, SURGICAL;CONSCIOUS SEDATION;CRITICAL CARE;FECES;GLOTTIS;ILEUM;NERVE BLOCK;POSTOPERATIVE COMPLICATIONS;PROBIOTICS;TREATMENT OUTCOME","5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ANESTHESIA AND SEDATION MANAGEMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIVERSITY AND FUNCTION OF GUT MICROBIOME;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ORGAN TRANSPLANTATION AND REJECTION;UROTRAUMA AND GENITOURINARY DEVELOPMENT","1;1;1;1;1;1;1","ACOUSTIC ANALYSIS;ANTIBIOTIC-ASSOCIATED DIARRHEA;BALLOON DILATATION;BIFIDOBACTERIUM LONGUM;BLADDER EXSTROPHY;CAROTID ARTERY STENOSIS;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CORDECTOMY;CORONARY STENTS;DEXMEDETOMIDINE;ENDOSCOPIC SEDATION;ENTERAL ADMINISTRATION;ENTERAL NUTRITION;FRACTIONAL FLOW RESERVE;INTRACRANIAL ARTERIAL STENOSIS;INTRAVASCULAR ULTRASOUND;MIDAZOLAM;NEUROMUSCULAR BLOCKING AGENTS;OBESITY;PEDIATRIC ANESTHESIA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANALGESIA SEDATION;BALLOON ANGIOPLASTY;BALLOON VERSUS;CADAVERIC DONOR;CARCINOMA RADIOTHERAPY;CARE UNITS;CLINICAL EXPERIENCE;CONVENTIONAL BALLOON;CUTTING BALLOON;EASY FAST;ENTERAL NUTRITION;GLOTTIC CARCINOMA;IN-STENT RESTENOSIS;INTENSIVE CARE;INTRAGASTRIC BALLOON;LASER CORDECTOMY;MORBID OBESITY;MYOCARDIAL REVASCULARIZATION;NEUROMUSCULAR BLOCK;PEDIATRIC INTENSIVE;RADIOTHERAPY VERSUS;RECENT PROGRESS;RELIABLE PROCEDURE;RENAL TRANSPLANTATION;TA GLOTTIC;TOTAL ENTERAL;VERSUS CONVENTIONAL;VERSUS LASER;VOICE QUALITY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DYNAMIC CTP;HEMODYNAMICALLY SIGNIFICANT;COMPUTED TOMOGRAPHY;DUAL-SOURCE CT;MULTICENTER STUDY;PROSPECTIVE MULTICENTER;SIGNIFICANT CAD;SIGNIFICANT STENOSIS;ACCURATE IDENTIFICATION;ADDING DYNAMIC;AMPLIFIED UMIN;ANALYSIS ADDING;ANATOMIC ASSESSMENT;ANGIOGRAPHY CTA;ANGIOGRAPHY ICA;ARTERY DISEASE;CAD COMPARED;CAD DEFINED;CADTHIS PROSPECTIVE;CENTERS ENROLLED;CHARACTERISTIC CURVE;CLINICAL SIGNIFICANCE;CLINICALLY REFERRED;COMBINED CORONARY;CORONARY ANGIOGRAPHY;CORONARY ARTERY;CORONARY COMPUTED;CORONARY CTA;CORONARY DIAMETER;CT AMPLIFIED","4;4;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,2,301.8,83.33,1,0.2,40.8,0,0,1,1,2,0,1,0,0,5,0,0,0,0,0,0,0,4,1,0,5,0,0,0,0,0,0,0,0,0,"Belgium;United States","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES","5;3;3;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;CARDIOVASCULAR;LUNG;RARE DISEASES;ATHEROSCLEROSIS;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN CANCER;BRAIN DISORDERS;BREAST CANCER;CHILDHOOD LEUKEMIA;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LUNG CANCER;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC","5;4;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","3;2","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","4;1","BRAIN TUMOR;BREAST CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER","1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2005,12,5.25,2.33333333333333,0.666666666666667,0.583333333333333,0.666666666666667,1.33333333333333,1.33333333333333,1,1.33333333333333,0.416666666666667,0,6,2,1,2,0.5,0.17,0.08,0.17,24.92,0.470625460445172,NA,0.0833333333333333,1,0.362,0.222,0.233,0.222,"ALESSANDRO CARRIERO;MARCO DOMINIETTO;ALESSANDRO STECCO;EUGENIO INGLESE;M. DEL PIANO;M. BALLARÈ;C SECCO;MARCO BRAMBILLA;ALESSIO COSER;BARBARA CANNILLO;CATERINA IAQUINTA;ILARIA SEREN BERNARDONE;ANNA BENINI;PIETRO BALBO;MASSIMILIANO MARINI;MASSIMO PIERGIUSEPPE FRANCHI;GARY GADDIS;ELENA MIGAZZO;ROBERTA MATHEOUD;RENZO BOLDORINI","3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","M. DEL PIANO;M. BALLARÈ;ALESSANDRO CARRIERO;ALESSANDRO STECCO;GARY GADDIS;ROBERTA PETRINO;MARCO DOMINIETTO;EUGENIO INGLESE;PAOLO NAVALESI;C SECCO;CESARE GREGORETTI;CARLO OLIVIERI;MARCO BRAMBILLA;CATERINA IAQUINTA;MATTEO BRUCOLI;ARNALDO BENECH;BARBARA CANNILLO;ROBERTA MATHEOUD;RENZO BOLDORINI;GIUSEPPE SESSA","1;1;0.51;0.51;0.5;0.5;0.44;0.33;0.33;0.33;0.33;0.33;0.33;0.2;0.2;0.2;0.17;0.17;0.17;0.17","ALESSANDRO CARRIERO;MARCO DOMINIETTO;ALESSANDRO STECCO;EUGENIO INGLESE;M. DEL PIANO;M. BALLARÈ;C SECCO;MARCO BRAMBILLA;BARBARA CANNILLO;PIETRO BALBO;ELENA MIGAZZO;ROBERTA PETRINO;MATTEO BRUCOLI;LUCIA LEVA;ANTONIO SAPONARO;PAOLO NAVALESI;PAOLO MARINO;C. BARBARA;CESARE GREGORETTI;CARLO OLIVIERI","3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","M. DEL PIANO;M. BALLARÈ;ALESSANDRO CARRIERO;ALESSANDRO STECCO;ROBERTA PETRINO;MARCO DOMINIETTO;EUGENIO INGLESE;PAOLO NAVALESI;C SECCO;CESARE GREGORETTI;CARLO OLIVIERI;MARCO BRAMBILLA;MATTEO BRUCOLI;BARBARA CANNILLO;LUCIA LEVA;ELENA MIGAZZO;ANTONIO SAPONARO;PAOLO MARINO;PIETRO BALBO;C. BARBARA","1;1;0.51;0.51;0.5;0.44;0.33;0.33;0.33;0.33;0.33;0.33;0.2;0.17;0.17;0.14;0.14;0.14;0.12;0.11","MARCO DOMINIETTO;C SECCO;EUGENIO INGLESE;MARCO BRAMBILLA;G. SACCHETTI;ROBERTA MATHEOUD;ANGELA AMORUSO;CLAUDIO BARDELLI;ELISA DEL BOCA;FEDERICA VARSALDI;GABRIELE GUNELLA;ILARIA SEREN BERNARDONE;PIETRO BALBO;SANDRA BRUNELLESCHI;ALESSANDRO CARRIERO;ALESSANDRO STECCO;BARBARA CANNILLO;LUCIA LEVA;AMELIA GIAMPIETRO;CLAUDIA QUIRICO","177;175;175;175;132;132;65;65;65;65;65;65;65;65;50;50;43;43;27;27","MARCO BRAMBILLA;PIETRO BALBO;ALESSANDRO STECCO;MARCO DOMINIETTO;BARBARA CANNILLO;C SECCO;EUGENIO INGLESE;LUCIA LEVA;ALESSANDRO CARRIERO;MATTEO BRUCOLI;ANTONIO SAPONARO;ELENA MIGAZZO;CARLO OLIVIERI;CESARE GREGORETTI;PAOLO NAVALESI;C. BARBARA;S. CHIARA;M. BALLARÈ;M. DEL PIANO;PAOLO MARINO","175;65;50;45;43;43;43;43;23;13;10;10;7;7;7;2;2;0;0;0","ALESSANDRO STECCO;ALESSANDRO CARRIERO;MARCO BRAMBILLA;MARCO DOMINIETTO;ANTONIO SAPONARO;BARBARA CANNILLO;C SECCO;C. BARBARA;CARLO OLIVIERI;CESARE GREGORETTI;ELENA MIGAZZO;EUGENIO INGLESE;LUCIA LEVA;MATTEO BRUCOLI;PAOLO NAVALESI;PIETRO BALBO;S. CHIARA;M. BALLARÈ;M. DEL PIANO;PAOLO MARINO","3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;0;0;0","MEDICINE;COMPUTER SCIENCE;ENGINEERING;MATERIALS SCIENCE;PHYSICS;BIOLOGY;CHEMISTRY;MATHEMATICS;PHILOSOPHY","11;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;NUCLEAR MEDICINE;RADIOLOGY;SURGERY;PATHOLOGY;ARTIFICIAL INTELLIGENCE;GENERAL SURGERY;METALLURGY;OPTICS;PSYCHIATRY;AEROSPACE ENGINEERING;ALGORITHM;ANATOMY;ANESTHESIA;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;COMPUTER SECURITY;COMPUTER VISION;ENDOCRINOLOGY;IMMUNOLOGY;INTERNET PRIVACY;LINGUISTICS;MECHANICAL ENGINEERING;NUCLEAR MAGNETIC RESONANCE;PHARMACOLOGY;PROGRAMMING LANGUAGE;QUANTUM MECHANICS;STATISTICS;WORLD WIDE WEB","5;4;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAGNETIC RESONANCE IMAGING;CONTRAST (VISION);ENDOSCOPY;ALTERNATIVE MEDICINE;ARTERIAL BLOOD;BLOOD PRESSURE;CANCER;COLLIMATOR;COMPLICATION;COMPUTED TOMOGRAPHY;CONUS;CYTOKINE;DETECTOR;DISSECTION (MEDICAL);ENZYME;FIDUCIAL MARKER;FILTER (SIGNAL PROCESSING);GADOLINIUM;GASTRIC OUTLET OBSTRUCTION;GLIOBLASTOMA;GLIOMA;HEAD TRAUMA;HEMATOMA;IMAGE (MATHEMATICS);IMAGING PHANTOM;INFLAMMATION;INTRACRANIAL INFECTION;INTRAMEDULLARY ROD;ITERATIVE RECONSTRUCTION;LOGIN;LOGO (PROGRAMMING LANGUAGE);LYMPH NODE;LYMPHATIC SYSTEM;MANN–WHITNEY U TEST;MAXIMUM LIKELIHOOD;MECHANICAL VENTILATION;MULTIPLE SCLEROSIS;MULTISLICE;MYOCARDIAL INFARCTION;ORBIT (DYNAMICS);OXIDE;PERFUSION;PERSONALLY IDENTIFIABLE INFORMATION;QUANTUM;RECEPTOR;RECTUM;REGISTER (SOCIOLINGUISTICS);RETROSPECTIVE COHORT STUDY;SCANNER;SPINAL CORD;TRACHEOTOMY;TUMOR NECROSIS FACTOR ALPHA;VENTILATION (ARCHITECTURE)","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AGONIST;ASTROCYTOMA;BREAST CANCER;COINCIDENCE;CONUS MEDULLARIS;EXPECTATION–MAXIMIZATION ALGORITHM;HEART RATE;NF-ΚB;NOISE (VIDEO);PHOTOMULTIPLIER;PRESSURE SUPPORT VENTILATION;PROSTATE;PROSTATE CANCER;QUANTUM ENTANGLEMENT;SPINAL CORD NEOPLASM;SUBDURAL HEMORRHAGE;SUPEROXIDE;THERAPEUTIC ENDOSCOPY;VENTRICULAR REMODELING;YTTRIUM","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COINCIDENCE COUNTING;LUTETIUM;RESPIRATORY RATE;SENTINEL NODE","1;1;1;1",";HUMANS;IMAGING, THREE-DIMENSIONAL;MALE;RECEPTORS, NEUROKININ-1;RETROBULBAR HEMORRHAGE;TOMOGRAPHY, X-RAY COMPUTED;ADULT;GENE EXPRESSION REGULATION;HEAD INJURIES, CLOSED;HEMATOMA, SUBDURAL;MACROPHAGES, ALVEOLAR;MIDDLE AGED;SIGNAL TRANSDUCTION;SMOKING;TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;AGED;BICYCLING;CHILD;CONTRAST MEDIA","6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2","ESOPHAGEAL INTERVENTION TECHNIQUES;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EMERGENCY DEPARTMENT CROWDING;EPIDEMIOLOGY AND MANAGEMENT OF MAXILLOFACIAL TRAUMA;FOCUSED ULTRASOUND TECHNOLOGY AND APPLICATIONS;INTRAOPERATIVE NEUROPHYSIOLOGICAL MONITORING IN SURGERY;RADIOMICS IN MEDICAL IMAGING ANALYSIS;ROLE OF NEUROPEPTIDES IN PHYSIOLOGY AND DISEASE","2;2;1;1;1;1;1;1;1;1","ENDOSCOPIC STENTING;ENDOSCOPIC THERAPY;GASTRIC OUTLET OBSTRUCTION;PERFUSION IMAGING;ARTERIAL BLOOD;CANCER IMAGING;CHIARI MALFORMATION;COINCIDENCE COUNTING;COLLIMATOR;CONUS;CONUS MEDULLARIS;DIFFUSION-WEIGHTED IMAGING;DUAL-ENERGY CT;DUODENAL OBSTRUCTION;EMERGENCY TRACHEAL INTUBATION;FIDUCIAL MARKER;FOCUSED ULTRASOUND;HEAD TRAUMA;IMAGING;INTRACRANIAL INFECTION","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ACUTE TRAUMATIC;ALVEOLAR MACROPHAGES;ANION PRODUCTION;ASSOCIATION NU;BACKPROJECTION INMTC;CHARACTERISTICS OBTAINED;CHILD DESCRIPTION;CONGRESS NICE;CONTRACTILE RESERVE;CONTRAST ECHOCARDIOGRAPHY;CONUS MEDULLARIS;CONVENTIONAL MECHANICAL;CYTOKINE RELEASE;DIMENSIONAL LUTETIUM;DOSE OPTIMISATION;ELECTRICAL MANUFACTURERS;EMERGENCY MEDICINE;EXPECTATION MAXIMIZATION;FILTERED BACKPROJECTION;FRANCE SEPTEMBER;FUNCTIONAL NKSUBSUB;FUSION IMAGES;GADOLINIUM DOSE;GAUSS FILTERING;GLIOBLASTOMA MULTIFORME;HUMAN ALVEOLAR;INFARCTION CORRELATION;INMTC SPECT;INTER-INDIVIDUAL COMPARISONS;INTRACRANIAL HEMORRHAGE","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","SENTINEL NODE;EXTERNAL ILIAC;GASTRIC OUTLET;ILIAC NODES;PUBMED SCOPUS;CROSSREF PUBMED;GI OUTLET;HEALTHY SMOKERS;MALIGNANT GI;METAL STENTS;OUTLET OBSTRUCTION;DRS ITHA;ENDOSC -ABSTRACT;GASTRIC EMPTYING;HUMAN AMS;OBSTRUCTIONGASTROINTEST ENDOSC;OUTLET OBSTRUCTIONGASTROINTEST;SPECT-CT FUSION;CYTOKINE RELEASE;DAY MORTALITY;DELAYED GASTRIC;DG BARON;EDITOR FULL-TEXT;ENDOSCOPIC PALLIATION;ENDOSCOPYVOL ISSUE;FULL-TEXT PDF;GASTROENTEROL -CROSSREF;INTRA-PROSTATE TRANS-RECTAL;ISSUE PREVIEWTO;LYMPHATIC DRAINAGE","10;6;6;6;6;5;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,5.6,1296.25,29.41,1,0.2,76.2,0,0,1,0,3,0,0,1,0,3,1,0,0,0,0,0,0,4,0,1,4,1,0,0,0,0,0,0,0,0,"Italy;United States","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS","5;3;1;1;1;1;1","CLINICAL RESEARCH;PATIENT SAFETY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;BIOMEDICAL IMAGING;CANCER;CARDIOVASCULAR;CHRONIC PAIN;HEMATOLOGY;PAIN RESEARCH;PROSTATE CANCER;STROKE;UROLOGIC DISEASES","4;3;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS","3","PROSTATE CANCER;STOMACH CANCER","1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2006,11,7.27272727272727,3.45454545454545,0.636363636363636,0.454545454545455,0.636363636363636,1.35714285714286,1,1,1,0.454545454545455,0,7,2,1,1,0.64,0.18,0.09,0.09,26.45,0.517922357006368,NA,0.0909090909090909,1,0.284,0.233,0.312,0.233,"MARCO BRAMBILLA;G. LOI;BARBARA CANNILLO;ERALDO OCCHETTA;PAOLO MARINO;E. MONÈS;MARCO KRENGLI;MIRIAM BORTNIK;EUGENIO INGLESE;VINCENZO RUTIGLIANO;S. BELLONE;PIERO EMILIO BALBO;ALESSANDRO CARRIERO;G BONA;CLAUDIO ROMANO;CLAUDIO FOGLIATI;RENZO BOLDORINI;ALESSANDRA RENGHI;GIOVANNA DI DIO;B. GHIDINI","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ERALDO OCCHETTA;PAOLO MARINO;MIRIAM BORTNIK;MARCO BRAMBILLA;G. LOI;BARBARA CANNILLO;MARCO KRENGLI;E. MONÈS;S. BELLONE;G BONA;CLAUDIO FOGLIATI;GIOVANNA DI DIO;PAOLO NAVALESI;VINCENZO SQUADRONE;ANDREA MAGNANI;GABRIELLA FRANCALACCI;CESARE GREGORETTI;S. LONATI;ANNA RAPA;CARLO OLIVIERI","0.53;0.53;0.53;0.5;0.34;0.24;0.24;0.22;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2","MARCO BRAMBILLA;G. LOI;BARBARA CANNILLO;ERALDO OCCHETTA;PAOLO MARINO;E. MONÈS;MARCO KRENGLI;MIRIAM BORTNIK;PIERO EMILIO BALBO;CLAUDIO FOGLIATI;ALESSANDRA RENGHI;M. BRUNERO;ANDREA CUMINO;EDOARDO NEGRI;MARCO DOMINIETTO;L GRAMAGLIA;PAOLO NAVALESI;A. FASSIOLA;VINCENZO SQUADRONE;PIERO BRUSTIA","4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","ERALDO OCCHETTA;PAOLO MARINO;MIRIAM BORTNIK;MARCO BRAMBILLA;G. LOI;BARBARA CANNILLO;MARCO KRENGLI;E. MONÈS;CLAUDIO FOGLIATI;PAOLO NAVALESI;VINCENZO SQUADRONE;ANDREA MAGNANI;GABRIELLA FRANCALACCI;CESARE GREGORETTI;S. LONATI;CARLO OLIVIERI;PIERO EMILIO BALBO;ALESSANDRA RENGHI;ANDREA CUMINO;L GRAMAGLIA","0.53;0.53;0.53;0.5;0.34;0.24;0.24;0.22;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.2;0.17;0.14;0.14;0.14","MARCO BRAMBILLA;G. LOI;E. MONÈS;BARBARA CANNILLO;MARCO KRENGLI;ERALDO OCCHETTA;MIRIAM BORTNIK;PAOLO MARINO;ANDREA MAGNANI;GABRIELLA FRANCALACCI;A. VEDDA;EVA NEGRI;FEDERICO MORETTI;GILBERTO BRAMBILLA;I. VERONESE;MAURO FASOLI;N. CHIODINI;ANDREA BALLARÈ;BRUNO FREA;ERVIN KOCJANCIC","150;134;88;85;85;62;62;62;53;53;49;49;49;49;49;49;49;46;46;46","MARCO BRAMBILLA;G. LOI;E. MONÈS;BARBARA CANNILLO;ERALDO OCCHETTA;MIRIAM BORTNIK;PAOLO MARINO;ANDREA MAGNANI;GABRIELLA FRANCALACCI;EVA NEGRI;EDOARDO NEGRI;MARCO DOMINIETTO;MARCO KRENGLI;PIERO EMILIO BALBO;A. FASSIOLA;ALESSANDRA RENGHI;ANDREA CUMINO;FRANÇESCO DELLA CORTE;L GRAMAGLIA;PIERO BRUSTIA","150;134;88;85;62;62;62;53;53;49;39;39;39;32;30;30;30;30;30;30","MARCO BRAMBILLA;G. LOI;BARBARA CANNILLO;E. MONÈS;ERALDO OCCHETTA;MIRIAM BORTNIK;PAOLO MARINO;A. FASSIOLA;ALESSANDRA RENGHI;ANDREA CUMINO;ANDREA MAGNANI;CARLO OLIVIERI;CESARE GREGORETTI;CLAUDIO FOGLIATI;EDOARDO NEGRI;EVA NEGRI;FRANÇESCO DELLA CORTE;GABRIELLA FRANCALACCI;L GRAMAGLIA;M. BRUNERO","4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;CHEMISTRY;ENGINEERING;PHYSICS;MATERIALS SCIENCE;COMPUTER SCIENCE","11;3;3;3;2;1","INTERNAL MEDICINE;NUCLEAR MEDICINE;ANESTHESIA;SURGERY;BIOMEDICAL ENGINEERING;CARDIOLOGY;NUCLEAR PHYSICS;OPTICS;BIOCHEMISTRY;CHROMATOGRAPHY;ELECTRICAL ENGINEERING;GASTROENTEROLOGY;GENERAL SURGERY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;MEDICAL PHYSICS;METALLURGY;NUCLEAR ENGINEERING;NUCLEAR MAGNETIC RESONANCE;OPERATING SYSTEM;OPTOELECTRONICS;ORGANIC CHEMISTRY;PATHOLOGY;QUANTUM MECHANICS;RADIOLOGY;THERMODYNAMICS","7;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIATION;ABDOMINAL SURGERY;ANEURYSM;ARTIFICIAL CARDIAC PACEMAKER;ATRIAL FIBRILLATION;ATRIOVENTRICULAR BLOCK;BEAM (STRUCTURE);BUPIVACAINE;CANCER;CATHETER;COPD;CUFF;CYTOKINE;DEFIBRILLATION;DETECTOR;DILUTION;DISEASE;DOSIMETRY;ELECTROCARDIOGRAPHY;ELECTROMAGNETIC INTERFERENCE;ENDOSCOPY;EXACERBATION;FIBROSIS;GADOLINIUM;HEART FAILURE;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;IN VITRO;INTENSIVE CARE UNIT;IODINE;IRRADIATION;LIPOPOLYSACCHARIDE;LYMPH;LYMPH NODE;LYMPHATIC SYSTEM;MAGNETIC FIELD;MECHANICAL VENTILATION;MODE (COMPUTER INTERFACE);NEUTRON;OPTICAL FIBER;PELVIS;QRS COMPLEX;REPRODUCIBILITY;RESPIRATORY BURST;RESPIRATORY FAILURE;SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY;STIMULATION;THYROID;TUMOR NECROSIS FACTOR ALPHA;ULTRASONOGRAPHY;VENTILATION (ARCHITECTURE);VENTRICLE;VENTRICULAR FIBRILLATION;VENTRICULAR TACHYCARDIA","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABDOMINAL AORTIC ANEURYSM;ABSORBED DOSE;ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE;CHERENKOV RADIATION;DOSIMETER;FIELD STRENGTH;GOITER;HEART BLOCK;IODINE DEFICIENCY;LINEAR PARTICLE ACCELERATOR;MACROPHAGE;METASTASIS;PARTICLE ACCELERATOR;PROSTATE;PROSTATE CANCER;PULMONARY FIBROSIS;REFLUX;SUPRAVENTRICULAR ARRHYTHMIA;VENTRICULAR PACING","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALVEOLAR MACROPHAGE;ESOPHAGITIS;PROSTATECTOMY;REFLUX ESOPHAGITIS","1;1;1;1","HUMANS;MALE;AGED;FEMALE;PELVIS;RESPIRATORY INSUFFICIENCY;AGED, 80 AND OVER;GOITER;HEART BLOCK;HEART VENTRICLES;IODINE;LYMPH NODES;MACROPHAGES, ALVEOLAR;MIDDLE AGED;NEOPLASMS;NF-KAPPA B;PROSTATIC NEOPLASMS;PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;RADIOTHERAPY;RETROSPECTIVE STUDIES","9;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;RADIOTHERAPY PHYSICS AND TECHNOLOGY;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;PROSTATE CANCER RESEARCH AND TREATMENT;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;THYROID DISEASE AND HORMONE REGULATION","2;2;1;1;1;1;1;1;1","ALVEOLAR MACROPHAGE;ARTIFICIAL CARDIAC PACEMAKER;ATRIOVENTRICULAR BLOCK;CANCER IMAGING;CARDIAC ELECTROPHYSIOLOGY;CUFF;DILUTION;ECHOCARDIOGRAPHY;EMERGENCY TRACHEAL INTUBATION;ENDOSCOPIC STENTING;EOSINOPHILIC ESOPHAGITIS;ESOPHAGEAL PERFORATION;ESOPHAGITIS;FAST-TRACK SURGERY;FIELD STRENGTH;GASTROESOPHAGEAL REFLUX DISEASE;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INFLAMMATION;INTENSITY-MODULATED RADIOTHERAPY;IODINE DEFICIENCY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ABDOMINAL AORTIC;ACCELERATOR OPERATING;ACUTE RESPIRATORY;AFFECTS HUMAN;ALVEOLAR MACROPHAGES;ANODAL PACEMAKER;AORTIC SURGERY;BLENDED ANESTHESIA;BURST CYTOKINE;CARDIOVERTER-DEFIBRILLATOR DISCHARGES;CE-DOPED OPTICAL;CHRONIC OBSTRUCTIVE;CYTOKINE RELEASE;DISCHARGES UNRELATED;DISEASE EXACERBATION;ELECTRON MODE;FAILURE SECONDARY;FAST-TRACK APPROACH;FEASIBILITY STUDY;FIELD STRENGTH;GADOLINIUM DILUTION;HISTORICALLY IODINE;HUMAN ALVEOLAR;IMAGE FUSION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INAPPROPRIATE IMPLANTABLE;INTRAOPERATIVE RADIATION;IODINE DEFICIENCY;IODINE STATUS;LEFT SUBCOSTAL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PULMONARY FIBROSIS;NF Κ;ABDOMINAL AORTIC;AGENT DILUTION;AORTIC SURGERY;CALORIC REQUIREMENT;CONTRAST AGENT;CYTOKINE RELEASE;DAILY CALORIC;EXTRACARDIAC SIGNALS;FIBROSIS SMOKERS;HEALTHY SMOKERS;HOSPITAL STAY;MAGNETIC FIELD;ML PHANTOMS;PEAK CNR;PHANTOMS FILLED;REGULAR VENTRICULAR;RESPIRATORY BURST;VENTRICULAR CAPTURE;ABDOMINAL CAVITY;ABSTRACT PURPOSE;ACID BISMETHYLAMIDE;ACTIVATION MSP;AGGRESSIVE POSTOPERATIVE;ALLOWED SENSORY;ALVEOLAR MACROPHAGES;ANDOR VENTRICULAR;ANEURYSM AORTO-AORTIC;ANODAL STIMULATION","4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,6.33,704.67,11.11,0,0,29,0,0,0,1,0,0,1,1,0,2,1,0,0,0,0,0,0,3,0,0,3,0,0,0,0,0,0,0,0,0,"Italy","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","3;1;1;1;1;1","CLINICAL RESEARCH;ATHEROSCLEROSIS;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;COST EFFECTIVENESS RESEARCH;GENETICS;HEMATOLOGY;LYMPHOMA;RARE DISEASES","3;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM","1;1","2.4 SURVEILLANCE AND DISTRIBUTION","1","NON-HODGKIN'S LYMPHOMA","1","4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2007,16,9.625,3.8125,0.5,0.5,0.5,1.10909090909091,0.888888888888889,0.888888888888889,0.888888888888889,0.125,0,9,4,0,2,0.56,0.25,0,0.12,32.62,0.618178823721278,NA,0.25,1,0.309,0.175,0.328,0.298,"ALESSANDRO CARRIERO;G. LOI;MARCO KRENGLI;EUGENIO INGLESE;MARCO BRAMBILLA;GIUSEPPINA GAMBARO;G. SACCHETTI;SALVATORE SIENA;GIOVANNI TEODORI;L. CANALIS;GIAMPIETRO GASPARINI;ANDREA ROGNONI;BARBARA CANNILLO;M. PAGLIARULO;R. BIASON;DEBORA BELDÌ;M. DI TERLIZZI;VINCENZO RUTIGLIANO;FABRIZIO BARBETTI;F. MONTINO","4;4;4;3;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1","ALESSANDRO CARRIERO;G. LOI;MARCO KRENGLI;EUGENIO INGLESE;MARCO BRAMBILLA;G. SACCHETTI;GIUSEPPINA GAMBARO;GIOVANNI TEODORI;ANDREA ROGNONI;FLAVIO RIBICHINI;VALERIA FERRERO;FABRIZIO BARBETTI;A. PAROLI;CARLO COLOMBO;ROBERTO CAVALLARO;PALMIERO MONTELEONE;JOSEPH C. KOSTER;CINZIA PERUZZI;G. ALLOCHIS;COLIN G. NICHOLS","0.5;0.49;0.46;0.36;0.36;0.36;0.35;0.25;0.25;0.25;0.25;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17;0.17","ALESSANDRO CARRIERO;G. LOI;MARCO KRENGLI;EUGENIO INGLESE;MARCO BRAMBILLA;GIUSEPPINA GAMBARO;G. SACCHETTI;SALVATORE SIENA;GIOVANNI TEODORI;L. CANALIS;ANDREA ROGNONI;BARBARA CANNILLO;M. PAGLIARULO;DEBORA BELDÌ;M. DI TERLIZZI;F. MONTINO;SALVATORE PUCCIARELLI;ERALDO OCCHETTA;M. DEL PIANO;GERARDO ROSATI","4;4;4;3;3;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1","ALESSANDRO CARRIERO;G. LOI;MARCO KRENGLI;EUGENIO INGLESE;MARCO BRAMBILLA;G. SACCHETTI;GIUSEPPINA GAMBARO;GIOVANNI TEODORI;ANDREA ROGNONI;FLAVIO RIBICHINI;VALERIA FERRERO;CINZIA PERUZZI;G. ALLOCHIS;FRANCESCO CADARIO;L. CANALIS;M. DI TERLIZZI;RITA FOSSACECA;E. MONÈS;F. TRAVAGLINI;ROBERTA AMBROSINI","0.5;0.49;0.46;0.36;0.36;0.36;0.35;0.25;0.25;0.25;0.25;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14","MARCO KRENGLI;G. LOI;GIUSEPPINA GAMBARO;ALESSANDRO CARRIERO;EUGENIO INGLESE;G. SACCHETTI;MARCO BRAMBILLA;CARLO COLOMBO;CINZIA PERUZZI;COLIN G. NICHOLS;FABRIZIO BARBETTI;FRANCESCO CADARIO;JOSEPH C. KOSTER;BARBARA CANNILLO;LUCIA TURRI;MARIA CHIARA BASSI;PIERDANIELE LA MATTINA;CORRADO MAGNANI;DANIELA FERRANTE;LAURA MASINI","264;212;169;142;139;139;139;104;104;104;104;104;104;95;95;95;95;84;84;84","G. LOI;MARCO BRAMBILLA;CINZIA PERUZZI;FRANCESCO CADARIO;BARBARA CANNILLO;DEBORA BELDÌ;GIUSEPPINA GAMBARO;MARCO KRENGLI;ALESSANDRO CARRIERO;LETIZIA MAZZINI;LUCIA TESTA;C SECCO;EUGENIO INGLESE;G. SACCHETTI;MARCO RUDONI;ROBERTA MATHEOUD;S. COMI;E. GARELLO;F. MONTINO;M. BALLARÈ","212;139;104;104;95;69;69;69;42;39;39;28;28;28;28;28;28;19;19;19","G. LOI;MARCO BRAMBILLA;ALESSANDRO CARRIERO;ALESSANDRO STECCO;ANDREA BONETTI;ANDREA ROGNONI;BARBARA CANNILLO;C SECCO;C. ASCHELE;CARMINE PINTO;CINZIA PERUZZI;DEBORA BELDÌ;E. BERTONA;E. GARELLO;E. MONÈS;ERALDO OCCHETTA;EUGENIO INGLESE;F. MONTINO;F. TRAVAGLINI;FLAVIO RIBICHINI","4;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;ENGINEERING;MATERIALS SCIENCE;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;PSYCHOLOGY","15;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;NUCLEAR MEDICINE;ENVIRONMENTAL HEALTH;CANCER RESEARCH;CARDIOLOGY;GASTROENTEROLOGY;GENETICS;ONCOLOGY;OPTICS;PALEONTOLOGY;ARTIFICIAL INTELLIGENCE;ATOMIC PHYSICS;CHROMATOGRAPHY;CIVIL ENGINEERING;ENDOCRINOLOGY;FAMILY MEDICINE;FINANCE;MECHANICAL ENGINEERING;NURSING;OPTOELECTRONICS;ORGANIC CHEMISTRY;PATHOLOGY;PSYCHIATRY;THERMODYNAMICS;UROLOGY","9;6;5;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIATION THERAPY;CANCER;POPULATION;DISEASE;GENE;POSITRON EMISSION TOMOGRAPHY;RETROSPECTIVE COHORT STUDY;ABLATION;ADVERSE EFFECT;ANALYTICAL CHEMISTRY (JOURNAL);ANEURYSM;ANGIOGENESIS;ANGIOGRAPHY;AORTA;ATRIAL FIBRILLATION;BLOOD PRESSURE;CHEMOTHERAPY;CHEST PAIN;COMPLICATION;CONCOMITANT;CONTEXT (ARCHAEOLOGY);DETECTOR;DIABETES MELLITUS;DOPING;ENDOSCOPY;FEEDING TUBE;FIGURE OF MERIT;FLUORESCENCE;GASTROSTOMY;GLIOMA;GRADING (ENGINEERING);HEART FAILURE;HISTOLOGY;IMAGE (MATHEMATICS);IMAGING PHANTOM;INSULIN;ION;ISOTHERMAL PROCESS;LUMINESCENCE;LUNG;LUNG CANCER;LYMPH NODE;MAGNETIC RESONANCE IMAGING;MEDICAL IMAGING;MENTAL HEALTH;MYOCARDIAL INFARCTION;PALPITATIONS;PARENTERAL NUTRITION;PEG RATIO;POTASSIUM CHANNEL;PRIMARY TREATMENT;PROSPECTIVE COHORT STUDY;PROTON-PUMP INHIBITOR;PULMONARY FUNCTION TESTING;QUALITY OF LIFE (HEALTHCARE);RANDOMIZED CONTROLLED TRIAL;REGIMEN;RIGHT ATRIUM;SCANNER;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING);SIGNAL-TO-NOISE RATIO (IMAGING);SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY;SKELETAL MUSCLE;SPECT IMAGING;STAGE (STRATIGRAPHY);STOMACH;STROKE (ENGINE)","5;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLORECTAL CANCER;AMYOTROPHIC LATERAL SCLEROSIS;ANAL CANCER;ANGINA;ANGIOGENIN;ASCENDING AORTA;BRACHYTHERAPY;BREAST CANCER;CLINICAL ENDPOINT;CODING REGION;CORONARY ANGIOGRAPHY;EMISSION COMPUTED TOMOGRAPHY;ENTERAL ADMINISTRATION;FLUORODEOXYGLUCOSE;GASTRIC EMPTYING;GERIATRIC ONCOLOGY;GLIBENCLAMIDE;GLICLAZIDE;HEART RATE;HIGH-RESOLUTION COMPUTED TOMOGRAPHY;IMAGE QUALITY;JEJUNOSTOMY;LUNG FUNCTION;LUNG VOLUMES;PEDIATRIC GASTROENTEROLOGY;PERCUTANEOUS ENDOSCOPIC GASTROSTOMY;PET-CT;PHOSPHORESCENCE;PHYSICAL HEALTH;PROTEIN SUBUNIT;PSEUDOANEURYSM;REFLUX;SCINTILLATION;THERMOLUMINESCENCE;TOLERABILITY","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIFFUSING CAPACITY;ESOPHAGITIS;GASTROPARESIS;KIR6.2;OXALIPLATIN;PRESYNCOPE;RADIOLUMINESCENCE;RIGHT CORONARY ARTERY;SULFONYLUREA RECEPTOR","1;1;1;1;1;1;1;1;1","HUMANS;AGED;FEMALE;MALE;MIDDLE AGED;TOMOGRAPHY, X-RAY COMPUTED;ADULT;AGED, 80 AND OVER;LUNG;POSITRON-EMISSION TOMOGRAPHY;ANEURYSM, FALSE;ATRIAL FIBRILLATION;BREAST NEOPLASMS;CARCINOMA, SQUAMOUS CELL;CORONARY ANEURYSM;CORONARY ARTERY DISEASE;DIABETES MELLITUS;DYSPNEA;ESOPHAGITIS, PEPTIC;LYMPHATIC METASTASIS","13;10;9;9;8;8;7;5;5;5;4;4;4;4;4;4;4;4;4;4","POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF KAWASAKI DISEASE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;FRAILTY IN OLDER ADULTS AND GERIATRIC CARE;LANTHANIDE LUMINESCENCE IN BIOMEDICAL APPLICATIONS;PATHOPHYSIOLOGY OF MYOCARDIAL REPERFUSION INJURY;PROVISION AND ASSESSMENT OF NUTRITION SUPPORT THERAPY;RADIOMICS IN MEDICAL IMAGING ANALYSIS;SCHIZOPHRENIA RESEARCH AND TREATMENT;SPINE SURGERY TECHNIQUES AND TECHNOLOGIES","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIOTHERAPY;METASTATIC COLORECTAL CANCER;PET/CT;ANEURYSMS;ANGIOGENIN;ATP-SENSITIVE POTASSIUM CHANNELS;ATRIAL FIBRILLATION;CANCER IMAGING;CANCER IN OLDER ADULTS;CANCER OF UNKNOWN PRIMARY;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL ENDPOINT;CODING REGION;COMPREHENSIVE GERIATRIC ASSESSMENT;CONCOMITANT;CORONARY ARTERY ABNORMALITIES;CORONARY ARTERY ANOMALIES;DLCO;DUAL-ENERGY CT;EMISSION COMPUTED TOMOGRAPHY","3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RECTAL CANCER;RETROSPECTIVE ANALYSIS;TARGET VOLUME;ADIUVANTE RETTO-;ADVANCED RECTAL;ALS AMYOTROPHIC;AMYOTROPHIC LATERAL;ANALYSIS ADDRESSED;ANEURYSM COMMUNICATING;ANG GENE;ANGIOGENIN ANG;ATRIAL FIBRILLATION;BODY PETCT;BREAST CANCER;CANCER PRELIMINARY;CANCER TREATMENT;CERVICAL LYMPH;CESUPSUP IONS;COLORECTAL CANCER;CON SCHIZOFRENIA;CONFORMAL RADIOTHERAPY;CONSERVATIVE TREATMENT;CORONARY ANEURYSM;DEL PAZIENTE;DELLA SALUTE;DPEJ PLACEMENT;ELDERLY PATIENTS;EMISSION SCAN;FDG-PETCT IMAGING;FIBRES DOPED","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GD CHANNELS;KIR MUTATIONS;PM DEPENDENCE;CHANNELS COEXPRESSED;ELECTRICAL ACTIVITY;ESCAPE RHYTHM;GD PATIENT;HEART FAILURE;HIGH-AFFINITY BLOCK;INTERMEDIATE DEND;NEONATAL DIABETES;PRE-SYNCOPE SYNCOPE;RF ABLATION;SKELETAL MUSCLE;SUPPRESS ELECTRICAL;UNCONTROLLED VENTRICULAR;VENTRICULAR RATE;ACTIVATING KIR;ACTIVITYTHE GD;ADULTHOODTHE OBJECTIVE;ANALYSED HUNDRED;ASYSTOLIC PAUSE;ATP INHIBITION;ATP SENSITIVITY;ATP-SENSITIVE POTASSIUM;ATRIAL FIBRILLATION;ATRIOVENTRICULAR AV;ATTACK TIA;AV BLOCK;AV JUNCTION","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,3.25,2352.12,16,2,0.25,112.62,0,0,0,1,6,0,0,1,0,8,0,0,0,0,0,0,0,7,0,1,8,0,0,0,0,0,0,0,0,0,"Italy;Switzerland","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE","8;8;2;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;AGING;BIOTECHNOLOGY;CANCER;DIGESTIVE DISEASES;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;IMMUNIZATION;INFECTIOUS DISEASES;INFLUENZA;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED;BIODEFENSE;BRAIN DISORDERS;CARDIOVASCULAR;COLO-RECTAL CANCER;LUNG","7;7;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;INFECTION;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL","2;1;1;1","6.1 PHARMACEUTICALS;3.4 VACCINES","6;2","COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2008,18,7.38888888888889,3,0.555555555555556,0.444444444444444,0.5,1.42105263157895,1,1.14285714285714,1,0.277777777777778,1,8,6,2,1,0.44,0.33,0.11,0.06,44.44,0.809967728222533,NA,0.0555555555555556,1,0.398,0.284,0.321,0.297,"EUGENIO INGLESE;MARCO BRAMBILLA;ERALDO OCCHETTA;G. LOI;MARCO KRENGLI;MIRIAM BORTNIK;BARBARA CANNILLO;ROBERTA MATHEOUD;PAOLO MARINO;C SECCO;MICHELA TRADA;E. MONÈS;LETIZIA DEANTONIO;SUSANNA ESPOSITO;ELISA LAZZARICH;DEBORA BELDÌ;MARTA DE LUCIA;M. CANNAS;AUSILIATRICE LUCENTI;SARA DONATI","4;4;3;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","DE MAURI A;ERALDO OCCHETTA;MIRIAM BORTNIK;MARCO BRAMBILLA;EUGENIO INGLESE;PAOLO MARINO;G. LOI;MARCO KRENGLI;ROBERTA MATHEOUD;C SECCO;M. BRUNERO;MICHAEL LEUTNER;C. MATTEOTTI;CHIARA RUGGERI;G SORRENTINO;LETIZIA DEANTONIO;BARBARA CANNILLO;E. MONÈS;S. RIDONE;MICHELA TRADA","1;0.67;0.67;0.62;0.61;0.58;0.42;0.41;0.37;0.37;0.25;0.25;0.25;0.25;0.25;0.24;0.21;0.21;0.2;0.18","EUGENIO INGLESE;MARCO BRAMBILLA;ERALDO OCCHETTA;G. LOI;MARCO KRENGLI;MIRIAM BORTNIK;BARBARA CANNILLO;ROBERTA MATHEOUD;PAOLO MARINO;C SECCO;E. MONÈS;LETIZIA DEANTONIO;MARTA DE LUCIA;GIANLUCA AIMARETTI;MARIA CHIARA BASSI;DAVIDE COLOMBO;MARIA ELISA MILIA;M. BRUNERO;LAURA FORTI;MICHAEL LEUTNER","4;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","DE MAURI A;ERALDO OCCHETTA;MIRIAM BORTNIK;MARCO BRAMBILLA;EUGENIO INGLESE;PAOLO MARINO;G. LOI;MARCO KRENGLI;ROBERTA MATHEOUD;C SECCO;M. BRUNERO;MICHAEL LEUTNER;C. MATTEOTTI;CHIARA RUGGERI;G SORRENTINO;LETIZIA DEANTONIO;BARBARA CANNILLO;E. MONÈS;MARTA DE LUCIA;DAVIDE COLOMBO","1;0.67;0.67;0.62;0.61;0.58;0.42;0.41;0.37;0.37;0.25;0.25;0.25;0.25;0.25;0.24;0.21;0.21;0.17;0.17","MICHELA TRADA;DAVIDE COLOMBO;FRANÇESCO DELLA CORTE;GIANMARIA CAMMAROTA;MARTA DE LUCIA;PAOLO NAVALESI;VALENTINA BERGAMASCHI;MARCO BRAMBILLA;FLAVIA PRODAM;FRANCESCO CADARIO;G. ALLOCHIS;GIANLUCA AIMARETTI;GIANNI BONA;MARCO BINOTTI;ROBERTO BALDELLI;SIMONETTA BELLONE;SUSANNA ESPOSITO;G. LOI;EUGENIO INGLESE;MARCO KRENGLI","414;219;219;219;219;219;219;217;207;207;207;207;207;207;207;207;207;205;192;160","DAVIDE COLOMBO;FRANÇESCO DELLA CORTE;GIANMARIA CAMMAROTA;MARTA DE LUCIA;PAOLO NAVALESI;VALENTINA BERGAMASCHI;MARCO BRAMBILLA;G. ALLOCHIS;GIANLUCA AIMARETTI;G. LOI;C SECCO;EUGENIO INGLESE;ROBERTA MATHEOUD;MARCO KRENGLI;BARBARA CANNILLO;E. MONÈS;ANNALISA CERUSO;DAVID CELLA;CARLO TERRONE;ERALDO OCCHETTA","219;219;219;219;219;219;217;207;207;205;77;77;77;71;57;57;33;33;28;28","MARCO BRAMBILLA;ERALDO OCCHETTA;G. LOI;MIRIAM BORTNIK;BARBARA CANNILLO;C SECCO;E. MONÈS;EUGENIO INGLESE;MARCO KRENGLI;PAOLO MARINO;ROBERTA MATHEOUD;ANGELO SANTE BONGO;ANNALISA CERUSO;CARLO TERRONE;CHIARA RUGGERI;DAVID CELLA;DAVIDE COLOMBO;FRANÇESCO DELLA CORTE;G. ALLOCHIS;GIANLUCA AIMARETTI","4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","MEDICINE;MATERIALS SCIENCE;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;BIOLOGY;ART;ECONOMICS","18;5;4;3;3;2;1;1","INTERNAL MEDICINE;NUCLEAR MEDICINE;RADIOLOGY;SURGERY;BIOMEDICAL ENGINEERING;GASTROENTEROLOGY;ANESTHESIA;BIOCHEMISTRY;CARDIOLOGY;CHROMATOGRAPHY;INTENSIVE CARE MEDICINE;METALLURGY;NUCLEAR PHYSICS;ONCOLOGY;OPTICS;ALGORITHM;ANATOMY;ARTIFICIAL INTELLIGENCE;CELL BIOLOGY;COMPOSITE MATERIAL;DERMATOLOGY;ECONOMIC GROWTH;EMERGENCY MEDICINE;ENDOCRINOLOGY;FAMILY MEDICINE;GERONTOLOGY;GYNECOLOGY;LITERATURE;NANOTECHNOLOGY;NURSING;OPTOELECTRONICS;ORGANIC CHEMISTRY;PALEONTOLOGY;PATHOLOGY;PEDIATRICS;PROGRAMMING LANGUAGE;PSYCHIATRY;QUANTUM MECHANICS;RADIOCHEMISTRY;UROLOGY","9;5;5;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIATION THERAPY;DISEASE;DOSIMETRY;POSITRON EMISSION TOMOGRAPHY;REPRODUCIBILITY;ABDOMINAL DISTENSION;ADSORPTION;ANALYTICAL CHEMISTRY (JOURNAL);ANESTHESIOLOGY;ASCITES;ATTENDANCE;BEAM (STRUCTURE);BIOCOMPATIBILITY;BIOMATERIAL;BLOOD PRESSURE;BLUNT;BLUNT TRAUMA;CANCER;CATALYSIS;CATECHOLAMINE;CHOLECYSTECTOMY;CREATININE;D-DIMER;DIABETES MELLITUS;DOPING;DUAL (GRAMMATICAL NUMBER);ELECTRON;FIRST LINE;GALLBLADDER;GENE;HEAD AND NECK;HORMONE;IMAGING PHANTOM;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INTERQUARTILE RANGE;INTERVENTION (COUNSELING);ION;IRRADIATION;LAPAROTOMY;LIGAMENT;MECHANICAL VENTILATION;MEDICAL IMAGING;MESENCHYMAL STEM CELL;OPTICAL FIBER;PANCREATITIS;PARTIAL VOLUME;PATHOGENESIS;PHEOCHROMOCYTOMA;POLYMER;PULMONARY EMBOLISM;PUNCHING;QUALITY OF LIFE (HEALTHCARE);RADIATION;RECEPTOR;RESPIRATORY FAILURE;RESPIRATORY SYSTEM;RHYTHM;SCAFFOLD;SCANNER;SIGNAL (PROGRAMMING LANGUAGE);SILK;STAGE (STRATIGRAPHY);STEM CELL;TISSUE ENGINEERING;TOMOGRAPHY;TRANSPLANTATION;VENTRICULAR TACHYCARDIA;WOUND HEALING;YOUNG ADULT","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","RADIATION TREATMENT PLANNING;FLUORODEOXYGLUCOSE;ACUTE RESPIRATORY FAILURE;ADULT CARE;COLORECTAL CANCER;DOSIMETER;ENDOCRINE SYSTEM;FIBROIN;FLUOROURACIL;GRANULATION TISSUE;HEPATORENAL SYNDROME;IONIZATION;LINEAR PARTICLE ACCELERATOR;MOLECULAR SIEVE;ORTHOSTATIC VITAL SIGNS;PAIN MEDICINE;PARACENTESIS;PERFORATION;PET-CT;POLYELECTROLYTE;POSITRON;POSITRON EMISSION;RARE DISEASE;RECEPTOR TYROSINE KINASE;RENAL TRANSPLANT;RESPIRATORY PHYSIOLOGY;TRANSITION (GENETICS);TYPE 2 DIABETES;ZEOLITE","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CAPECITABINE;GAS6;IONIZATION CHAMBER","1;1;1","HUMANS;MALE;ADULT;AGED;FEMALE;POSITRON-EMISSION TOMOGRAPHY;MIDDLE AGED;;ADRENAL GLAND NEOPLASMS;BIOMARKERS;CARCINOMA, RENAL CELL;CREATININE;DEOXYCYTIDINE;FLUORODEOXYGLUCOSE F18;FLUOROURACIL;HYPOTENSION, ORTHOSTATIC;KIDNEY NEOPLASMS;PATTERN RECOGNITION, AUTOMATED;RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;RETROSPECTIVE STUDIES","14;8;7;7;7;7;6;4;4;4;4;4;4;4;4;4;4;4;4;4","POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN MEDICAL SCIENCE AND PRACTICE;AORTIC ATHEROSCLEROTIC DISEASE AND EMBOLIC EVENTS;BIOMEDICAL APPLICATIONS OF SILK BIOMATERIALS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;MANAGEMENT OF RIB FRACTURES IN TRAUMA PATIENTS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF APOPTOTIC CELL CLEARANCE AND IMMUNE REGULATION;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;RADIOTHERAPY PHYSICS AND TECHNOLOGY;RENAL CELL CARCINOMA;SUPPORTING HEALTH CARE TRANSITION FROM ADOLESCENCE TO ADULTHOOD;TREATMENT AND MANAGEMENT OF ANAL CANCER","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","FLUORODEOXYGLUCOSE;ABDOMINAL DISTENSION;ACUTE RESPIRATORY FAILURE;ADULT CARE;ANAL CANCER;ATTENDANCE;BIOCOMPATIBILITY;BIOMATERIAL;BLUNT TRAUMA;CARDIAC EFFECTS;CHOLECYSTITIS;CHOLESTASIS;CLINICAL FEATURES;D-DIMER;DIABETES;DOSIMETRY;FDG-PET/CT IMAGING;FIBROIN;GAS6;GRANULATION TISSUE","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT PLANNING;RADIOTHERAPY TREATMENT;ACUTE DYSPNEA;ACUTE RESPIRATORY;ADJUSTED VENTILATORY;ADULT HEALTH;ANAL CANAL;BLOCK COMPLICATING;BLUNT CHEST;CANCER PATIENTS;CAP POLYPOSIS;CAP-CR STUDY;CARE SERVICE;CE-DOPED OPTICAL;CELL CARCINOMA;CHEST TRAUMA;CLINICAL MANIFESTATION;COLORECTAL CANCER;COMPLICATING MYOCARDIAL;DIABETES TDM;DIRECT MEDICAL;DISCRIMINATION ALGORITHM;DUAL-CHAMBER IMPLANTABLE;DYSPNEA DUE;EMISSION TOMOGRAPHY;F-FDG-PETTC IMAGING;FAST VENTRICULAR;FDG-PETCT IMAGING;FIRST-LINE INFUSIONAL;GALLBLADDER PERFORATION","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LICP PATIENTS;ASSIST LEVEL;ASSIST LEVELS;FLOW-BASED TIMING;HEALTHY VOLUNTEERS;PE DIAGNOSIS;PEAK EADI;STATISTICALLY SIGNIFICANT;TREATMENT PLANNING;TWENTY-TWO PATIENTS;ABDOMINAL PARACENTESIS;ABGS TIDAL;ACALCULOUS PERFORATION;ACCURACY MEASURES;ACTIVE INSPIRATION;ACTIVITY EADI;ACUTE DYSPNEA;ACUTE INFLAMMATION;ACUTE PANCREATITIS;ADJUSTED VENTILATORY;AGE-MATCHED HEALTHY;AI EXCEEDED;AIMSMORPHOLOGY DISCRIMINATION;AIRWAY PRESSURE;ALBUMIN GRADIENT;ALCOHOL ABUSE;ALGORITHM BASED;AMYLASE APPROXIMATELY;AMYLASE CONCENTRATION;ANIMAL MODELSMETHODSWE","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,3.4,1195.2,17.14,2,0.33,60.33,0,0,0,0,4,0,2,0,0,5,0,0,0,0,0,0,0,6,0,0,5,1,0,0,0,0,0,0,0,0,"Italy;Portugal;Switzerland;United Kingdom","2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","6;3;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;BIOTECHNOLOGY;CANCER;COLO-RECTAL CANCER;DIGESTIVE DISEASES;CARDIOVASCULAR;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;COMPARATIVE EFFECTIVENESS RESEARCH;GENETICS;HEART DISEASE;IMMUNIZATION;LUNG;NEURODEGENERATIVE;PEDIATRIC;PREVENTION;VACCINE RELATED","5;5;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;GENERIC HEALTH RELEVANCE;NEUROLOGICAL;RESPIRATORY","2;1;1;1;1","6.1 PHARMACEUTICALS;3.4 VACCINES;6.7 PHYSICAL;7.3 MANAGEMENT AND DECISION MAKING","6;1;1;1","COLON AND RECTAL CANCER","2","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","2",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2009,30,8.56666666666667,4.36666666666667,0.6,0.533333333333333,0.633333333333333,1.27184466019417,1,1.23076923076923,1,0.3,1,10,8,3,4,0.33,0.27,0.1,0.13,29.83,0.644944333017066,NA,0.1,1,0.346,0.194,0.306,0.198,"G. MARCHIORO;CARLO TERRONE;PAOLO MARINO;E. MONÈS;DEBORA BELDÌ;ALESSANDRO CARRIERO;ALESSANDRO VOLPE;G. LOI;ANDREA BALLARÈ;MARCO KRENGLI;FRANCESCO VARVELLO;MATTEO VIDALI;STEFANO ANDREONI;MICHELE BILLIA;ANTONIO FARNIA;ERALDO OCCHETTA;ANNA CAMAGGI;VESSELINA KROUMOVA;MAURO FASOLI;N. CHIODINI","4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","DE MAURI A;PAOLO NAVALESI;VALENTINA BERGAMASCHI;ALESSANDRO CARRIERO;PAOLO MARINO;E. MONÈS;DEBORA BELDÌ;G. LOI;ANDREA BALLARÈ;MARCO KRENGLI;G. MARCHIORO;CARLO TERRONE;M GARAVOGLIA;ALBERTO OLDANI;FABRIZIO BUTERA;ERALDO OCCHETTA;FRANCESCO VARVELLO;MATTEO VIDALI;MIRIAM BORTNIK;ALESSANDRO VOLPE","1;0.5;0.5;0.45;0.43;0.42;0.4;0.4;0.4;0.4;0.36;0.36;0.33;0.33;0.33;0.27;0.27;0.27;0.27;0.26","G. MARCHIORO;CARLO TERRONE;PAOLO MARINO;E. MONÈS;DEBORA BELDÌ;ALESSANDRO CARRIERO;ALESSANDRO VOLPE;G. LOI;ANDREA BALLARÈ;MARCO KRENGLI;MATTEO VIDALI;STEFANO ANDREONI;ERALDO OCCHETTA;ANNA CAMAGGI;VESSELINA KROUMOVA;FEDERICA DE VECCHI;GIACOMO FORTINA;CESARE BOLCHINI;CRISTINA PICCININO;ELISA RONDANO","4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","DE MAURI A;VALENTINA BERGAMASCHI;ALESSANDRO CARRIERO;PAOLO MARINO;E. MONÈS;DEBORA BELDÌ;G. LOI;ANDREA BALLARÈ;MARCO KRENGLI;G. MARCHIORO;CARLO TERRONE;M GARAVOGLIA;ALBERTO OLDANI;FABRIZIO BUTERA;ERALDO OCCHETTA;MATTEO VIDALI;MIRIAM BORTNIK;ALESSANDRO VOLPE;CESARE BOLCHINI;STEFANO ANDREONI","1;0.5;0.45;0.43;0.42;0.4;0.4;0.4;0.4;0.36;0.36;0.33;0.33;0.33;0.27;0.27;0.27;0.26;0.23;0.22","CLARA DEAMBROGI;DANIELA CAPELLO;DAVIDE ROSSI;ELISA SOZZI;FRANCESCO FORCONI;FRANCESCO LAURIA;GIANLUCA GAÏDANO;LORENZO DE PAOLI;MICHAELA CERRI;SILVIA RASI;STEFANIA CRESTA;VALERIA SPINA;VALTER GATTEI;E. MONÈS;PAOLO MARINO;ELISA RONDANO;FRANCESCO MONACO;CLAUDIA RIZZO;ELENA FRANCHI;ETTORE CASSETTI","300;300;300;300;300;300;300;300;300;300;300;300;300;152;151;148;133;120;120;120","CLARA DEAMBROGI;DANIELA CAPELLO;DAVIDE ROSSI;GIANLUCA GAÏDANO;LORENZO DE PAOLI;MICHAELA CERRI;SILVIA RASI;STEFANIA CRESTA;VALERIA SPINA;E. MONÈS;PAOLO MARINO;ELISA RONDANO;CLAUDIA RIZZO;ELENA FRANCHI;ETTORE CASSETTI;FRANCESCO MONACO;GABRIELE DELL’ERA;GIOEL GABRIO SECCO;GIORGIO BELLOMO;GIUSEPPE DE LUCA","300;300;300;300;300;300;300;300;300;152;151;148;120;120;120;120;120;120;120;120","E. MONÈS;PAOLO MARINO;CARLO TERRONE;G. LOI;ANDREA BALLARÈ;ANDREA MAGNANI;BARBARA MASSÈ;CESARE BOLCHINI;CRISTINA PICCININO;DEBORA BELDÌ;ELISA RONDANO;ERALDO OCCHETTA;FEDERICA DE VECCHI;G SARASSO;GABRIELLA FRANCALACCI;GIULIANO MARTI;MARCO BRAMBILLA;MARCO KRENGLI;MIRIAM BORTNIK;STEFANO ANDREONI","4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATERIALS SCIENCE;MATHEMATICS;PHYSICS;CHEMISTRY;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE","29;5;5;4;4;4;3;1;1;1","INTERNAL MEDICINE;RADIOLOGY;SURGERY;CARDIOLOGY;NUCLEAR MEDICINE;ONCOLOGY;ANESTHESIA;ARTIFICIAL INTELLIGENCE;ENDOCRINOLOGY;OPTICS;PATHOLOGY;PHYSICAL THERAPY;UROLOGY;GASTROENTEROLOGY;GENETICS;GEOMETRY;MEDICAL PHYSICS;OPTOELECTRONICS;QUANTUM MECHANICS;TELECOMMUNICATIONS","19;10;7;5;5;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2","CANCER;DIABETES MELLITUS;RADIATION THERAPY;ASYMPTOMATIC;BIOPSY;BLOOD PRESSURE;CORE (OPTICAL FIBER);DETECTOR;DOPING;GENE;HEART FAILURE;IMAGE (MATHEMATICS);MAGNETIC RESONANCE IMAGING;MITRAL VALVE;MYOCARDIAL INFARCTION;PLATELET;RADIATION;REHABILITATION;REPRODUCIBILITY;TOXICITY;URINARY SYSTEM","6;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PROSTATE CANCER;PROSTATE;BREAST CANCER;EJECTION FRACTION;ABDOMINAL AORTIC ANEURYSM;ACUTE RESPIRATORY FAILURE;ACUTE TOXICITY;AIRWAY OBSTRUCTION;ANGINA;ANTAGONIST;BRACHYTHERAPY;BRAGG PEAK;CAESAREAN SECTION;CANCER DETECTION;CARDIAC MAGNETIC RESONANCE IMAGING;CHLAMYDIA TRACHOMATIS INFECTION;CHORDAE TENDINEAE;CHROMOGRANIN A;CHROMOSOME;CHRONIC LYMPHOCYTIC LEUKEMIA;CLOCKWISE;COLORECTAL CANCER;COPPER DEFICIENCY;DIASTOLE;DOSE PROFILE;DOSIMETER;ECTOPIC THYROID;FACTOR VII;FLUOROURACIL;FRESH FROZEN PLASMA;HAZARD RATIO;HEART RATE;HEART RUPTURE;HIP FRACTURE;HOUNSFIELD SCALE;IMAGE QUALITY;IMAGE REGISTRATION;IMAGE-GUIDED RADIATION THERAPY;INSULIN RESISTANCE;IONIZATION;LABETALOL;MEAN PLATELET VOLUME;MUTATION;MYCOBACTERIUM;MYCOBACTERIUM TUBERCULOSIS;NEPHROPATHY;NEURORADIOLOGY;OCTREOTIDE;PARTICLE DETECTOR;PHOTOMULTIPLIER;PLATELET ACTIVATION;PROGRESSIVE DISEASE;PROTON THERAPY;RADIAL STRESS;RADIATION HARDENING;RADIODENSITY;SCINTILLATION;THYROID CARTILAGE;TYPE 2 DIABETES;VENOUS THROMBOSIS","5;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CORE BIOPSY;SPECKLE TRACKING ECHOCARDIOGRAPHY;CARDIAC RESYNCHRONIZATION THERAPY;CONTRAST-INDUCED NEPHROPATHY;EXTERNAL BEAM RADIOTHERAPY;FLUORESCENCE IN SITU HYBRIDIZATION;GLUCOSE TOLERANCE TEST;IMPAIRED GLUCOSE TOLERANCE;INFERIOR VENA CAVA FILTER;IONIZATION CHAMBER;NEUROENDOCRINE DIFFERENTIATION;NONTUBERCULOUS MYCOBACTERIA;PENCIL-BEAM SCANNING;PROSTATE BIOPSY;PROSTATECTOMY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SYSTOLE;URAPIDIL;YOHIMBINE","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;AGED;MALE;MIDDLE AGED;PROSTATIC NEOPLASMS;MITRAL VALVE INSUFFICIENCY;TREATMENT OUTCOME;TOMOGRAPHY, X-RAY COMPUTED;ADULT;ADRENERGIC ALPHA-ANTAGONISTS;AGED, 80 AND OVER;AORTIC ANEURYSM, ABDOMINAL;CARDIAC PACING, ARTIFICIAL;COPPER;HEART RUPTURE;LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;NEUROTOXICITY SYNDROMES;POLYNEUROPATHIES","18;12;12;10;10;10;10;7;7;6;5;4;4;4;4;4;4;4;4;4","PROSTATE CANCER RESEARCH AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT OF VALVULAR HEART DISEASE;BRANCHIAL ANOMALIES AND THYROID ABNORMALITIES;COPPER AND ZINC IN HEALTH AND DISEASE;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;INCIDENCE AND MANAGEMENT OF HIP FRACTURES;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;MANAGEMENT AND TREATMENT OF HEMOPHILIA;MANAGEMENT OF POISONING AND TOXIC EXPOSURES;MATERNAL MORBIDITY ASSOCIATED WITH PREGNANCY AND CHILDBIRTH;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PANCREATIC CANCER RESEARCH AND TREATMENT;PARTICLE THERAPY FOR CANCER TREATMENT;PATHOGENESIS AND MANAGEMENT OF BILIARY ATRESIA;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","BIOPSY;CORE BIOPSY;IMAGE-GUIDED RADIOTHERAPY;LEFT VENTRICULAR DYSFUNCTION;MITRAL REGURGITATION;POSTINFARCTION VENTRICULAR SEPTAL DEFECT;POSTPARTUM HEMORRHAGE;PROSTATE CANCER;SPECKLE TRACKING ECHOCARDIOGRAPHY;SPECTRAL IMAGING;VENTRICULAR RECONSTRUCTION;ACUTE RESPIRATORY FAILURE;AIRWAY OBSTRUCTION;ANEURYSM RUPTURE;AORTIC ANEURYSMS;AORTIC DISSECTION;APEX (GEOMETRY);ARRHYTHMIAS;CANCER DETECTION;CARDIAC RESYNCHRONIZATION THERAPY","2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","PROSTATE CANCER;ACTIVATED FACTOR;BIOPSY DETECTION;CONFORMAL RADIOTHERAPY;DETECTION RATE;FACTOR VII;HAEMORRHAGE DATA;IMPROVE SATURATION;ITALIAN REGISTRY;POST-PARTUM HAEMORRHAGE;RECOMBINANT ACTIVATED;SATURATION BIOPSY;SEVERE POST-PARTUM;ABDOMINAL AORTIC;ACTING OCTREOTIDE;ACUTE MITRAL;ACUTE NEUROTOXICITY;ADVANCED PROSTATE;ADVANCED WELL-DIFFERENTIATED;AORTIC ANEURYSM;AORTOCAVAL FISTULA;AORTOMITRAL APPARATUS;APPARATUS FUNCTION;ARTERY DISEASE;ARTICULAR INFECTIONS;BODY BUILDER;BODY PETCT;CANCER ANALYSIS;CANCER TECHNICAL;CARDIAC DYSSYNCHRONY","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TP MUTATIONS;MITRAL VALVE;AML MOVEMENT;AORTIC ANNULUS;AORTOMITRAL APPARATUS;CARDIAC MAGNETIC;EFFECTIVE MITRAL;LEFT VENTRICULAR;LVOT DIAMETER;MAGNETIC RESONANCE;MM HG;PARTIAL CIRCUMFERENCE;RESONANCE IMAGING;SURFACE IMAGE;TRANSMITRAL VALVE;VALVE GRADIENT;APPARATUS FUNCTION;IMAGE REGISTRATION;INDEPENDENT PREDICTOR;LAR OCTREOTIDE;PROSTATE CANCER;REGISTRATION SYSTEM;WELL-DIFFERENTIATED NEUROENDOCRINE;ADJUSTS PROPORTIONALLY;AML PIVOTAL;ANALYSIS SELECTED;ANNULAR RINGS;ANNULUS ADJUSTS;ANNULUS IMPROVE;ANTERIOR MITRAL","9;8;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,1,687.25,9.09,0,0,7.89,0,0,1,0,3,0,4,1,0,3,1,0,0,0,0,0,0,8,1,0,4,5,0,0,0,0,0,0,0,0,"Italy;Switzerland","8;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4204 MIDWIFERY;44 HUMAN SOCIETY;4404 DEVELOPMENT STUDIES;5202 BIOLOGICAL PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","9;6;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION;ATHEROSCLEROSIS;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;BRAIN DISORDERS;DEPRESSION;IMMUNIZATION;MENTAL HEALTH;NEUROSCIENCES;REHABILITATION;STROKE;VACCINE RELATED","3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","2;1;1;1;1","6.1 PHARMACEUTICALS","2","COLON AND RECTAL CANCER;LUNG CANCER","1;1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2010,42,7.45238095238095,4.4047619047619,0.69047619047619,0.642857142857143,0.761904761904762,1.48,1.16,1.5,1.18518518518519,0.30952380952381,1,17,17,3,2,0.4,0.4,0.07,0.05,38.29,0.847205385367981,NA,0.214285714285714,1,0.367,0.379,0.418,0.399,"MARCO KRENGLI;MARCO BRAMBILLA;PAOLO MARINO;DEBORA BELDÌ;ELENA GROSSINI;PATRIZIA ZEPPEGNO;EUGENIO INGLESE;E. TORRE;GIORGIO BELLOMO;ALESSANDRO CARRIERO;ERALDO OCCHETTA;ROBERTA MATHEOUD;V. DALÒ;GIOVANNI VACCA;GIUSEPPE DE LUCA;ALESSANDRO STECCO;BARBARA CANNILLO;M. COLOMBO;PIERFRANCESCO FRANCO;MARIA CHIARA BASSI","9;7;6;5;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2","MARCO KRENGLI;MASSIMO SARTORI;PAOLO MARINO;MARCO BRAMBILLA;DEBORA BELDÌ;PATRIZIA ZEPPEGNO;ELENA GROSSINI;E. TORRE;PIERFRANCESCO FRANCO;GIANLUCA AIROLDI;MAURO CAMPANINI;GIORGIO BELLOMO;ALESSANDRO CARRIERO;EUGENIO INGLESE;V. DALÒ;ALESSANDRO STECCO;ELISA RONDANO;GABRIELE DELL’ERA;ROBERTA MATHEOUD;GIOVANNI VACCA","1.29;1;0.89;0.84;0.78;0.71;0.67;0.62;0.53;0.5;0.5;0.49;0.47;0.45;0.45;0.44;0.42;0.42;0.41;0.4","MARCO KRENGLI;MARCO BRAMBILLA;PAOLO MARINO;DEBORA BELDÌ;ELENA GROSSINI;PATRIZIA ZEPPEGNO;EUGENIO INGLESE;E. TORRE;GIORGIO BELLOMO;ALESSANDRO CARRIERO;ERALDO OCCHETTA;ROBERTA MATHEOUD;V. DALÒ;GIOVANNI VACCA;GIUSEPPE DE LUCA;ALESSANDRO STECCO;BARBARA CANNILLO;M. COLOMBO;PIERFRANCESCO FRANCO;MARIA CHIARA BASSI","9;7;6;5;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2","MARCO KRENGLI;MASSIMO SARTORI;PAOLO MARINO;MARCO BRAMBILLA;DEBORA BELDÌ;PATRIZIA ZEPPEGNO;ELENA GROSSINI;E. TORRE;PIERFRANCESCO FRANCO;GIANLUCA AIROLDI;MAURO CAMPANINI;GIORGIO BELLOMO;ALESSANDRO CARRIERO;EUGENIO INGLESE;V. DALÒ;ALESSANDRO STECCO;ELISA RONDANO;GABRIELE DELL’ERA;ROBERTA MATHEOUD;GIOVANNI VACCA","1.29;1;0.89;0.84;0.78;0.71;0.67;0.62;0.53;0.5;0.5;0.49;0.47;0.45;0.45;0.44;0.42;0.42;0.41;0.4","ANDREI IVASHYNKA;GEIR BRÅTHEN;MATTI HILLBOM;MAURIZIO LEONE;R. GALVIN;RADU TĂNĂSESCU;PAOLO MARINO;GIORGIO BELLOMO;GIUSEPPE DE LUCA;ETTORE CASSETTI;GIOEL GABRIO SECCO;LORENZO COPPO;LUCA VENEGONI;MONICA VERDOIA;SERGIO IORIO;MARCO BRAMBILLA;MARCO KRENGLI;ERALDO OCCHETTA;EUGENIO INGLESE;LETIZIA DEANTONIO","588;588;588;588;588;588;398;272;263;228;228;228;228;228;228;217;203;153;139;133","MAURIZIO LEONE;GIORGIO BELLOMO;PAOLO MARINO;MARCO BRAMBILLA;MARCO KRENGLI;GIUSEPPE DE LUCA;LETIZIA DEANTONIO;EUGENIO INGLESE;ELISA RONDANO;GABRIELE DELL’ERA;BARBARA CANNILLO;LUCIA TURRI;MARIA CHIARA BASSI;ERALDO OCCHETTA;ETTORE CASSETTI;GIOEL GABRIO SECCO;LORENZO COPPO;LUCA VENEGONI;MATTEO SANTAGOSTINO;MONICA VERDOIA","588;272;246;207;195;145;133;131;124;124;121;121;121;119;110;110;110;110;110;110","MARCO KRENGLI;MARCO BRAMBILLA;DEBORA BELDÌ;E. TORRE;ELENA GROSSINI;GIORGIO BELLOMO;PAOLO MARINO;PATRIZIA ZEPPEGNO;EUGENIO INGLESE;ALESSANDRO STECCO;ALESSANDRO CARRIERO;ANTONINA PARAFIORITI;BARBARA CANNILLO;CARLO TERRONE;E. MONÈS;ELISA RONDANO;ERALDO OCCHETTA;F. RESSICO;G. LOI;G. MARCHIORO","8;6;5;4;4;4;4;4;3;3;2;2;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;PSYCHOLOGY;GEOGRAPHY;GEOLOGY;MATERIALS SCIENCE;POLITICAL SCIENCE;SOCIOLOGY","41;7;7;5;4;4;3;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;NUCLEAR MEDICINE;BIOCHEMISTRY;ENDOCRINOLOGY;PATHOLOGY;PSYCHIATRY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;MICROBIOLOGY;ONCOLOGY;ANATOMY;GENETICS;PHARMACOLOGY;UROLOGY;ARTIFICIAL INTELLIGENCE;BIOMEDICAL ENGINEERING;CELL BIOLOGY;COMPUTER NETWORK;OPTICS;PEDIATRICS;QUANTUM MECHANICS","31;10;9;9;8;5;5;5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2","CANCER;RADIATION THERAPY;DISEASE;POPULATION;ATRIAL FIBRILLATION;DIABETES MELLITUS;APOPTOSIS;ASYNCHRONOUS COMMUNICATION;CONCOMITANT;CORONARY ARTERY DISEASE;ENCEPHALOPATHY;GENE;IMAGING PHANTOM;IN VITRO;MYOCARDIAL INFARCTION;NITRIC OXIDE;PHARMACOKINETICS;PLATELET;POSITRON EMISSION TOMOGRAPHY;SCANNER;SCHIZOPHRENIA (OBJECT-ORIENTED PROGRAMMING);VENTRICLE","7;6;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;PROSTATE CANCER;ASYNCHRONY (COMPUTER PROGRAMMING);CARDIOVERSION;CORRECTION FOR ATTENUATION;GENOTYPE;MARITAL STATUS;ABDOMINAL TRAUMA;ABSORBED DOSE;ACUTE TOXICITY;AMOXICILLIN;ANAL CANCER;ANTIDEPRESSANT;APATHY;APOLIPOPROTEIN B;ATRIUM (ARCHITECTURE);AUTOPHAGY;BIODISTRIBUTION;BIPOLAR DISORDER;BRIEF PSYCHIATRIC RATING SCALE;BURULI ULCER;C-REACTIVE PROTEIN;CARDIOPROTECTION;CATATONIA;CENSUS;CEREBRAL BLOOD VOLUME;CLOPIDOGREL;COCHRANE LIBRARY;COLONY-FORMING UNIT;COLORECTAL CANCER;CYTOCHROME P450;CYTOTOXICITY;DIABETIC NEPHROPATHY;DIASTOLE;DIFFUSION MRI;EFFECTIVE DIFFUSION COEFFICIENT;EJECTION FRACTION;EXOTOXIN;GLOBAL ASSESSMENT OF FUNCTIONING;HACAT;HALOPERIDOL;HEART RATE;HEK 293 CELLS;HYDATID CYST;HYPERURICEMIA;HYPERVITAMINOSIS;INSULIN RESISTANCE;KERATINOCYTE;LACTIC ACID;LACTOBACILLUS;LEFT ATRIUM;LEVOSIMENDAN;LIPID PROFILE;LIVER BIOPSY;METABOLIC SYNDROME;METASTASIS;MYCOBACTERIUM ULCERANS;NEONATAL SEPSIS;NEPHROPATHY;OBSTRUCTIVE CARDIOMYOPATHY;ORGAN DYSFUNCTION;P WAVE;PERCUTANEOUS CORONARY INTERVENTION;PHYLOGENETIC TREE;PHYLOGENETICS;PITUITARY ADENOMA;PITUITARY GLAND;PLACEBO;PLASMA CLEARANCE;PROBIOTIC;PROCALCITONIN;PROGRAMMED CELL DEATH;PROSTATE;RADIATION ONCOLOGY;RADIOBIOLOGY;RETINOL;SEPTIC SHOCK;SIGMOID COLON;SPLENECTOMY;STUPOR;SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;THERAPEUTIC DRUG MONITORING;THIAMINE DEFICIENCY;THYROID CARCINOMA;THYROIDECTOMY;UNIVARIATE ANALYSIS;UROKINASE RECEPTOR;VASCULAR ACCESS;VENTRICULAR ANEURYSM;VENTRICULOTOMY;VIABILITY ASSAY;VIRULENCE;WERNICKE ENCEPHALOPATHY;WHITE MATTER","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ELECTRICAL CARDIOVERSION;PROSTATECTOMY;ALIEN;BIFIDOBACTERIUM;CARDIAC RESYNCHRONIZATION THERAPY;CLINICAL GLOBAL IMPRESSION;CYP2D6;FRACTIONAL ANISOTROPY;HORMONAL THERAPY;HYPERVITAMINOSIS A;INTERATRIAL SEPTUM;LACTOBACILLUS PLANTARUM;MANAGEMENT OF PROSTATE CANCER;MANIA;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;MOLECULAR EPIDEMIOLOGY;P2Y12;PHARMACOGENETICS;PITUITARY APOPLEXY;PRASUGREL;SCALE FOR THE ASSESSMENT OF NEGATIVE SYMPTOMS;SEPTAL MYECTOMY;SUPAR;THIENOPYRIDINE;TICLOPIDINE;VENLAFAXINE;WERNICKE'S ENCEPHALOPATHY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;MIDDLE AGED;AGED;ATRIAL FIBRILLATION;TOMOGRAPHY, X-RAY COMPUTED;CORONARY ARTERY DISEASE;NEOPLASM RECURRENCE, LOCAL;POSITRON-EMISSION TOMOGRAPHY;RADIOPHARMACEUTICALS;RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;ADULT;AGED, 80 AND OVER;BONE NEOPLASMS;ADENOCARCINOMA, FOLLICULAR;BREAST NEOPLASMS;CARCINOMA;ORGANOMETALLIC COMPOUNDS","28;17;16;13;13;12;12;10;8;7;7;7;7;6;6;6;5;5;5;5","ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PROSTATE CANCER RESEARCH AND TREATMENT;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BIOLOGICAL, EPIDEMIOLOGICAL, AND CLINICAL ASPECTS OF ECHINOCOCCOSIS;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CANCER OF UNKNOWN PRIMARY SITE;COLORECTAL CANCER RESEARCH AND TREATMENT;DEVELOPMENT AND APPLICATIONS OF RADIOPHARMACEUTICALS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND MANAGEMENT OF WERNICKE-KORSAKOFF SYNDROME;DIAGNOSIS, TREATMENT, AND EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIAL DISEASES;EFFECTS OF KETOGENIC DIET ON HEALTH;EFFICACY AND SAFETY OF ELECTROCONVULSIVE THERAPY;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HEPATITIS C INFECTION AND TREATMENT","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ASYNCHRONY (COMPUTER PROGRAMMING);ATRIAL FIBRILLATION;CANCER IMAGING;CARDIAC ELECTROPHYSIOLOGY;CONCOMITANT;CORRECTION FOR ATTENUATION;DIABETES;ELECTRICAL CARDIOVERSION;ENDOTHELIAL DYSFUNCTION;FEATURE EXTRACTION;IMAGE-GUIDED RADIOTHERAPY;MARITAL STATUS;NEUROIMAGING;TREATMENT;ALCOHOL ABUSE;ALCOHOLIC NEUROPATHY;ANAL CANCER;ANTIBIOTIC THERAPY;APATHY;ARRHYTHMIA DETECTION","2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","BREAST CANCER;ARTERY DISEASE;ATRIAL ASYNCHRONY;ATRIAL FIBRILLATION;CORONARY ARTERY;DISEASE RESULTS;ELECTRICAL CARDIOVERSION;FDG-PETCT IMAGING;NITRIC OXIDE;PRELIMINARY DATA;PROSPECTIVE STUDY;PROSTATE CANCER;TARGET VOLUME;VOLUME DELINEATION;ABSORBED DOSE;ACUTE PATIENTS;ADVANCED PROSTATE;ALIEN HAND;AMOXICILLIN PLASMA;ANAL CARCINOMA;ANTHROPOMORPHIC THORACIC;APOBAPOA-I RATIO;BIOGRAPH HI-REZ;BRAIN TISSUE;C-REACTIVE PROTEIN;CANCER ANALYSIS;CANCER FEASIBILITY;CANCER INTER-OBSERVER;CANCER UNDERGOING;CARDIAC CYCLE","3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TYPE STRAINS;PHYLOGENETIC TYPE;SEPTIC SHOCK;CONVENTIONAL FRACTIONATION;ANAL CANAL;IRON DEPLETION;LA MECHANICAL;LATE TOXICITY;MILD IRON;PETCT IMAGING;TARGET VOLUME;VENTRICULAR SEPTAL;ACUTE CORONARY;AF RECURRENCE;ANTIVIRAL THERAPY;BLUNT ABDOMINAL;BURULI ULCER;CELL CARCINOMA;ENDOCRINE PROFILE;FUSED IMAGES;HAEMATIC ISOLATES;HISTOLOGICAL IMPROVEMENT;HUMAN KERATINOCYTE;HYPOFRACTIONATED RADIOTHERAPY;INDUCES APOPTOSIS;LA VOLUME;LOGISTIC ANALYSIS;LV DIASTOLIC;MYCOLACTONE AB;OPN SUPAR","7;6;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,4.38,2079.88,10.62,3,0.25,80.08,0,0,2,1,5,0,2,2,0,7,1,0,0,0,0,0,0,11,1,0,8,4,0,0,0,0,0,0,0,0,"Italy;Germany;Spain","7;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3203 DENTISTRY;3209 NEUROSCIENCES;3210 NUTRITION AND DIETETICS;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4207 SPORTS SCIENCE AND EXERCISE","11;4;3;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;NEUROSCIENCES;PATIENT SAFETY;RARE DISEASES;AGING;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BRAIN DISORDERS;REHABILITATION;CARDIOVASCULAR;LUNG;LYMPHOMA;NEURODEGENERATIVE;NUTRITION;ORPHAN DRUG;PARKINSON'S DISEASE;PEDIATRIC","8;7;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER;NEUROLOGICAL;CARDIOVASCULAR;INJURIES AND ACCIDENTS","3;3;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY","6;1;1","LEUKEMIA / LEUKAEMIA;HODGKIN'S DISEASE;NON-HODGKIN'S LYMPHOMA;SARCOMA","2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","3;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"PUBLIC LIBRARY OF SCIENCE","6","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3103 ECOLOGY;3105 GENETICS;3204 IMMUNOLOGY;4901 APPLIED MATHEMATICS","5;4;3;2;2;1;1","NEUROSCIENCES;BRAIN DISORDERS;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;AUTOIMMUNE DISEASE;CLINICAL RESEARCH;GENETICS;PREVENTION","4;2;2;2;1;1;1;1","NEUROLOGICAL","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","BASIC SCIENCE;PUBLIC HEALTH","1;1",NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2011,61,7.77049180327869,2.9344262295082,0.655737704918033,0.491803278688525,0.721311475409836,1.84536082474227,1.48148148148148,2,1.51724137931034,0.327868852459016,2,21,10,17,7,0.34,0.16,0.28,0.11,22.59,0.531104798957594,NA,0.213114754098361,1,0.48,0.447,0.437,0.398,"ARNALDO BENECH;MATTEO BRUCOLI;FRANCESCO ARCURI;MARIANGELA GIARDA;MARCO KRENGLI;VITTORIO GEBBIA;OSCAR ALABISO;STEFANO ANDREONI;MASSIMO DI MAÏO;ANGELO DINOTA;FABIO PUGLISI;M. DEL PIANO;MARK SPEAKMAN;ROBERTA MATHEOUD;VESSELINA KROUMOVA;STEFANIA GORI;MESUT REMZI;ORAZIO CAFFO;ELENA GROSSINI;PAOLO GONTERO","13;11;11;6;6;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ARNALDO BENECH;MATTEO BRUCOLI;FRANCESCO ARCURI;MARIANGELA GIARDA;STEFANO ANDREONI;E DONEGANI;MARCO KRENGLI;PAOLO MARINO;GIUSEPPE POGLIO;ERALDO OCCHETTA;MIRIAM BORTNIK;VESSELINA KROUMOVA;ELISA GOBBATO;LETIZIA DEANTONIO;MARIO MIGLIARIO;ALESSANDRO VOLPE;ROBERTA MATHEOUD;MARCO BRAMBILLA;NICOLA BARAGIOTTA;ELENA GROSSINI","3.25;2.8;2.58;1.57;1.39;1;0.82;0.78;0.65;0.53;0.53;0.51;0.51;0.5;0.5;0.49;0.48;0.48;0.45;0.43","ARNALDO BENECH;MATTEO BRUCOLI;FRANCESCO ARCURI;MARIANGELA GIARDA;MARCO KRENGLI;OSCAR ALABISO;STEFANO ANDREONI;M. DEL PIANO;ROBERTA MATHEOUD;VESSELINA KROUMOVA;ELENA GROSSINI;ALESSANDRO VOLPE;CLAUDIO MOLINARI;GIOVANNI VACCA;PHILIPPE PRIMO CAIMMI;PAOLO MARINO;MAURIZIO LEONE;LETIZIA DEANTONIO;MARIO MIGLIARIO;GIUSEPPE POGLIO","13;11;11;6;6;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ARNALDO BENECH;MATTEO BRUCOLI;FRANCESCO ARCURI;MARIANGELA GIARDA;STEFANO ANDREONI;E DONEGANI;MARCO KRENGLI;PAOLO MARINO;GIUSEPPE POGLIO;ERALDO OCCHETTA;MIRIAM BORTNIK;VESSELINA KROUMOVA;ELISA GOBBATO;LETIZIA DEANTONIO;MARIO MIGLIARIO;ALESSANDRO VOLPE;ROBERTA MATHEOUD;MARCO BRAMBILLA;NICOLA BARAGIOTTA;ELENA GROSSINI","3.25;2.8;2.58;1.57;1.39;1;0.82;0.78;0.65;0.53;0.53;0.51;0.51;0.5;0.5;0.49;0.48;0.48;0.45;0.43","ARNALDO BENECH;FRANCESCO ARCURI;MATTEO BRUCOLI;MARCO KRENGLI;CARLO OLIVIERI;GIORGIO CONTI;PAOLO NAVALESI;ROBERTA COSTA;MAURIZIO LEONE;NADIA BARIZZONE;MARIANGELA GIARDA;ALESSANDRO SALVIATI;DONATO GEMMATI;ELISA ORIOLI;ELVEZIA MARIA PARABOSCHI;G ZERI;GIULIA SOLDÀ;MARIA DONATA BENEDETTI;ROBERTA CAVENAGHI;ROSANNA ASSELTA","323;295;295;175;162;162;162;162;139;117;110;105;105;105;105;105;105;105;105;105","ARNALDO BENECH;MATTEO BRUCOLI;FRANCESCO ARCURI;CARLO OLIVIERI;MARCO KRENGLI;MAURIZIO LEONE;MARIANGELA GIARDA;ROBERTA CAVENAGHI;DAVIDE COLOMBO;GIANMARIA CAMMAROTA;ROSANNA VASCHETTO;GIUSEPPINA GAMBARO;LAURA MASINI;ALESSIO BARICICH;PHILIPPE PRIMO CAIMMI;MARCO RUDONI;MATTEO NICOLOTTI;PAOLO MARINO;ALESSANDRO CARRIERO;CLAUDIO MOLINARI","307;295;279;162;129;127;110;105;83;83;83;73;73;66;58;57;50;49;47;47","ARNALDO BENECH;MATTEO BRUCOLI;FRANCESCO ARCURI;MARIANGELA GIARDA;MARCO KRENGLI;OSCAR ALABISO;ELISA GOBBATO;GIUSEPPE POGLIO;PAOLO MARINO;PHILIPPE PRIMO CAIMMI;VESSELINA KROUMOVA;GIACOMO FORTINA;M. DEL PIANO;LETIZIA DEANTONIO;ALESSANDRO VOLPE;CARLO OLIVIERI;CLAUDIO MOLINARI;DAVID MARY;DEBORA BELDÌ;ELENA GROSSINI","12;11;10;6;5;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;PHYSICS;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;PSYCHOLOGY;SOCIOLOGY;BUSINESS;GEOLOGY","56;19;10;9;6;5;4;2;2;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;GENETICS;ONCOLOGY;ANATOMY;CARDIOLOGY;PATHOLOGY;ANESTHESIA;BOTANY;DENTISTRY;IMMUNOLOGY;PHARMACOLOGY;ARTIFICIAL INTELLIGENCE;BIOINFORMATICS;FAMILY MEDICINE;GASTROENTEROLOGY;GEOMETRY;NUCLEAR MEDICINE;AEROSPACE ENGINEERING;BIOCHEMISTRY;CELL BIOLOGY;COMPUTER SECURITY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GYNECOLOGY;MEDICAL PHYSICS;MICROBIOLOGY;ORTHODONTICS","30;16;10;9;7;6;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","CANCER;BACTERIA;GENE;HEART FAILURE;POPULATION;ANTIBIOTICS;AUTHORIZATION;DEFORMITY;FORMULARY;IDENTIFICATION (BIOLOGY);IMAGE (MATHEMATICS);MAGNETIC RESONANCE IMAGING;MARKETING AUTHORIZATION;MYOCARDIAL INFARCTION;ORBIT (DYNAMICS);PRIOR AUTHORIZATION;RADIATION THERAPY;RECEPTOR;ADSORPTION;ALTERNATIVE MEDICINE;ANALYTICAL CHEMISTRY (JOURNAL);ANTIGEN;BIOPSY;BLOOD PRESSURE;CARCINOMA;COHORT;CONFOUNDING;DISEASE;DRUG;ENDOSCOPY;FACIAL NERVE;FACIAL SKELETON;GENUS;GLOMUS TUMOR;HEMODYNAMICS;IN VITRO;ION;LOGISTIC REGRESSION;MASS SPECTROMETRY;MATRIX (CHEMICAL ANALYSIS);MAXILLA;MORTALITY RATE;ORBITAL FRACTURE;ORTHOGNATHIC SURGERY;PARAGANGLIOMA;PAROTID GLAND;RETROSPECTIVE COHORT STUDY;THYROID;WEAKNESS","10;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;PROSTATE;PROSTATE CANCER;BREAST CANCER;CARDIAC FUNCTION CURVE;CARDIAC OUTPUT;COLORECTAL CANCER;DESORPTION;EPIDERMAL GROWTH FACTOR RECEPTOR;HEART RATE;IONIZATION;MANDIBLE (ARTHROPOD MOUTHPART);ACUTE CORONARY SYNDROME;ADRENERGIC RECEPTOR;AGONIST;ALCOHOL CONSUMPTION;ALLELE;AMELOBLASTOMA;ANTIFUNGAL DRUGS;AUTOCRINE SIGNALLING;BISPHOSPHONATE;BLOOD CULTURE;BUCCAL FAT PAD;CARDIOGENIC SHOCK;CARDIOMYOPATHY;CARDIOPROTECTION;CASE FATALITY RATE;CELL MIGRATION;CHOLECYSTOKININ;CISPLATIN;CLOSTRIDIUM;CLOSTRIDIUM DIFFICILE;ENOPHTHALMOS;EUROPEAN COMMISSION;EXPECTATION–MAXIMIZATION ALGORITHM;FIBULA;FIXATION (POPULATION GENETICS);FLUORODEOXYGLUCOSE;GADOBUTROL;GASTRIN;GEMCITABINE;GENE EXPRESSION;GENETIC DISORDER;GENETIC DIVERSITY;GESTATION;GESTATIONAL AGE;GRAM STAINING;GRAM-POSITIVE BACTERIA;HUMAN LEUKOCYTE ANTIGEN;IMAGE QUALITY;IMAGE REGISTRATION;IMAGE SEGMENTATION;IMPLANTABLE LOOP RECORDER;ITEM ANALYSIS;ITEM RESPONSE THEORY;ITRACONAZOLE;KERATINOCYTE;KERATOCYSTIC ODONTOGENIC TUMOR;LEVOSIMENDAN;LIPOSARCOMA;LIVER BIOPSY;MEAN AIRWAY PRESSURE;MEAN CORPUSCULAR VOLUME;MELATONIN RECEPTOR;MERKEL CELL CARCINOMA;METASTASIS;MICROBIOLOGICAL CULTURE;MICROORGANISM;MICRORNA;MINOR SALIVARY GLANDS;NEOPLASM STAGING;NODULAR FASCIITIS;OSSEOINTEGRATION;PALSY;PERCUTANEOUS CORONARY INTERVENTION;PERIPHERAL BLOOD MONONUCLEAR CELL;PHYLOGENETIC TREE;PLACEBO;PLEOMORPHIC ADENOMA;PRESSURE SUPPORT VENTILATION;QUALITY ASSURANCE;RADICAL SURGERY;RENAL VEIN;RESPIRATORY MINUTE VOLUME;ROSIGLITAZONE;SEIZURE TYPES;SORAFENIB;SPASTIC;STANDARDIZED UPTAKE VALUE;SUMMARY OF PRODUCT CHARACTERISTICS;SUNITINIB;SUPEROXIDE;SYPHILIS;THRESHOLDING;THYROID CANCER;UNIVARIATE ANALYSIS;UPPER GASTROINTESTINAL BLEEDING;VASCULAR RESISTANCE","3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PCA3;ERLOTINIB;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;PROSTATE BIOPSY;SINGLE-NUCLEOTIDE POLYMORPHISM;ABDUCENS NERVE;AMPLIFIED FRAGMENT LENGTH POLYMORPHISM;CARBOHYDRATE DEFICIENT TRANSFERRIN;CARBOPLATIN;CARDIAC INDEX;CETUXIMAB;CHOLECYSTOKININ B RECEPTOR;CHOLECYSTOKININ RECEPTOR;CROSSOVER STUDY;FAMILIAL ADENOMATOUS POLYPOSIS;FOLD CHANGE;GENE EXPRESSION PROFILING;GSTP1;HAPLOTYPE;MULTILOCUS SEQUENCE TYPING;POLYTOMOUS RASCH MODEL;PRIMARY TUMOR;RESPIRATORY RATE;RESTRICTION FRAGMENT LENGTH POLYMORPHISM;TIME-OF-FLIGHT MASS SPECTROMETRY;TNM STAGING SYSTEM","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;ADULT;FEMALE;MIDDLE AGED;;NERVOUS SYSTEM NEOPLASMS;PARAGANGLIOMA, EXTRA-ADRENAL;ITALY;TOMOGRAPHY, X-RAY COMPUTED;ANTINEOPLASTIC AGENTS;AGED;RETROSPECTIVE STUDIES;CISPLATIN;MANDIBULAR NEOPLASMS;ORBITAL FRACTURES;POSITRON-EMISSION TOMOGRAPHY;RECONSTRUCTIVE SURGICAL PROCEDURES;TREATMENT OUTCOME;VASODILATOR AGENTS","41;27;23;21;21;15;12;12;11;11;9;8;8;7;7;7;7;7;7;7","EPIDEMIOLOGY AND MANAGEMENT OF MAXILLOFACIAL TRAUMA;MICROBIAL IDENTIFICATION AND DIAGNOSIS;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;ECONOMIC BURDEN OF CANCER TREATMENT;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;PHEOCHROMOCYTOMA AND PARAGANGLIOMA;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;BIOLOGICAL BASIS AND CLINICAL MANAGEMENT OF SYPHILIS;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLASSIFICATION AND MANAGEMENT OF ODONTOGENIC TUMORS;CLOSTRIDIUM DIFFICILE INFECTION AND TREATMENT;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;DIVERSITY AND EVOLUTION OF FUNGAL PATHOGENS;ECONOMICS OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT","5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;DRUG PRICING;FORMULARY;IDENTIFICATION (BIOLOGY);MARKETING AUTHORIZATION;MICROORGANISM IDENTIFICATION;ORBIT (DYNAMICS);PRIOR AUTHORIZATION;AVAILABILITY OF MEDICINES;BACTERIAL IDENTIFICATION;FACIAL FRACTURES;FACIAL SKELETON;GLOMUS TUMOR;IMAGING;MALDI-TOF MS;MALIGNANT GLOMUS TUMOR;MANDIBLE (ARTHROPOD MOUTHPART);MANDIBULAR FRACTURES;MATRIX (CHEMICAL ANALYSIS);MATRIX-ASSISTED LASER DESORPTION IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY","4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","PROSTATE CANCER;ANTI-CANCER DRUGS;ITALIAN SOCIETY;MEDICAL ONCOLOGY;ONCOLOGY AIOM;REGIONS RESULTS;BLOOD CULTURE;BREAST CANCER;CANCER GENE;CARDIAC FAILURE;CELL CARCINOMA;DIRECT IDENTIFICATION;EXPERT OPINION;GENE PCA;GLOMUS VAGALE;ITALIAN REGIONS;MALIGNANT PARAGANGLIOMA;MASS SPECTROMETRY;MULTIDISCIPLINARY APPROACH;MULTIPLE SCLEROSIS;NITRIC OXIDE;PATIENT ACCESS;RETROAURICULAR TRANSMEATAL;SURVEY CONDUCTED;TRANSMEATAL APPROACH;ACTIVE SURVEILLANCE;ACUTE CARDIAC;ADAPTIVE THRESHOLDING;ADJUSTED VENTILATORY;ADULT STROKE","4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","SUSCEPTIBILITY TESTING;ANTIFUNGAL SUSCEPTIBILITY;ASA SCORE;BACTERIAL IDENTIFICATION;HUMAN MONOCYTES;MONOCYTEDERIVED MPS;PROTECTIVE EFFECT;VARICEAL UGIH;ADAPTIVE THRESHOLDING;BLOOD CULTURE;BREAST CANCER;CYTOKINE RELEASE;DUODENAL ULCER;GESTATIONAL WEEK;HEALTH STATUS;HEMODYNAMIC SENSORS;NFΚB ACTIVATION;RESPIRATORY RATE;TB RATIO;WOUND HEALING;AIR LEAKS;ANION PRODUCTION;ANTIGEN GDH;CANDIDATE REFERENCE;CELL TYPES;CLINICAL CONDITIONS;CLINICALLY RELEVANT;COMMON ANTIGEN;DEATH NA;DIAGNOSTIC ACCURACY","6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,5.71,1570.14,16.3,5,0.33,47.6,1,0,3,0,3,0,1,7,0,9,5,0,0,0,0,0,0,14,1,0,14,1,0,0,0,0,0,0,0,0,"Italy;Germany;United States;United Kingdom","10;2;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4202 EPIDEMIOLOGY;4203 HEALTH SERVICES AND SYSTEMS","14;6;4;4;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;ATHEROSCLEROSIS;HEART DISEASE - CORONARY HEART DISEASE;HEMATOLOGY;RARE DISEASES;CANCER;LYMPHOMA;NEUROSCIENCES;PATIENT SAFETY;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;TRANSPLANTATION;ALS;BRAIN DISORDERS;BREAST CANCER;CHRONIC PAIN;COMPARATIVE EFFECTIVENESS RESEARCH","11;7;6;6;5;5;5;5;4;3;3;3;2;2;2;1;1;1;1;1","CARDIOVASCULAR;CANCER;NEUROLOGICAL","6;4;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","5;3;3;1;1;1;1","NON-HODGKIN'S LYMPHOMA;BREAST CANCER;LEUKEMIA / LEUKAEMIA;MYELOMA;NOT SITE-SPECIFIC CANCER","2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2012,66,9.87878787878788,3.24242424242424,0.560606060606061,0.409090909090909,0.590909090909091,1.58518518518519,1.23333333333333,1.58823529411765,1.3448275862069,0.363636363636364,1,29,13,12,6,0.44,0.2,0.18,0.09,23.08,0.552470134889787,4.21212121212121,0.181818181818182,1,0.419,0.409,0.432,0.396,"ALESSANDRO CARRIERO;MARCO BRAMBILLA;RITA FOSSACECA;PAOLO MARINO;ARNALDO BENECH;GIUSEPPE GUZZARDI;MATTEO BRUCOLI;OSCAR ALABISO;PIERO BRUSTIA;PAOLO CERINI;FRANCESCO ARCURI;M. DI TERLIZZI;ROBERTA MATHEOUD;MARCO KRENGLI;GIORGIO BELLOMO;ERALDO OCCHETTA;M. DEL PIANO;CARMELO STANCA;LUCIA LEVA;EMANUELE MALATESTA","10;8;6;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3","MIRIAM BORTNIK;ARNALDO BENECH;ALESSANDRO CARRIERO;MARCO BRAMBILLA;MATTEO BRUCOLI;PAOLO MARINO;FRANCESCO ARCURI;RITA FOSSACECA;GIUSEPPE GUZZARDI;OTTAVIO RENA;CATERINA CASADIO;PIERO BRUSTIA;OSCAR ALABISO;ROBERTA MATHEOUD;M. DEL PIANO;PAOLO CERINI;GIORGIO BELLOMO;FABRIZIO GRIVETTO;MARCO KRENGLI;STEFANIA CARMAGNOLA","1.39;1.23;1.19;1.07;1.03;1.01;0.98;0.75;0.75;0.67;0.67;0.63;0.61;0.58;0.57;0.55;0.53;0.5;0.47;0.46","ALESSANDRO CARRIERO;MARCO BRAMBILLA;RITA FOSSACECA;PAOLO MARINO;ARNALDO BENECH;GIUSEPPE GUZZARDI;MATTEO BRUCOLI;OSCAR ALABISO;PIERO BRUSTIA;PAOLO CERINI;FRANCESCO ARCURI;M. DI TERLIZZI;ROBERTA MATHEOUD;MARCO KRENGLI;GIORGIO BELLOMO;ERALDO OCCHETTA;M. DEL PIANO;CARMELO STANCA;LUCIA LEVA;EMANUELE MALATESTA","10;8;6;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3","MIRIAM BORTNIK;ARNALDO BENECH;ALESSANDRO CARRIERO;MARCO BRAMBILLA;MATTEO BRUCOLI;PAOLO MARINO;FRANCESCO ARCURI;RITA FOSSACECA;GIUSEPPE GUZZARDI;OTTAVIO RENA;CATERINA CASADIO;PIERO BRUSTIA;OSCAR ALABISO;ROBERTA MATHEOUD;M. DEL PIANO;PAOLO CERINI;GIORGIO BELLOMO;FABRIZIO GRIVETTO;MARCO KRENGLI;STEFANIA CARMAGNOLA","1.39;1.23;1.19;1.07;1.03;1.01;0.98;0.75;0.75;0.67;0.67;0.63;0.61;0.58;0.57;0.55;0.53;0.5;0.47;0.46","OSCAR ALABISO;ALESSANDRO CARRIERO;GIANNI BONA;RENZO BOLDORINI;ANDREA MAGRÌ;ANNA MARIA NICOSIA;EILI HUHTAMO;FRANCESCO RIVASI;LUCA SERVINO;MARIA GRAZIA CROBU;OLLI VAPALAHTI;PAOLO RAVANINI;ROSALBA MINISINI;SARA ALLEGRINI;UMBERTO MIGLIO;VALENTINA ILARIA;CARLO DE SANCTIS;EGLE PERISSINOTTO;F. RIGON;FABIO BUZI","177;168;138;138;121;121;121;121;121;121;121;121;121;121;121;121;120;120;120;120","OSCAR ALABISO;ALESSANDRO CARRIERO;GIANNI BONA;ANNA MARIA NICOSIA;LUCA SERVINO;MARIA GRAZIA CROBU;PAOLO RAVANINI;VALENTINA ILARIA;MARCO BRAMBILLA;GIANMARIA CAMMAROTA;CATERINA CASADIO;OTTAVIO RENA;GIUSEPPE GUZZARDI;PAOLO CERINI;RITA FOSSACECA;ARNALDO BENECH;PIERO BRUSTIA;GAIA DONATA OGGIONI;LETIZIA MAZZINI;FRANCESCO ARCURI","177;139;138;121;121;121;121;121;105;102;101;101;99;99;99;94;92;84;84;81","ALESSANDRO CARRIERO;MARCO BRAMBILLA;ARNALDO BENECH;OSCAR ALABISO;PIERO BRUSTIA;GIUSEPPE GUZZARDI;PAOLO CERINI;RITA FOSSACECA;FRANCESCO ARCURI;M. DI TERLIZZI;MATTEO BRUCOLI;PAOLO MARINO;CARMELO STANCA;EMANUELE MALATESTA;I. DI GESÙ;M. DEL PIANO;MARCO KRENGLI;CATERINA CASADIO;D MONIACI;GIANMARIA CAMMAROTA","7;6;6;6;5;5;5;5;4;4;4;4;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;PHYSICS;ENGINEERING;CHEMISTRY;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;HISTORY;MATERIALS SCIENCE;SOCIOLOGY","62;14;11;6;3;3;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;RADIOLOGY;GENETICS;ONCOLOGY;NUCLEAR MEDICINE;PATHOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;ASTRONOMY;MECHANICAL ENGINEERING;MICROBIOLOGY;OPTICS;PEDIATRICS;ANESTHESIA;BIOCHEMISTRY;BIOMEDICAL ENGINEERING;CANCER RESEARCH;IMMUNOLOGY;INTENSIVE CARE MEDICINE;MEDICAL PHYSICS","43;20;13;13;9;8;7;7;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","CANCER;GENE;ANEURYSM;HEART FAILURE;POPULATION;STENT;CHEMOTHERAPY;ADJUVANT;BACTERIA;DIABETES MELLITUS;DISEASE;INCIDENCE (GEOMETRY);LESION;LUNG;LUNG CANCER;MYOCARDIAL INFARCTION;PERFUSION;RETROSPECTIVE COHORT STUDY;STENOSIS;VIRUS","11;6;5;5;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3","ENDOVASCULAR TREATMENT;EJECTION FRACTION;ABDOMINAL AORTIC ANEURYSM;BREAST CANCER;CLOPIDOGREL;DOCETAXEL;ENCEPHALITIS;EPIDERMAL GROWTH FACTOR RECEPTOR;FUNGEMIA;GENOTYPE;RESTENOSIS;ACUTE CORONARY SYNDROME;ACUTE TOXICITY;ADENOCARCINOMA;ADJUVANT RADIOTHERAPY;ALLELE;AMYOTROPHIC LATERAL SCLEROSIS;AORTIC ANEURYSM;AUTOPHAGY;BACTERIOLOGY;BASAL CELL CARCINOMA;BERG BALANCE SCALE;BETA OXIDATION;BEVACIZUMAB;BLOOD CULTURE;BYPASS GRAFTING;CANDIDA AURIS;CARCINOGENESIS;CARDIOMYOPATHY;CEFOTAXIME;CEFTRIAXONE;CERVICAL CANCER;CESAREAN DELIVERY;CHEMOKINE;CHOLECALCIFEROL;CHROMOSOME;CHRONIC CONSTIPATION;CISPLATIN;COLORECTAL CANCER;COMMON ILIAC ARTERY;CONTRAINDICATION;CULEX;CULEX PIPIENS;DEHYDROGENASE;DEMENTIA;DIFFUSION MRI;DIGITAL SUBTRACTION ANGIOGRAPHY;DIGOXIN;DIPHTHERIA;DOSIMETER;ELECTROCARDIOGRAPHY IN MYOCARDIAL INFARCTION;EPIGENETICS;FIBROBLAST GROWTH FACTOR;FLAVIVIRUS;GAIT TRAINING;GENE EXPRESSION;GLYCINE;GRAM STAINING;GROWTH FACTOR;HAZARD RATIO;HEART RATE;HEMIPARESIS;HEPATOCYTE GROWTH FACTOR;HIP FLEXION;HYPOGLYCEMIA;IMMUNIZATION;INTERLEUKIN;INTIMA-MEDIA THICKNESS;IONIZING RADIATION;LACTIC ACID;LAXATIVE;MEAN PLATELET VOLUME;MEASLES;MENSTRUAL CYCLE;METASTASIS;MULTICENTER STUDY;MYOCARDIAL PERFUSION IMAGING;NEURORADIOLOGY;OVARIAN CANCER;PARACENTESIS;PARKINSON'S DISEASE;PEPTIDE NUCLEIC ACID;PERFUSION SCANNING;PHENOTYPE;PLACEBO;PLATELET ACTIVATION;PNEUMONECTOMY;PNEUMONITIS;POLIOVIRUS;POLYMERASE CHAIN REACTION;PRESSURE SUPPORT VENTILATION;PROGRAMMED CELL DEATH;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;PROSTATE CANCER;PSEUDOANEURYSM;RENAL ARTERY;RESPIRATORY DISEASE;SACCHAROMYCES CEREVISIAE;SCINTILLATION;SECRETIN;SINUS RHYTHM;SKIN CANCER;SOCIOECONOMIC STATUS;ST ELEVATION;ST SEGMENT;STAIN;TETANUS;THERAPEUTIC ENDOSCOPY;THYMECTOMY;THYROGLOBULIN;THYROID CANCER;THYROIDITIS;TIDAL VOLUME;TOXOCARA CANIS;TOXOCARIASIS;UPPER GASTROINTESTINAL BLEEDING;VASCULAR ENDOTHELIAL GROWTH FACTOR;VIRAL DISEASE;VITAMIN D DEFICIENCY;WHOLE BODY IMAGING;YERSINIA ENTEROCOLITICA","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ENDOVASCULAR ANEURYSM REPAIR;ERLOTINIB;ACYL COA DEHYDROGENASE;AMPLICON;ANTHRACYCLINE;ANTIPLATELET DRUG;AORTIC RUPTURE;BASIC FIBROBLAST GROWTH FACTOR;BENIGN EARLY REPOLARIZATION;BOOSTER DOSE;CARBOPLATIN;CERVICAL INTRAEPITHELIAL NEOPLASIA;DIGITOXIN;ELECTRICAL CARDIOVERSION;EXTRAPLEURAL PNEUMONECTOMY;FLAVIVIRIDAE;FLUORESCENCE IN SITU HYBRIDIZATION;FRONTOTEMPORAL DEMENTIA;GATED SPECT;HAPLOTYPE;HORMONAL THERAPY;HPV INFECTION;HYPERGLYCINEMIA;INACTIVATED POLIOVIRUS VACCINE;JAPANESE ENCEPHALITIS;KRAS;MICROARRAY;MITOPHAGY;PEAK INSPIRATORY PRESSURE;PENETRANCE;PLEURAL DISEASE;PRIMARY TUMOR;RADIOLUMINESCENCE;REACTOGENICITY;RENAL ARTERY STENOSIS;RESPIRATORY RATE;SINGLE-NUCLEOTIDE POLYMORPHISM;SPECKLE TRACKING ECHOCARDIOGRAPHY;TAKOTSUBO SYNDROME;TAMOXIFEN;TAXANE;TRASTUZUMAB;TRINUCLEOTIDE REPEAT EXPANSION","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;;ADULT;TREATMENT OUTCOME;POSTOPERATIVE COMPLICATIONS;ITALY;AGED, 80 AND OVER;PROSPECTIVE STUDIES;ATRIAL FIBRILLATION;TIME FACTORS;ADOLESCENT;BLOOD VESSEL PROSTHESIS IMPLANTATION;RETROSPECTIVE STUDIES;TICLOPIDINE;ENDOVASCULAR PROCEDURES;HEART","43;35;35;28;27;19;15;15;13;12;9;9;8;8;7;7;7;7;6;6","ADVANCEMENTS IN LUNG CANCER RESEARCH;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;ATRIAL FIBRILLATION;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;METABOLIC DISORDERS AND BIOCHEMICAL GENETICS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHRONIC RHINOSINUSITIS AND NASAL POLYPS;CLASSIFICATION AND INTERVENTIONS FOR CEREBRAL PALSY;CRANIOFACIAL RECONSTRUCTION TECHNIQUES;CRISIS RESOLUTION AND HOME TREATMENT TEAMS IN MENTAL HEALTH;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND MANAGEMENT OF POLYCYSTIC OVARY SYNDROME","3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","ANEURYSM SCREENING;CARDIOVASCULAR EVALUATION;TREATMENT;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY;CUMULATIVE DOSE;DIFFUSION-WEIGHTED IMAGING;ECHOCARDIOGRAPHY;ENDOVASCULAR ANEURYSM REPAIR;ENDOVASCULAR REPAIR;FUNGEMIA;MANDIBULAR FRACTURES;NEOADJUVANT THERAPY;NONINVASIVE VENTILATION;POPLITEAL ARTERY;REGIMEN;STRENGTH TRAINING;STROKE (ENGINE);TREATMENT GUIDELINES;ACADEMIC YEAR","3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","ENDOVASCULAR TREATMENT;AORTIC ANEURYSM;ARTERY ANEURYSMS;ATRIAL FIBRILLATION;BLOOD CULTURES;COMPARING ERLOTINIB;IDENTIFICATION DIRECTLY;III TRIAL;ITALIAN EXPERIENCE;LEFT ATRIAL;LUNG CANCER;MYOCARDIAL INFARCTION;NON-SMALL-CELL LUNG;NSCLC PATIENTS;PHASE III;POSITIVE BLOOD;SECOND-LINE TREATMENT;TRIAL COMPARING;WILD-TYPE WT;WT EGFR;YEAST IDENTIFICATION;ABDOMINAL AORTIC;ACCIDENTAL DIAGNOSIS;ACCIDENTAL DIGITOXIN;ACID FLUORESCENCE;ACQUISITION TIME;ACUTE CORONARY;ACUTE INFERIOR;ACUTE RESPIRATORY;ACUTE SYMPTOMATIC","4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","SUPINE POSITION;PRONE POSITION;LEFT SIDED;LEFT ATRIAL;ADJUVANT BREAST;IPSILATERAL LUNG;LUNG HEART;PATIENTS CANDIDATES;PENDULOUS BREASTS;POSITION CC;WALK TEST;ADJUVANT CHEMOTHERAPY;CARDIAC FUNCTION;ATRIAL VOLUME;CORONARY ARTERY;GAIT TRAINING;GT DAYS;LEFT VENTRICULAR;SECRETIN RECEPTORS;ADDING MM;ADVANTAGEOUS ALTERNATIVE;AGE RANGED;ANALYZE DOSIMETRIC;ANTERIOR DESCENDING;BLOOD FLOW;BREAST BOARD;BREAST POSIBOARD;BREAST RADIATION;BREAST RT;BREAST TISSUE","20;12;9;7;6;6;6;6;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,10,5.3,883,8.06,4,0.4,113.8,0,0,1,0,6,0,1,2,0,8,2,0,0,0,0,0,0,10,0,0,10,0,0,0,0,0,0,0,0,0,"Italy;Switzerland;United States","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","10;5;3;2;2;2;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;HEMATOLOGY;ATHEROSCLEROSIS;BREAST CANCER;CARDIOVASCULAR;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;LYMPHOMA;ASSISTIVE TECHNOLOGY;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN DISORDERS;DIGESTIVE DISEASES;EPILEPSY;IMMUNIZATION;LIVER CANCER;LIVER DISEASE","8;6;6;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR","5;2","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","6;1;1;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;LIVER CANCER;MYELOMA","2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","5;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2013,77,9.45454545454546,2.93506493506494,0.454545454545455,0.441558441558442,0.48051948051948,1.62589928057554,1.25,1.41666666666667,1.15625,0.363636363636364,1,33,17,16,7,0.43,0.22,0.21,0.09,16.27,0.466366614695207,4.42934782608696,0.272727272727273,1,0.401,0.38,0.392,0.365,"ALON SCHAFFER;PAOLO MARINO;GIUSEPPE DE LUCA;MONICA VERDOIA;LUCIA BARBIERI;ETTORE CASSETTI;MARCO BRAMBILLA;CARLO CISARI;GIOEL GABRIO SECCO;MARCO INVERNIZZI;MARCO KRENGLI;GIORGIO BELLOMO;FABIOLA SINIGAGLIA;STEFANO ANDREONI;MARCO QUAGLIA;SAVERIO CINIERI;STEFANO CARDA;ALESSANDRO CARRIERO;GABRIELLA DI GIOVINE;RENZO BOLDORINI","9;9;8;8;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","ALON SCHAFFER;PAOLO MARINO;M. CAMPANINI;GIUSEPPE DE LUCA;MONICA VERDOIA;LUCIA BARBIERI;MAURO CAMPANINI;CARLO CISARI;MARCO INVERNIZZI;MARCO BRAMBILLA;ETTORE CASSETTI;PIER PAOLO SAINAGHI;DANIELE SOLA;MARIO PIRISI;STEFANO CARDA;ALESSIO BARICICH;GIORGIO BELLOMO;M. FALZONI;E BELLORA;G. AIROLDI","1.26;1.26;1.1;1.06;1.06;0.91;0.83;0.77;0.77;0.64;0.62;0.58;0.58;0.58;0.57;0.57;0.56;0.5;0.5;0.5","ALON SCHAFFER;PAOLO MARINO;GIUSEPPE DE LUCA;MONICA VERDOIA;LUCIA BARBIERI;ETTORE CASSETTI;MARCO BRAMBILLA;CARLO CISARI;GIOEL GABRIO SECCO;MARCO INVERNIZZI;MARCO KRENGLI;GIORGIO BELLOMO;STEFANO ANDREONI;MARCO QUAGLIA;STEFANO CARDA;ALESSANDRO CARRIERO;GABRIELLA DI GIOVINE;RENZO BOLDORINI;OSCAR ALABISO;PIERO STRATTA","9;9;8;8;7;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3","ALON SCHAFFER;PAOLO MARINO;M. CAMPANINI;GIUSEPPE DE LUCA;MONICA VERDOIA;LUCIA BARBIERI;MAURO CAMPANINI;CARLO CISARI;MARCO INVERNIZZI;MARCO BRAMBILLA;ETTORE CASSETTI;PIER PAOLO SAINAGHI;DANIELE SOLA;MARIO PIRISI;STEFANO CARDA;ALESSIO BARICICH;GIORGIO BELLOMO;E BELLORA;G. AIROLDI;M. CAMPANINI","1.26;1.26;1.1;1.06;1.06;0.91;0.83;0.77;0.77;0.64;0.62;0.58;0.58;0.58;0.57;0.57;0.56;0.5;0.5;0.5","MARCO BRAMBILLA;ALON SCHAFFER;PAOLO MARINO;GIUSEPPE DE LUCA;MONICA VERDOIA;STEFANO ANDREONI;MARCO KRENGLI;ANASTASIOS STATHIS;ANNARITA CONCONI;EMANUELE ZUCCA;FRANCESCO BERTONI;FRANCO CAVALLI;GIANLUCA GAÏDANO;MICHELE GHIELMINI;SILVIA FRANCESCHETTI;LETIZIA DEANTONIO;MARCO QUAGLIA;PIERO STRATTA;A. CELIA;A. SALVAGGIO","161;113;113;109;109;95;91;86;86;86;86;86;86;86;86;85;84;84;81;81","MARCO BRAMBILLA;STEFANO ANDREONI;ANNARITA CONCONI;GIANLUCA GAÏDANO;SILVIA FRANCESCHETTI;ALON SCHAFFER;PAOLO MARINO;S. ZARAMELLA;LUCIA BARBIERI;MONICA VERDOIA;GIORGIO BELLOMO;ALESSANDRA MOSCA;DAVID MARY;ELENA GROSSINI;GIOVANNI VACCA;LORENZO COPPO;GIUSEPPE DE LUCA;MARCO QUAGLIA;PIERO STRATTA;CRISTINA MOMBELLO","161;95;86;86;86;82;82;81;78;78;66;63;57;57;57;55;54;53;53;50","ALON SCHAFFER;PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;GIUSEPPE DE LUCA;MARCO BRAMBILLA;CARLO CISARI;ETTORE CASSETTI;GIORGIO BELLOMO;MARCO INVERNIZZI;GABRIELLA DI GIOVINE;ALESSANDRO LUPI;ALESSIO BARICICH;STEFANO ANDREONI;MARCO KRENGLI;ALESSANDRA MOSCA;ALESSANDRO CARRIERO;ALESSANDRO STECCO;ANDREA ROGNONI;ANGELO SANTE BONGO","8;8;7;7;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;CHEMISTRY;ECONOMICS;MATHEMATICS;ART;ENGINEERING;MATERIALS SCIENCE;GEOGRAPHY;PHILOSOPHY;POLITICAL SCIENCE;SOCIOLOGY","72;11;7;7;6;5;3;3;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;ONCOLOGY;RADIOLOGY;GASTROENTEROLOGY;NUCLEAR MEDICINE;ENDOCRINOLOGY;GENETICS;OPTICS;UROLOGY;INTENSIVE CARE MEDICINE;PHARMACOLOGY;PSYCHIATRY;ANESTHESIA;BIOCHEMISTRY;IMMUNOLOGY;PEDIATRICS;ECONOMIC GROWTH;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;FAMILY MEDICINE;MICROBIOLOGY;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;STATISTICS","55;20;14;14;12;10;8;8;6;6;6;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3","CANCER;MYOCARDIAL INFARCTION;COHORT;GENE;PLATELET;DISEASE;MULTIVARIATE ANALYSIS;RADIATION THERAPY;CONFIDENCE INTERVAL;HEALTH CARE;RANDOMIZED CONTROLLED TRIAL;STENT;THROMBOSIS;CHEMOTHERAPY;CORONARY ARTERY DISEASE;DIABETES MELLITUS;DIFFERENTIAL DIAGNOSIS;KIDNEY;LYMPHOMA;MULTIPLE SCLEROSIS;POPULATION;PROSPECTIVE COHORT STUDY;THYROID","14;10;6;6;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","PERCUTANEOUS CORONARY INTERVENTION;CONVENTIONAL PCI;BREAST CANCER;UNIVARIATE ANALYSIS;ACUTE CORONARY SYNDROME;COLORECTAL CANCER;ADENOCARCINOMA;CLOPIDOGREL;CUMULATIVE INCIDENCE;MANTLE CELL LYMPHOMA;MEAN PLATELET VOLUME;METASTASIS;MUTATION;PERFORMANCE STATUS;PROSTATE;RESTENOSIS;RITUXIMAB;THYROID CANCER;THYROID CARCINOMA;TROPONIN I;VENOUS THROMBOEMBOLISM;VENOUS THROMBOSIS","7;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CAPECITABINE;INTERNATIONAL PROGNOSTIC INDEX;NEOADJUVANT THERAPY;PAPILLARY THYROID CANCER;RADIOLUMINESCENCE;TOTAL MESORECTAL EXCISION;BIVALIRUDIN;BLASTOID;CASPOFUNGIN;CEREBRAL VASCULITIS;CLADE;COLONOSCOPY;CONNECTIVE TISSUE DISEASE;CORONARY STENTING;CYSTECTOMY;DISEASE MANAGEMENT;DRUG-ELUTING STENT;ECHINOCANDIN;EGFR INHIBITORS;ENOS;EQUINE CHORIONIC GONADOTROPIN;FARNESYL PYROPHOSPHATE;FONDAPARINUX;FRONTOTEMPORAL DEMENTIA;GALLERIA MELLONELLA;GASTRIC VARICES;GENE MUTATION;HERPESVIRIDAE;KRAS;LOWER URINARY TRACT SYMPTOMS;METHYLENETETRAHYDROFOLATE REDUCTASE;MICAFUNGIN;P2Y12;PRASUGREL;PROSTATECTOMY;RIVAROXABAN;SENTINEL LYMPH NODE;SILENT PERIOD;SUGAMMADEX;TBARS;THIENOPYRIDINE;TICLOPIDINE;TIMI;TRANSURETHRAL RESECTION OF THE PROSTATE","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;;ADULT;MYOCARDIAL INFARCTION;AGED, 80 AND OVER;ITALY;PROSPECTIVE STUDIES;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LYMPHOMA, MANTLE-CELL;BIOMARKERS;POSTOPERATIVE COMPLICATIONS;RISK FACTORS;BLOOD PLATELETS;THYROID NEOPLASMS;TREATMENT OUTCOME;TROPONIN I","50;37;37;29;26;24;20;20;14;14;12;11;11;10;10;10;9;9;9;8","PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;LYMPHOID NEOPLASMS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PRINCIPLES AND INTERVENTIONS IN STROKE REHABILITATION;RENAL CELL CARCINOMA;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANESTHESIA AND SEDATION MANAGEMENT;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;CHOLESTEROL-LOWERING TREATMENT;CINEMEDUCATION IN MEDICAL AND MANAGEMENT EDUCATION;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS","4;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","MYOCARDIAL REVASCULARIZATION;UNIVARIATE ANALYSIS;MANTLE CELL LYMPHOMA;BLEEDING RISK;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;CORONARY STENTS;CUMULATIVE INCIDENCE;DEEP VEIN THROMBOSIS;DIFFERENTIATED THYROID CANCER;DRUG-ELUTING STENTS;FDG-PET/CT IMAGING;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;INTERNATIONAL PROGNOSTIC INDEX;LIVER BIOPSY;MEAN PLATELET VOLUME;MEDULLARY THYROID CANCER;MYOCARDIAL INFARCTION;MYOCARDIAL PERFUSION;NEOADJUVANT THERAPY","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MYOCARDIAL INFARCTION;PERIPROCEDURAL MYOCARDIAL;ARTERY DISEASE;CORONARY ARTERY;PATIENTS UNDERGOING;PERCUTANEOUS CORONARY;TREADMILL TRAINING;ASSOCIAZIONE ITALIANA;CANCER SURVEY;CELL CARCINOMA;CELL LYMPHOMA;CEREBROSPINAL VENOUS;CHRONIC CEREBROSPINAL;CONTROLLED TRIAL;CORONARY ANGIOPLASTY;CORONARY INTERVENTION;DI RADIOTERAPIA;DISTRIBUTION WIDTH;DRUG ELUTING;ELUTING STENT;GAIT IMPAIRMENT;ITALIANA DI;KIDNEY TRANSPLANT;LUPUS ERYTHEMATOSUS;LYMPH NODE;MANTLE CELL;METASTATIC RENAL;MULTIPLE SCLEROSIS;ONCOLOGICA AIRO;PAPILLARY THYROID","6;6;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","SUPINE POSITION;GENE MUTATIONS;MULTIPLE SCLEROSIS;CONTROL THERAPY;LUNG CANCER;SUSPECTED PE;ΜMOL L-;ACUTE CORONARY;CELL LYMPHOMA;HNRNPA AB;IMMUNOSUPPRESSIVE THERAPY;LOWER URINARY;MEDIAN AGE;ORAL IMMUNOSUPPRESSIVE;OXIDATIVE STRESS;PATIENTS TREATED;PIOPED II;PRIMARY ENDPOINT;PROBABLE FFIS;PRONE POSITION;PULMONARY EMBOLISM;URINARY TRACT;ADVANCED STAGE;ANESTHETIZED RATS;ANTIBODY TESTS;BETA MICROGLOBULIN;BLOOD CELL;BRT BOOST;CANCER PATIENTS;CAREFUL REVIEW","6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2",1,0.01,1.5,3,0,0,0,0,0,0,0,3,0,0,3,0,0,0,1,2,0,0,0,44,44,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,5.55,1024.55,9.09,3,0.27,78.91,0,0,3,0,2,0,2,4,0,8,3,0,0,0,0,0,0,11,0,0,11,0,0,0,0,0,0,0,0,0,"Italy;United States;Switzerland","4;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","10;5;2;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;PREVENTION;CANCER;AUTOIMMUNE DISEASE;COMPLEMENTARY AND INTEGRATIVE HEALTH;NUTRITION;PATIENT SAFETY;RARE DISEASES;ARTHRITIS;CARDIOVASCULAR;COLO-RECTAL CANCER;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIABETES;HEMATOLOGY;IMMUNIZATION;INFLAMMATORY BOWEL DISEASE;KIDNEY DISEASE;MENTAL HEALTH","10;5;4;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;STROKE","4;1;1;1;1;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","1;1","COLON AND RECTAL CANCER;MYELOMA","2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"PUBLIC LIBRARY OF SCIENCE","8","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;4202 EPIDEMIOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3105 GENETICS;34 CHEMICAL SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","7;4;4;2;2;2;2;1;1;1","AUTOIMMUNE DISEASE;CLINICAL RESEARCH;BRAIN DISORDERS;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;GENETICS;HUMAN GENOME","3;3;2;2;2;2;1;1","NEUROLOGICAL","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,"CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","3;1",NA,NA,"4 QUALITY EDUCATION","3"
"AOU_NOVARAGALLIATE",2014,87,10.8045977011494,3.54022988505747,0.482758620689655,0.436781609195402,0.586206896551724,1.91304347826087,1.5,1.65217391304348,1.64516129032258,0.482758620689655,0,39,20,11,8,0.45,0.23,0.13,0.09,30.67,0.811465633871034,4.38260869565217,0.28735632183908,1,0.472,0.435,0.373,0.419,"PAOLO MARINO;ALON SCHAFFER;LUCIA BARBIERI;GIUSEPPE DE LUCA;MONICA VERDOIA;ETTORE CASSETTI;MARCO KRENGLI;ANDREA ROGNONI;ANGELO SANTE BONGO;ROBERTO CANTELLO;OTTAVIO RENA;PAOLO NAVALESI;PATRIZIA ZEPPEGNO;FABIO DAVOLI;ALESSANDRO LUPI;CATERINA CASADIO;CARLA GRAMAGLIA;HARRY SURYAPRANATA;STEFANO ANDREONI;GABRIELLA DI GIOVINE","12;11;10;10;10;9;7;6;6;6;5;5;5;5;5;5;5;5;4;4","PAOLO MARINO;ALON SCHAFFER;GIUSEPPE DE LUCA;MONICA VERDOIA;LUCIA BARBIERI;ETTORE CASSETTI;MARCO KRENGLI;ANDREA ROGNONI;ANGELO SANTE BONGO;ALESSANDRO LUPI;FABIO DAVOLI;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;CATERINA CASADIO;HARRY SURYAPRANATA;OTTAVIO RENA;LETIZIA DEANTONIO;ROBERTO CANTELLO;GIOEL GABRIO SECCO;PAOLO NAVALESI","1.72;1.4;1.32;1.32;1.24;1.15;1.01;0.95;0.95;0.82;0.74;0.71;0.71;0.7;0.69;0.68;0.68;0.62;0.62;0.52","PAOLO MARINO;ALON SCHAFFER;LUCIA BARBIERI;GIUSEPPE DE LUCA;MONICA VERDOIA;ETTORE CASSETTI;MARCO KRENGLI;ANDREA ROGNONI;ANGELO SANTE BONGO;ROBERTO CANTELLO;OTTAVIO RENA;PATRIZIA ZEPPEGNO;FABIO DAVOLI;ALESSANDRO LUPI;CATERINA CASADIO;CARLA GRAMAGLIA;STEFANO ANDREONI;GABRIELLA DI GIOVINE;RENZO BOLDORINI;CARLO TERRONE","12;11;10;10;10;9;7;6;6;6;5;5;5;5;5;5;4;4;4;4","PAOLO MARINO;ALON SCHAFFER;GIUSEPPE DE LUCA;MONICA VERDOIA;LUCIA BARBIERI;ETTORE CASSETTI;MARCO KRENGLI;ANDREA ROGNONI;ANGELO SANTE BONGO;ALESSANDRO LUPI;FABIO DAVOLI;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;CATERINA CASADIO;OTTAVIO RENA;LETIZIA DEANTONIO;ROBERTO CANTELLO;GABRIELLA DI GIOVINE;RENZO BOLDORINI;DAVIDE TURELLO","1.72;1.4;1.32;1.32;1.24;1.15;1.01;0.95;0.95;0.82;0.74;0.71;0.71;0.7;0.68;0.68;0.62;0.49;0.47;0.47","PAOLO NAVALESI;ROSANNA VASCHETTO;ANDREA CATALDO;ANDREA DE GAETANO;F ANTONICELLI;FRANCESCO IDONE;LUCA MONTINI;MASSIMO ANTONELLI;R. FESTA;SALVATORE MAURIZIO MAGGIORE;ADRIANO CHIÒ;LETIZIA MAZZINI;ANDREA CALVO;GABRIELE MORA;AMMAR AL‐CHALABI;ANNE E VISSER;CATHY ELLIS;CHRISTOPHER E. SHAW;JAMES ROONEY;JAN H. VELDINK","650;568;486;486;486;486;486;486;486;486;455;440;402;402;339;339;339;339;339;339","ROSANNA VASCHETTO;LETIZIA MAZZINI;PAOLO MARINO;ALON SCHAFFER;MONICA VERDOIA;GIUSEPPE DE LUCA;ETTORE CASSETTI;GIANLUCA GAÏDANO;SILVIA FRANCESCHETTI;LUCIA BARBIERI;DAVIDE ROSSI;ALESSANDRO VOLPE;MARCO KRENGLI;ENRICA BERSANO;ALESSANDRO LUPI;STEFANO ANDREONI;CARLO TERRONE;CATERINA CASADIO;E. MONÈS;ROBERTO CANTELLO","568;387;261;249;249;233;225;176;176;153;139;116;103;101;93;86;75;73;70;66","PAOLO MARINO;ALON SCHAFFER;MONICA VERDOIA;GIUSEPPE DE LUCA;LUCIA BARBIERI;ETTORE CASSETTI;ANGELO SANTE BONGO;MARCO KRENGLI;ANDREA ROGNONI;CATERINA CASADIO;FABIO DAVOLI;OTTAVIO RENA;ALESSANDRO LUPI;CARLO TERRONE;GABRIELLA DI GIOVINE;PATRIZIA ZEPPEGNO;STEFANO ANDREONI;ALESSANDRO VOLPE;CARLA GRAMAGLIA;E. MONÈS","11;10;10;9;9;8;6;6;5;5;5;5;5;4;4;4;4;3;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;ENGINEERING;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;SOCIOLOGY;ECONOMICS;MATERIALS SCIENCE;ART;GEOGRAPHY;POLITICAL SCIENCE","83;12;11;7;7;4;3;3;3;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;GASTROENTEROLOGY;ENDOCRINOLOGY;RADIOLOGY;OPTICS;PATHOLOGY;ANESTHESIA;INTENSIVE CARE MEDICINE;ONCOLOGY;MECHANICAL ENGINEERING;PSYCHIATRY;UROLOGY;IMMUNOLOGY;MICROBIOLOGY;CLINICAL PSYCHOLOGY;ENVIRONMENTAL HEALTH;BIOCHEMISTRY;DEMOGRAPHY;FAMILY MEDICINE;GENETICS;PEDIATRICS;PHARMACOLOGY","62;26;23;14;10;10;9;9;7;7;7;6;6;6;5;5;4;4;3;3;3;3;3;3","CANCER;MYOCARDIAL INFARCTION;DIABETES MELLITUS;CORONARY ARTERY DISEASE;DISEASE;CONFIDENCE INTERVAL;RADIATION THERAPY;CREATININE;HEART FAILURE;INCIDENCE (GEOMETRY);ODDS RATIO;POPULATION;CHEMOTHERAPY;COHORT;MECHANICAL VENTILATION;RENAL CELL CARCINOMA;RESPIRATORY SYSTEM;VENTILATION (ARCHITECTURE);ADVERSE EFFECT;ANGIOPLASTY;BLOOD PRESSURE;GENE;HOMOCYSTEINE;INTENSIVE CARE UNIT;KIDNEY;LUNG CANCER;MULTIVARIATE ANALYSIS;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY","13;13;9;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","PERCUTANEOUS CORONARY INTERVENTION;CONVENTIONAL PCI;COLORECTAL CANCER;ADENOCARCINOMA;AMYOTROPHIC LATERAL SCLEROSIS;EJECTION FRACTION;NEPHROPATHY;ACUTE CORONARY SYNDROME;ANTIFUNGAL DRUG;BRACHYTHERAPY;CANDIDA GLABRATA;CLINICAL ENDPOINT;CORONARY ANGIOGRAPHY;CYCLOPHOSPHAMIDE;GENOTYPE;INSULIN RESISTANCE;IONIZING RADIATION;LENALIDOMIDE;MINIMUM INHIBITORY CONCENTRATION;NEPHRECTOMY;PHASES OF CLINICAL RESEARCH;PNEUMONECTOMY;PROSTATE;RADIOSURGERY;SURGICAL MARGIN;TIDAL VOLUME;TYPE 2 DIABETES;UNIVARIATE ANALYSIS","12;7;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CONTRAST-INDUCED NEPHROPATHY;BIVALIRUDIN;BROTH MICRODILUTION;IMPAIRED GLUCOSE TOLERANCE;PRIMARY ANGIOPLASTY;PROSTATECTOMY;ADIPOKINE;ADIPONECTIN;ANDROGEN DEPRIVATION THERAPY;ASENAPINE;BRONCHOPLEURAL FISTULA;CARDIAC RESYNCHRONIZATION THERAPY;CARFILZOMIB;CASPOFUNGIN;COLONOSCOPY;CORONARY PERFUSION PRESSURE;DIASTOLIC HEART FAILURE;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DRUG-ELUTING STENT;EXTERNAL BEAM RADIOTHERAPY;FEBRILE NEUTROPENIA;FOCAL SEGMENTAL GLOMERULOSCLEROSIS;FRONTOTEMPORAL DEMENTIA;GERMLINE MUTATION;GLOMERULOSCLEROSIS;GLUCOSE TOLERANCE TEST;GLYCATED HEMOGLOBIN;HAMILTON RATING SCALE FOR DEPRESSION;HEART RATE VARIABILITY;IL-2 RECEPTOR;INTERNATIONAL PROGNOSTIC INDEX;KRAS;OSTEONECROSIS OF THE JAW;PANCREATIC DUCTAL ADENOCARCINOMA;PEAK INSPIRATORY PRESSURE;PHENOCOPY;PRASUGREL;PREDIABETES;PROSTATE-SPECIFIC ANTIGEN;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;SILICA FIBER;SINGLE-NUCLEOTIDE POLYMORPHISM;STREPTOCOCCUS THERMOPHILUS;THORACIC VERTEBRAE;TICAGRELOR;VENTRICULAR RATE;VINCRISTINE","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ITALY;AGED, 80 AND OVER;CORONARY ARTERY DISEASE;ADULT;MYOCARDIAL INFARCTION;DIABETES MELLITUS;PERCUTANEOUS CORONARY INTERVENTION;RISK FACTORS;TREATMENT OUTCOME;AMYOTROPHIC LATERAL SCLEROSIS;NONINVASIVE VENTILATION;CORONARY ANGIOGRAPHY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;HYPERTENSION","51;45;44;36;36;33;22;18;17;16;13;12;12;11;11;10;10;9;8;8","MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;RENAL CELL CARCINOMA;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MANAGEMENT AND OUTCOMES OF ACUTE KIDNEY INJURY;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;IMPACT OF BURNOUT ON HEALTHCARE PROFESSIONALS AND STUDENTS;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;AETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF MYOCARDITIS;ATRIAL FIBRILLATION;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CHOLANGIOCARCINOMA;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION","6;5;5;4;4;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1","CARDIAC IMAGING;NONINVASIVE VENTILATION;ANTIFUNGAL RESISTANCE;CARDIOVASCULAR RISK ASSESSMENT;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CONTRAST-INDUCED NEPHROPATHY;MYOCARDIAL REVASCULARIZATION;POSITIVE END-EXPIRATORY PRESSURE;ANTIFUNGAL DRUG;ANTIFUNGAL THERAPY;ATRIAL FIBRILLATION;BIVALIRUDIN;BROTH MICRODILUTION;CANDIDA GLABRATA;CARDIAC RESYNCHRONIZATION THERAPY;CHORDOMA;CLINICAL ENDPOINT;DEPRESSION (ECONOMICS);DIABETES;GLUCOSE METABOLISM","5;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","CORONARY ARTERY;PATIENTS UNDERGOING;ARTERY DISEASE;CELL CARCINOMA;UNDERGOING CORONARY;AMYOTROPHIC LATERAL;CORONARY ANGIOGRAPHY;LATERAL SCLEROSIS;MYOCARDIAL INFARCTION;PERIPROCEDURAL MYOCARDIAL;PREDICTIVE FACTORS;RENAL CELL;ANTIFUNGAL SUSCEPTIBILITY;ATRIAL FIBRILLATION;CARE UNIT;CLINICAL LABORATORY;COHORT STUDY;CONTRAST INDUCED;CORONARY INTERVENTIONS;HEART FAILURE;INDUCED NEPHROPATHY;INTENSIVE CARE;INTRACORONARY BIVALIRUDIN;ITALIAN RADIATION;JOB SATISFACTION;LUNG CANCER;METASTATIC RENAL;MULTICENTRE STUDY;NON-SMALL-CELL LUNG;ONCOLOGISTS JOB","5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HEART FAILURE;AMYOTROPHIC LATERAL;HUMAN MONOMERIC;LATERAL SCLEROSIS;MONOMERIC ADIPONECTIN;CHRONIC HEART;INTESTINAL PERMEABILITY;LUNG CANCER;TARA GUM;TOTAL BACTERIA;ACOUSTIC NEURINOMAS;ANTITHROMBOTIC THERAPIES;BLOOD FLOW;CIRCULAR STAPLER;CONSECUTIVE PATIENTS;CORONARY BLOOD;GLUCOSE TOLERANCE;INDEPENDENT PREDICTORS;LUNG ADENOCARCINOMA;MULTIVARIABLE ANALYSIS;NEUROLOGICAL EXAMINATION;PATIENTS TREATED;POSTOPERATIVE PSA;RESPIRATORY FAILURE;STAPLER EEATM;STUDY PERIOD;SUPPORT BAR;SURGICAL TECHNIQUE;SURVIVAL OS;SURVIVAL RATES","11;7;7;7;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",1,0.01,0.5,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,28,28,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,5.55,806.36,7.43,6,0.55,31.73,0,1,3,0,0,0,0,7,0,5,6,0,0,0,0,0,0,10,0,1,11,0,0,0,0,0,0,0,0,0,"Italy;United Kingdom;Netherlands;Sweden;United States","2;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","9;6;4;3;2;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;BIOENGINEERING;HEMATOLOGY;LYMPHOMA;RARE DISEASES;REGENERATIVE MEDICINE;TRANSPLANTATION;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;CARDIOVASCULAR;COMPARATIVE EFFECTIVENESS RESEARCH;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PATIENT SAFETY;STEM CELL RESEARCH;AGING;ANTIMICROBIAL RESISTANCE;BRAIN DISORDERS","10;6;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;INFECTION","5;2;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES","4;4;1;1;1","NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;LUNG CANCER;MELANOMA;NOT SITE-SPECIFIC CANCER;PROSTATE CANCER","4;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;1.4 CANCER PROGRESSION AND METASTASIS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.2 SURVEILLANCE;6.4 COST ANALYSES AND HEALTH CARE DELIVERY","5;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS","6;1","32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;40 ENGINEERING;3213 PAEDIATRICS;38 ECONOMICS;3801 APPLIED ECONOMICS;4010 ENGINEERING PRACTICE AND EDUCATION;4901 APPLIED MATHEMATICS;4905 STATISTICS","6;5;2;2;1;1;1;1;1;1","BRAIN DISORDERS;EPILEPSY;NEURODEGENERATIVE;NEUROSCIENCES;CLINICAL RESEARCH;INFANT MORTALITY;LUNG;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN","2;2;2;2;1;1;1;1;1;1","RESPIRATORY","1",NA,NA,"CLINICAL","1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","3;1",NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2015,100,11.73,3.29,0.46,0.35,0.69,1.80769230769231,1.53333333333333,1.59090909090909,1.56818181818182,0.58,4,58,15,12,5,0.58,0.15,0.12,0.05,35.47,0.951749548000245,5.88888888888888,0.33,1,0.491,0.381,0.436,0.437,"PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;GIUSEPPE DE LUCA;HARRY SURYAPRANATA;ALON SCHAFFER;GIORGIO BELLOMO;ROBERTA ROLLA;MARCO BRAMBILLA;VINCENZO MONTESARCHIO;ANDREA P. SPONGHINI;A. BENEDETTI;OTTAVIO RENA;DOMENICO SANSONNO;ANTONIO GASBARRINI;MATTEO NARDIN;PAOLO NAVALESI;A.F. ATTILI;SALVATORE D’ANGELO;TERESA ZOLFINO","13;11;11;9;8;7;7;6;6;5;5;5;5;5;5;5;5;5;5;5","ROBERTA RE;ELIA ARMELLINI;PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;ANDREA ANDERLONI;GIUSEPPE DE LUCA;HARRY SURYAPRANATA;ALON SCHAFFER;MAURO CAMPANINI;GIORGIO BELLOMO;PIETRO OCCHIPINTI;M. BALLARÈ;MARCO BRAMBILLA;ROBERTO NARDI;ANDREA P. SPONGHINI;OTTAVIO RENA;ROBERTA ROLLA;MARCO KRENGLI;DAVID RONDONOTTI","2.17;1.73;1.67;1.45;1.45;1.33;1.23;1.04;0.78;0.77;0.75;0.73;0.73;0.7;0.68;0.65;0.65;0.64;0.63;0.55","PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;GIUSEPPE DE LUCA;ALON SCHAFFER;GIORGIO BELLOMO;ROBERTA ROLLA;MARCO BRAMBILLA;ANDREA P. SPONGHINI;OTTAVIO RENA;MATTEO NARDIN;PATRIZIA PERGOLINI;MARCO KRENGLI;MARIO PIRISI;FRANÇESCO DELLA CORTE;MAURO CAMPANINI;ELIA ARMELLINI;M. BALLARÈ;FABIO DAVOLI;CHIARA SARTORI","13;11;11;9;7;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4","ROBERTA RE;ELIA ARMELLINI;PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;ANDREA ANDERLONI;GIUSEPPE DE LUCA;ALON SCHAFFER;MAURO CAMPANINI;GIORGIO BELLOMO;PIETRO OCCHIPINTI;M. BALLARÈ;MARCO BRAMBILLA;ANDREA P. SPONGHINI;OTTAVIO RENA;ROBERTA ROLLA;MARCO KRENGLI;DAVID RONDONOTTI;FRANCESCA PLATINI;FABIO DAVOLI","2.17;1.73;1.67;1.45;1.45;1.33;1.23;0.78;0.77;0.75;0.73;0.73;0.7;0.65;0.65;0.64;0.63;0.55;0.55;0.55","ALESSANDRO LUPI;BERNARDO CORTESE;ALESSANDRA REPETTO;ANDREA GAGNOR;ANDREA SANTARELLI;ANTONIO ZINGARELLI;ARTURO AUSIELLO;CARLO BRIGUORI;DIK HEG;ENRICO FRIGOLI;FERDINANDO VARBELLA;GENNARO SARDELLA;GIOVANNI ESPOSITO;GIUSEPPE ANDÒ;MARCO VALGIMIGLI;MARTINA ROTHENBÜHLER;NICOLETTA DE CESARE;PAOLO CALABRÒ;PAOLO RUBARTELLI;PAOLO SGANZERLA","1483;1477;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472;1472","ALESSANDRO LUPI;GIAN PIERO CARNEVALE SCHIANCA;PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;CARLO CISARI;ALON SCHAFFER;MAURILIO MASSARA;GIUSEPPE DE LUCA;FEDERICO D’ANDREA;MARCO BRAMBILLA;GIORGIO BELLOMO;PATRIZIA PERGOLINI;ROBERTA ROLLA;ELIA ARMELLINI;ALDO CRESPI;CATHERINE KLERSY;EMANUELE CEREDA;MARCELLA SERIOLI;ANTONIO RAMPONI","1483;425;253;241;241;222;198;176;159;143;121;113;113;113;109;108;108;108;108;107","PAOLO MARINO;LUCIA BARBIERI;MONICA VERDOIA;GIUSEPPE DE LUCA;ALON SCHAFFER;ANDREA P. SPONGHINI;MARCO BRAMBILLA;MARCO KRENGLI;MARIO PIRISI;MATTEO NARDIN;MAURO CAMPANINI;GIORGIO BELLOMO;PATRIZIA PERGOLINI;ROBERTA ROLLA;CHIARA SARTORI;ELIA ARMELLINI;M. BALLARÈ;ROBERTA RE;ALESSANDRO LUPI;DOMENICO LIZIO","13;11;11;10;7;5;5;5;5;5;5;5;5;5;4;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;MATHEMATICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;GEOGRAPHY;HISTORY;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","96;15;10;6;5;4;4;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;RADIOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;ANESTHESIA;CANCER RESEARCH;OPTICS;BIOCHEMISTRY;PHARMACOLOGY;PSYCHIATRY;CELL BIOLOGY;GENETICS;IMMUNOLOGY;UROLOGY","80;28;21;14;12;12;12;12;9;9;9;8;7;7;6;6;6;5;5;5;5","CANCER;ADVERSE EFFECT;MYOCARDIAL INFARCTION;POPULATION;RADIATION THERAPY;COHORT;DIABETES MELLITUS;CORONARY ARTERY DISEASE;DISEASE;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;HEPATOCELLULAR CARCINOMA;INCIDENCE (GEOMETRY);LUNG;MECHANICAL VENTILATION;ODDS RATIO;PLATELET;CONCOMITANT;CREATININE;HEART FAILURE;PANCREATITIS;POSITRON EMISSION TOMOGRAPHY;RENAL FUNCTION","14;12;12;12;10;8;8;7;7;7;5;5;5;5;5;5;5;5;4;4;4;4;4;4","ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;CLOPIDOGREL;SORAFENIB;BEVACIZUMAB;COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS;CONVENTIONAL PCI;EJECTION FRACTION;PLATELET AGGREGATION INHIBITOR;TOLERABILITY;UNIVARIATE ANALYSIS;ABDOMINAL AORTIC ANEURYSM;AMYOTROPHIC LATERAL SCLEROSIS;ARDS;AUTOIMMUNE PANCREATITIS;BREAST CANCER;CD34;CERVICAL CANCER;CLINICAL ENDPOINT;DYSGEUSIA;ENDOMETRIAL CANCER;GLYCEMIC;HAEMATOPOIESIS;HYPOGLYCEMIA;INTERSTITIAL PNEUMONIA;IONIZING RADIATION;KIDNEY TRANSPLANTATION;LIPOPROTEIN;METASTASIS;NITRIC OXIDE SYNTHASE;PANCREATIC MASS;PHENOTYPE;POSITIVE END-EXPIRATORY PRESSURE;PROGRAMMED CELL DEATH;PROSTATE CANCER;PROTEIN KINASE B;PSEUDOANEURYSM;PULSE PRESSURE;REVASCULARIZATION;STANDARDIZED UPTAKE VALUE;SUBGROUP ANALYSIS;TEMOZOLOMIDE","7;7;5;5;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TICAGRELOR;P2Y12;BIVALIRUDIN;ENOS;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;PROSTATECTOMY;ANAPLASTIC LYMPHOMA KINASE;ANDROGEN DEPRIVATION THERAPY;APPLANATION TONOMETRY;BILLROTH I;BRONCHOPULMONARY SEQUESTRATION;CARDIAC RESYNCHRONIZATION THERAPY;CD99;CONTRAST-INDUCED NEPHROPATHY;CORONARY STENT;CRIZOTINIB;ENDOVASCULAR ANEURYSM REPAIR;ERYTHROBLAST;FLUORESCENCE IN SITU HYBRIDIZATION;GASTROINTESTINAL CANCER;GATED SPECT;GENE MUTATION;LIPOPROTEIN(A);LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;MARGINAL ZONE;MOLECULAR MEDICINE;MOTOR NEURONE DISEASE;MUCOSA-ASSOCIATED LYMPHOID TISSUE;NUCLEOTIDE EXCISION REPAIR;NUTCRACKER SYNDROME;ONCOGENE;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PEAK INSPIRATORY PRESSURE;PEMETREXED;PLATEAU PRESSURE;PLATELET INHIBITION;PRASUGREL;PRIMARY TUMOR;RIBOSOME;ROS1;SILENT PERIOD;STROKE VOLUME;SUPAR;THYMIDYLATE SYNTHASE;TIMI;TRINUCLEOTIDE REPEAT EXPANSION;VAGINAL CANCER;VEMURAFENIB;VENOUS THROMBOEMBOLIC DISEASE","6;4;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;;FEMALE;AGED;MIDDLE AGED;ACUTE CORONARY SYNDROME;ADULT;AGED, 80 AND OVER;ADENOSINE;CORONARY ARTERY DISEASE;PERCUTANEOUS CORONARY INTERVENTION;PLATELET AGGREGATION INHIBITORS;ITALY;BIOMARKERS;BLOOD PLATELETS;PANCREATIC NEOPLASMS;CARDIOVASCULAR DISEASES;HEAD AND NECK NEOPLASMS;ASPIRIN","56;44;43;40;38;35;19;17;17;16;14;14;13;12;11;11;11;10;10;9","ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT AND PATHOPHYSIOLOGY OF ABDOMINAL AORTIC ANEURYSMS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLIOMAS;HEPATOCELLULAR CARCINOMA;MELANOMA;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY;PANCREATIC CANCER RESEARCH AND TREATMENT;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;PREVENTION AND TREATMENT OF PRESSURE ULCERS;RENAL CELL CARCINOMA;SARCOMA RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVANCES IN PHOTOACOUSTIC IMAGING AND TOMOGRAPHY","6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1","PLATELET REACTIVITY;TREATMENT;CONCOMITANT;SORAFENIB;ANEURYSM SCREENING;CARDIOVASCULAR EVALUATION;CARDIOVASCULAR RISK ASSESSMENT;ENDOSCOPIC STENTING;REGIMEN;TOLERABILITY;UNIVARIATE ANALYSIS;ACUTE PANCREATITIS;AUTOIMMUNE PANCREATITIS;BIVALIRUDIN;CANCER IMAGING;CARDIAC IMAGING;CLINICAL ENDPOINT;CONTINUOUS BLOOD PRESSURE ESTIMATION;DIABETES;DIAGNOSIS","6;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","PATIENTS TREATED;PLATELET REACTIVITY;CORONARY ARTERY;FINAL RESULTS;PATIENTS UNDERGOING;ARTERY DISEASE;INTERNAL MEDICINE;ACUTE CORONARY;ANTIPLATELET THERAPY;CORONARY SYNDROMES;DUAL ANTIPLATELET;GIDEON STUDY;HEPATOCELLULAR CARCINOMA;THERAPEUTIC DECISIONS;AINO ITALIAN;AMYOTROPHIC LATERAL;AORTIC ANEURYSM;AUTOIMMUNE PANCREATITIS;B-CELL LYMPHOMA;BREAST CANCER;CANCER PATIENTS;CELL LUNG;CHRONIC OBSTRUCTIVE;CLIP SYSTEM;CONTROLLED TRIAL;ELDERLY PATIENTS;ENDOSCOPIC OVER-THE-SCOPE;ENDOTHELIAL CELLS;FLUID RESPONSIVENESS;GIDEON GLOBAL","6;6;5;5;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FACTOR VIII;ADVERSE EVENTS;CLINICAL PRACTICE;CONTRAST-INDUCED NEPHROPATHY;WILD TYPE;HR CI;ELDERLY PTS;LINE CHEMOTHERAPY;CONSECUTIVE PATIENTS;ENDOTHELIAL CELLS;MEDIAN AGE;PATIENTS TREATED;ADVERSE EFFECTS;BRAF MUTATION;CORF EXPANSION;MEDIAN OS;MET COPY;PATIENTS RECEIVING;SARDINIAN ALS;ADJUVANT CHEMOTHERAPY;CLINICAL TRIALS;GIDEON STUDY;INTERMEDIATE LENGTH;INTERNAL MEDICINE;PATIENTS PTS;PATIENTS RANGE;PATIENTS UNDERGOING;PERCUTANEOUS CORONARY;ADVANCED NSCLC;ALS PATIENTS","13;12;11;10;10;9;8;8;7;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4",1,0.01,70.5,103,3,1,0,1,0,0,0,111,0,1,97,0,0,3,16,55,23,0,0,97,97,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4.62,2718.62,4.82,6,0.75,163.38,0,0,0,0,2,0,0,6,0,4,4,0,0,0,0,0,0,8,0,0,8,0,0,0,0,0,0,0,0,0,"Italy;Japan;Australia;Netherlands;United Kingdom","4;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3210 NUTRITION AND DIETETICS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","8;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CARDIOVASCULAR;HEART DISEASE;NUTRITION;PEDIATRIC;PREVENTION;AUTOIMMUNE DISEASE;BIOENGINEERING;DIABETES;OBESITY;PATIENT SAFETY;ASSISTIVE TECHNOLOGY;CROHN'S DISEASE;DIGESTIVE DISEASES;HEMATOLOGY;INFANT MORTALITY;INFLAMMATORY BOWEL DISEASE;LUNG;NEONATAL RESPIRATORY DISTRESS","8;5;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1","CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","2;2;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;1;1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,13,"PUBLIC LIBRARY OF SCIENCE","13","32 BIOMEDICAL AND CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;4905 STATISTICS","17;6;3;2;2","AGING;EYE DISEASE AND DISORDERS OF VISION;CLINICAL RESEARCH;ESTROGEN;NEURODEGENERATIVE;NEUROSCIENCES","3;3;1;1;1;1","EYE","3","2.4 SURVEILLANCE AND DISTRIBUTION;6.1 PHARMACEUTICALS","1;1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","5",NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2016,121,11.7190082644628,3.47107438016529,0.429752066115702,0.40495867768595,0.479338842975207,1.95348837209302,1.57575757575758,2.33333333333333,1.56756756756757,0.504132231404959,1,64,28,11,7,0.53,0.23,0.09,0.06,12.69,0.390795521322509,5.6777108433735,0.305785123966942,0.991735537190083,0.49,0.434,0.491,0.456,"MARCO KRENGLI;PAOLO MARINO;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;MARCO BRAMBILLA;G. LOI;LETIZIA DEANTONIO;MARIO PIRISI;C. DELICATO;ROBERTA MATHEOUD;LUCIA BARBIERI;PIER PAOLO SAINAGHI;GIUSEPPE DE LUCA;DANIELE SOLA;MONICA VERDOIA;ALON SCHAFFER;DOMENICO LIZIO;MATTIA BELLAN;MATTEO NARDIN;ANDREA MINERVINI","15;12;11;11;11;9;8;7;6;6;6;6;6;6;6;5;5;5;5;5","MARCO KRENGLI;PAOLO MARINO;ROBERTA MATHEOUD;LETIZIA DEANTONIO;MARCO BRAMBILLA;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;G. LOI;MAURO CAMPANINI;M. FUSELLA;CARLA PISANI;DANIELE SOLA;LUCIA BARBIERI;GIUSEPPE DE LUCA;MONICA VERDOIA;AILIA GIUBERTONI;MARIO PIRISI;ANTONINO MAZZONE;DOMENICO LIZIO;PIER PAOLO SAINAGHI","2.5;1.67;1.64;1.51;1.49;1.2;1.2;1.11;0.85;0.83;0.79;0.76;0.7;0.7;0.7;0.68;0.67;0.67;0.64;0.62","MARCO KRENGLI;PAOLO MARINO;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;MARCO BRAMBILLA;G. LOI;LETIZIA DEANTONIO;MARIO PIRISI;ROBERTA MATHEOUD;LUCIA BARBIERI;PIER PAOLO SAINAGHI;GIUSEPPE DE LUCA;DANIELE SOLA;MONICA VERDOIA;ALON SCHAFFER;DOMENICO LIZIO;MATTIA BELLAN;MATTEO NARDIN;M. FUSELLA;GIORGIO BELLOMO","15;12;11;11;11;9;8;7;6;6;6;6;6;6;5;5;5;5;5;5","MARCO KRENGLI;PAOLO MARINO;ROBERTA MATHEOUD;LETIZIA DEANTONIO;MARCO BRAMBILLA;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;G. LOI;MAURO CAMPANINI;M. FUSELLA;CARLA PISANI;DANIELE SOLA;LUCIA BARBIERI;GIUSEPPE DE LUCA;MONICA VERDOIA;AILIA GIUBERTONI;MARIO PIRISI;DOMENICO LIZIO;PIER PAOLO SAINAGHI;MATTEO NARDIN","2.5;1.67;1.64;1.51;1.49;1.2;1.2;1.11;0.85;0.83;0.79;0.76;0.7;0.7;0.7;0.68;0.67;0.64;0.62;0.58","MARCO KRENGLI;PAOLO MARINO;GIUSEPPE DE LUCA;HARRY SURYAPRANATA;LUCIA BARBIERI;MONICA VERDOIA;MARIO PIRISI;PIER PAOLO SAINAGHI;LETIZIA DEANTONIO;MATTEO NARDIN;GIORGIO BELLOMO;ALON SCHAFFER;MATTIA BELLAN;MARCO BRAMBILLA;PATRIZIA PERGOLINI;ROBERTA ROLLA;CORRADO MAGNANI;RENZO BOLDORINI;ADRIANO CHIÒ;ANDREA CALVO","151;138;132;132;132;132;116;116;112;111;107;98;97;89;86;86;83;80;78;78","PAOLO MARINO;GIUSEPPE DE LUCA;LUCIA BARBIERI;MONICA VERDOIA;MARCO KRENGLI;PIER PAOLO SAINAGHI;MATTEO NARDIN;GIORGIO BELLOMO;MARIO PIRISI;LETIZIA DEANTONIO;PATRIZIA PERGOLINI;ROBERTA ROLLA;ALON SCHAFFER;LETIZIA MAZZINI;GARAVELLI PL;M ZARAMELLA;MATTIA BELLAN;OLIVIA BARGIACCHI;STEFANO DE CILLÀ;MARCO BRAMBILLA","138;132;132;132;130;116;111;107;107;105;86;86;85;78;72;72;72;72;72;71","MARCO KRENGLI;PAOLO MARINO;MARCO BRAMBILLA;G. LOI;LETIZIA DEANTONIO;PIER PAOLO SAINAGHI;GIUSEPPE DE LUCA;LUCIA BARBIERI;MONICA VERDOIA;ROBERTA MATHEOUD;MARIO PIRISI;CARLA PISANI;DOMENICO LIZIO;GIORGIO BELLOMO;M. FUSELLA;MATTEO NARDIN;AILIA GIUBERTONI;DANIELE SOLA;DAVID MARY;E. MONÈS","13;12;10;9;7;6;6;6;6;6;5;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;PSYCHOLOGY;ECONOMICS;ENGINEERING;MATERIALS SCIENCE;POLITICAL SCIENCE;ENVIRONMENTAL SCIENCE;GEOLOGY;SOCIOLOGY","115;22;19;14;12;8;7;6;6;5;4;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;RADIOLOGY;NUCLEAR MEDICINE;CARDIOLOGY;PATHOLOGY;MEDICAL PHYSICS;PSYCHIATRY;ENVIRONMENTAL HEALTH;GENETICS;PEDIATRICS;OPTICS;ARTIFICIAL INTELLIGENCE;GASTROENTEROLOGY;ENDOCRINOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;BIOCHEMISTRY;CLINICAL PSYCHOLOGY;UROLOGY","71;24;23;23;18;17;14;13;13;12;12;12;10;8;8;7;7;7;6;6;6","CANCER;GENE;POPULATION;RADIATION THERAPY;DISEASE;MYOCARDIAL INFARCTION;CLINICAL TRIAL;COHORT;CONFIDENCE INTERVAL;IMAGING PHANTOM;BIOPSY;DETECTOR;DOSIMETRY;HEART FAILURE;IMAGE (MATHEMATICS);KIDNEY;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;ANXIETY;BEAM (STRUCTURE);CHEMOTHERAPY;COHORT STUDY;DIABETES MELLITUS;OBSERVATIONAL STUDY","24;11;11;11;10;9;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4","BREAST CANCER;CLINICAL ENDPOINT;COLORECTAL CANCER;CONVENTIONAL PCI;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;EJECTION FRACTION;LINEAR PARTICLE ACCELERATOR;CLOPIDOGREL;DOSIMETER;HAZARD RATIO;IMAGE QUALITY;METASTASIS;NEPHRECTOMY;PROSTATE CANCER;SCINTILLATOR;TOLERABILITY;ACUTE CARE;AMYOTROPHIC LATERAL SCLEROSIS;BRACHYTHERAPY;CONTINUOUS POSITIVE AIRWAY PRESSURE;CORONARY ANGIOGRAPHY;DIAPHRAGM (ACOUSTICS);GENOTYPE;GESTATIONAL AGE;GLOBAL ASSESSMENT OF FUNCTIONING;HEAD AND NECK CANCER;IMAGE REGISTRATION;IMAGE-GUIDED RADIATION THERAPY;IMMUNIZATION;INSULIN RESISTANCE;MYOCARDIAL PERFUSION IMAGING;PERFORMANCE STATUS;PLATELET ACTIVATION;PLATELET AGGREGATION INHIBITOR;PROGRESSION-FREE SURVIVAL;RADIOSURGERY;RANDOMIZATION;SINUS RHYTHM;SORAFENIB;SUICIDE PREVENTION;WHITE MATTER","9;7;6;6;6;5;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TICAGRELOR;CARDIAC RESYNCHRONIZATION THERAPY;ADIPONECTIN;CETUXIMAB;METASTATIC BREAST CANCER;OXALIPLATIN;P2Y12;SENTINEL LYMPH NODE;SPECKLE TRACKING ECHOCARDIOGRAPHY;SPLENIUM;SUICIDE ATTEMPT;TIMI;ABATACEPT;ADIPOKINE;ANDROGEN DEPRIVATION THERAPY;ASENAPINE;BIVALIRUDIN;BK VIRUS;BOOSTER DOSE;BRONCHOPULMONARY DYSPLASIA;CD3;CONTRAST-INDUCED NEPHROPATHY;CRIZOTINIB;CROSSOVER STUDY;DNA EXTRACTION;EXTERNAL BEAM RADIOTHERAPY;FEBRILE NEUTROPENIA;FRONTOTEMPORAL DEMENTIA;GAMETOCYTE;GAS6;GENOMICS;GERMLINE MUTATION;GIANT CELL ARTERITIS;GSTP1;HAPLOTYPE;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IDIOPATHIC SHORT STATURE;INTERPERSONAL REACTIVITY INDEX;IRINOTECAN;KRAS;LYMPHOVASCULAR INVASION;MARGINAL ZONE;MASS-CASUALTY INCIDENT;MASTECTOMY;MEDIASTINAL LYMPH NODE;MEN1;MENINGOCOCCAL VACCINE;METASTASECTOMY;MITOCHONDRIAL DISEASE;MITOCHONDRIAL MYOPATHY;MULTILEAF COLLIMATOR;NATIONAL DEATH INDEX;NEONATAL RESPIRATORY DISTRESS SYNDROME;PITTSBURGH SLEEP QUALITY INDEX;PLASMODIUM VIVAX;PROSTATECTOMY;ROS1;RUBELLA;SABR VOLATILITY MODEL;SENTINEL NODE;STEREOTACTIC RADIOTHERAPY;SUICIDE RATES;TAQMAN;TAXANE;TRANSIENT ELASTOGRAPHY;TRINUCLEOTIDE REPEAT EXPANSION;VACCINATION SCHEDULE;VARICELLA VACCINE;VECTOR (MOLECULAR BIOLOGY)","5;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADENOSINE;ADULT;BREAST NEOPLASMS;PLATELET AGGREGATION INHIBITORS;AGED, 80 AND OVER;ITALY;TICLOPIDINE;ACUTE CORONARY SYNDROME;BIOMARKERS;PERCUTANEOUS CORONARY INTERVENTION;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;PROSTATIC NEOPLASMS;SKIN NEOPLASMS","71;48;40;35;28;27;18;13;13;13;12;11;11;10;10;10;9;9;8;8","RADIOTHERAPY PHYSICS AND TECHNOLOGY;MOLECULAR RESEARCH ON BREAST CANCER;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;RENAL CELL CARCINOMA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;MAGNETIC RESONANCE IMAGING APPLICATIONS IN MEDICINE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BIOLOGICAL AND CLINICAL EFFECTS OF IONIZING RADIATION;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;DIAGNOSIS AND MANAGEMENT OF HYPONATREMIA;EATING DISORDERS AND BODY IMAGE CONCERNS;EPIDEMIOLOGY AND PATHOGENESIS OF BACTERIAL MENINGITIS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;INFLAMMATION AND OBESITY-RELATED METABOLIC DISORDERS","9;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;CANCER IMAGING;IMAGING;TREATMENT;CARDIAC IMAGING;IMAGE-GUIDED RADIOTHERAPY;PERFUSION IMAGING;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOVASCULAR RISK ASSESSMENT;CETUXIMAB;CONCOMITANT;DOSIMETRY;INTENSITY-MODULATED RADIOTHERAPY;MAGNETIC RESONANCE IMAGING;PET IMAGING;PET/CT;PLATELET REACTIVITY;RADIATION SENSITIZATION;RADIOTHERAPY;REGIMEN","7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","PATIENTS UNDERGOING;BREAST CANCER;CANCER PATIENTS;RECTAL CANCER;CONTROLLED TRIAL;PLATELET REACTIVITY;ADJUSTED VENTILATORY;ANTIPLATELET THERAPY;AORTIC ENDOTHELIAL;ATRIAL FIBRILLATION;ATRIAL STRAIN;CALCIUM MOVEMENTS;CELL CARCINOMA;CLINICAL PRACTICE;CORTEX INVOLVEMENT;DISTRESS SYNDROME;DOSIMETRIC CHARACTERIZATION;DUAL ANTIPLATELET;ENDOSCOPIC ULTRASOUND-GUIDED;ENDOTHELIAL CELLS;EXPRESSED EMOTION;FRONTAL CORTEX;GLUCOSE CONDITIONS;IMAGE QUALITY;LATE ONSET;LONG-LASTING PSYCHIATRIC;LONG-TERM FOLLOW-UP;LUNG CANCER;LYMPH NODE;MODULATES NITRIC","7;6;5;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PATIENTS UNDERGOING;BREAST CANCER;MMRV MENC;ST SEGMENT;CANCER PATIENTS;CANCER TREATMENT;INSPIRATORY EFFORT;PRIMARY ENDPOINT;RADIATION ONCOLOGY;SEGMENT ELEVATION;AIRO ITALIAN;CARDIOVASCULAR EVENTS;CONTEMPORARY BRACHYTHERAPY;DISTANT METASTASES;DISTANT SITES;GYNECOLOGICAL CANCER;ITALIAN ASSOCIATION;NECK CANCER;ONCOLOGY JOURNAL;PATIENTS RECEIVING;PIEDMONT LIGURIA;PRIMARY PCI;RELATIVE RISK;VALLE DAOSTA;ACUTE TOXICITY;ADVERSE CARDIOVASCULAR;AL SURVEY;BODY IMAGE;CARDIAC OUTPUT;EORTC QLQ","10;8;8;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5",1,0.01,76.8,29,1,1,0,8,0,0,0,31,0,0,19,0,0,2,3,13,1,0,0,63,63,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,4,376.29,3.83,3,0.38,59,0,1,2,0,2,0,0,3,0,6,2,0,0,0,0,0,0,8,0,0,7,0,0,0,1,0,0,0,0,0,"United States;Italy;Japan","3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","8;5;3;2;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;ORPHAN DRUG;RARE DISEASES;LYMPHOMA;LUNG;PATIENT SAFETY;PEDIATRIC;ASSISTIVE TECHNOLOGY;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN DISORDERS;CHILDHOOD LEUKEMIA;LUNG CANCER;NEUROSCIENCES;PEDIATRIC CANCER","8;5;4;4;4;4;3;2;2;2;1;1;1;1;1;1;1;1;1","CANCER","4","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","6;3;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;LUNG CANCER","3;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT","4;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2017,70,13,2.74285714285714,0.357142857142857,0.328571428571429,0.414285714285714,1.47692307692308,1.04166666666667,1.27777777777778,1.07407407407407,0.528571428571429,1,30,14,14,3,0.43,0.2,0.2,0.04,92.66,3.14358126102771,5.3945945945946,0.342857142857143,1,0.385,0.285,0.334,0.316,"MARIO PIRISI;PAOLO MARINO;PATRIZIA ZEPPEGNO;RENZO BOLDORINI;MATTIA BELLAN;G. LOI;MARCO KRENGLI;GIORGIO BELLOMO;CARLA GRAMAGLIA;MARCO BRAMBILLA;ROSALBA MINISINI;ANNA CANDONI;PAOLO BOSSI;VESSELINA KROUMOVA;ENRICO BOGGIO;SALVATORE GALLO;PIER PAOLO SAINAGHI;A. FEGGI;OSCAR ALABISO;LISA LICITRA","7;6;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","ALESSIO BARICICH;PAOLO MARINO;MARIO PIRISI;MARCO BRAMBILLA;GIORGIO BELLOMO;PATRIZIA ZEPPEGNO;MATTIA BELLAN;CARLA GRAMAGLIA;DORIANA CHIARINOTTI;ANDREANA DE MAURI;MONICA VERDOIA;STEFANO DE CILLÀ;PIER PAOLO SAINAGHI;ENRICO BOGGIO;A. FEGGI;G. LOI;ROBERTA ROLLA;MICOL ALKABES;LUIGI MARIO CASTELLO;GIUSEPPE DE LUCA","1.29;0.89;0.84;0.63;0.6;0.55;0.52;0.49;0.47;0.47;0.44;0.43;0.42;0.4;0.39;0.36;0.35;0.34;0.33;0.32","MARIO PIRISI;PAOLO MARINO;PATRIZIA ZEPPEGNO;RENZO BOLDORINI;MATTIA BELLAN;G. LOI;MARCO KRENGLI;GIORGIO BELLOMO;MARCO BRAMBILLA;ROSALBA MINISINI;ENRICO BOGGIO;PIER PAOLO SAINAGHI;A. FEGGI;OSCAR ALABISO;E. MONÈS;LUIGI MARIO CASTELLO;ROBERTA ROLLA;MONICA VERDOIA;ALESSIO BARICICH;LETIZIA MAZZINI","7;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","ALESSIO BARICICH;PAOLO MARINO;MARIO PIRISI;MARCO BRAMBILLA;GIORGIO BELLOMO;PATRIZIA ZEPPEGNO;MATTIA BELLAN;MONICA VERDOIA;STEFANO DE CILLÀ;PIER PAOLO SAINAGHI;ENRICO BOGGIO;A. FEGGI;G. LOI;ROBERTA ROLLA;MICOL ALKABES;LUIGI MARIO CASTELLO;GIUSEPPE DE LUCA;RENZO BOLDORINI;LUCIA BARBIERI;FEDERICA DE VECCHI","1.29;0.89;0.84;0.63;0.6;0.55;0.52;0.44;0.43;0.42;0.4;0.39;0.36;0.35;0.34;0.33;0.32;0.32;0.31;0.31","STEFANO DE CILLÀ;LUCA ROSSETTI;STELA VUJOSEVIC;DAVID MARY;DAVIDE FILIPPINI;ELENA GROSSINI;GIULIA RAINA;SERENA FARRUGGIO;NAUSICAA CLEMENTE;DIEGO VEZZOLA;GIAMBERTO CASINI;VALENTINA GATTI;ANNA CANDONI;PAOLO CORRADINI;ALESSANDRO BUSCA;ALICE BERTAINA;ANNA MARCHESE;G. MARCACCI;GIULIA PALAZZO;GIUSEPPE MILONE","4996;4985;4985;4908;4908;4908;4908;4908;4890;4874;4874;4874;325;285;256;256;256;256;256;256","STEFANO DE CILLÀ;STELA VUJOSEVIC;DIEGO VEZZOLA;VALENTINA GATTI;ALESSANDRO VOLPE;LETIZIA MAZZINI;G. LOI;LUCA NASSI;MICOL ALKABES;ENRICA BERSANO;MARIO PIRISI;ANDREA MURACA;CATERINA CASADIO;ANDREA P. SPONGHINI;MONIA LUNGHI;PAOLO MARINO;E. MONÈS;ANGELA CAROLI;LUCIA TURRI;PIER PAOLO SAINAGHI","4996;4985;4874;4874;164;142;133;128;122;117;114;111;85;78;69;66;64;57;57;54","MARIO PIRISI;PAOLO MARINO;G. LOI;MARCO BRAMBILLA;MARCO KRENGLI;ALESSIO BARICICH;E. MONÈS;GIORGIO BELLOMO;GIUSEPPE DE LUCA;LETIZIA MAZZINI;MONICA VERDOIA;PIER PAOLO SAINAGHI;RENZO BOLDORINI;ROBERTA ROLLA;STEFANO DE CILLÀ;A. FEGGI;ANDREA MAGNANI;ANDREA P. SPONGHINI;ANDREA ROGNONI;ANTONELLA ROSSATI","6;6;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;MATERIALS SCIENCE;COMPUTER SCIENCE;BUSINESS;ECONOMICS;POLITICAL SCIENCE;SOCIOLOGY;HISTORY;MATHEMATICS;PHILOSOPHY","68;16;11;7;6;6;4;3;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;PSYCHIATRY;RADIOLOGY;OPTICS;ANESTHESIA;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;GENETICS;NUCLEAR MEDICINE;PEDIATRICS;BIOCHEMISTRY;CLINICAL PSYCHOLOGY;INTENSIVE CARE MEDICINE;MEDICAL PHYSICS","45;20;14;11;10;8;8;8;8;7;6;6;6;6;6;6;4;4;4;4","CANCER;CHEMOTHERAPY;DISEASE;POPULATION;ADVERSE EFFECT;COHORT;RADIATION THERAPY;DOSIMETRY;GENE;HEART FAILURE;MYOCARDIAL INFARCTION;VIRUS;ANTIBODY;BIOPSY;BLOOD PRESSURE;COHORT STUDY;CONFIDENCE INTERVAL;CORONARY ARTERY DISEASE;DIABETES MELLITUS;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;POISON CONTROL;RADIATION;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY","14;8;8;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;DOSIMETER;EJECTION FRACTION;HEAD AND NECK CANCER;IMMUNOTHERAPY;SUICIDE PREVENTION;ALLELE;AMYOTROPHIC LATERAL SCLEROSIS;BACTEREMIA;CERVICAL CANCER;CHEMOTHERAPY REGIMEN;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CORONARY ANGIOGRAPHY;DOCETAXEL;FINE-NEEDLE ASPIRATION;HAZARD RATIO;HEPATITIS C VIRUS;KIDNEY CANCER;NEUTROPENIA;PLACEBO;PROGRESSION-FREE SURVIVAL;PROTEIN KINASE B;RADIATION ONCOLOGY;SCINTILLATOR;TOLERABILITY;TYPE 2 DIABETES MELLITUS","6;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CETUXIMAB;SUICIDE ATTEMPT;CARDIAC RESYNCHRONIZATION THERAPY;KRAS;NIVOLUMAB;PAPANICOLAOU STAIN;RADIOLUMINESCENCE;BACLOFEN;BECK HOPELESSNESS SCALE;BOOSTER DOSE;CARFILZOMIB;CITALOPRAM;CROSSOVER STUDY;CRYOGLOBULINEMIA;DASATINIB;DIGIT SYMBOL SUBSTITUTION TEST;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;DNA METHYLATION;ESOPHAGEAL VARICES;ESTROGEN RECEPTOR;FINE NEEDLE BIOPSY;FOVEAL AVASCULAR ZONE;FRACTIONAL FLOW RESERVE;FRAMINGHAM HEART STUDY;FUNDUS PHOTOGRAPHY;GENOTYPING;GERMLINE MUTATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IPILIMUMAB;MACULAR HOLE;MEN WHO HAVE SEX WITH MEN;MENINGOCOCCAL VACCINE;METASTATIC BREAST CANCER;MYCOBACTERIUM CHELONAE;MYCOBACTERIUM MARINUM;NEOADJUVANT THERAPY;NON-SMALL CELL LUNG CANCER (NSCLC);OCCIPITAL NEURALGIA;P2Y12;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PARACELLULAR TRANSPORT;PAZOPANIB;PD-L1;PHILADELPHIA CHROMOSOME;POLYMORPHISM (COMPUTER SCIENCE);PROSTATECTOMY;SEXUAL TRANSMISSION;SKIN INFECTION;STROKE VOLUME;SUICIDAL IDEATION;TICAGRELOR;TRANSIENT ELASTOGRAPHY;VORTIOXETINE","3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;;AGED;MIDDLE AGED;ITALY;ADULT;AGED, 80 AND OVER;DIABETES MELLITUS, TYPE 2;RISK FACTORS;BACTEREMIA;CORONARY ARTERY DISEASE;CORONARY STENOSIS;PROSPECTIVE STUDIES;ACUTE CORONARY SYNDROME;AMYOTROPHIC LATERAL SCLEROSIS;RETROSPECTIVE STUDIES;COMBINED MODALITY THERAPY;HYPERTENSION","42;33;30;26;24;23;19;12;10;10;10;9;9;8;8;7;7;7;6;6","RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;SUICIDAL BEHAVIOR AND PREVENTION STRATEGIES;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;GLIOMAS;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;BLOOD-BRAIN BARRIER AND NEUROVASCULAR INTERACTIONS;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;CANCER IMMUNOTHERAPY;CELL MECHANICS AND EXTRACELLULAR MATRIX INTERACTIONS;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND MANAGEMENT OF SYNCOPE","5;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","CLINICAL ENDPOINT;TREATMENT;CARDIAC IMAGING;BACTEREMIA;CARDIAC RESYNCHRONIZATION THERAPY;CETUXIMAB;CHEMOTHERAPY REGIMEN;COMPUTED TOMOGRAPHY;COMPUTED TOMOGRAPHY ANGIOGRAPHY;DIABETES;ECHOCARDIOGRAPHY;ENDOSCOPIC ULTRASOUND;HELP-SEEKING BEHAVIORS;INTERQUARTILE RANGE;KIDNEY CANCER;PROGRESSION-FREE SURVIVAL;RADIATION ONCOLOGY;RADIOLUMINESCENCE;RADIOTHERAPY;REGIMEN","4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AMYOTROPHIC LATERAL;BLIND RANDOMIZED;BRAIN INJURY;COHERENCE TOMOGRAPHY;COHORT STUDY;DIALYZED PATIENTS;ENDOSCOPIC ULTRASOUND-GUIDED;LATERAL SCLEROSIS;NECK CANCER;OPTICAL COHERENCE;PATIENTS AFFECTED;PATIENTS UNDERGOING;PHASE STUDY;PROSPECTIVE STUDY;RANDOMIZED PHASE;RISK FACTOR;RISK FACTORS;SEVERE BRAIN;SILICA OPTICAL;TYPE DIABETES;YB-DOPED SILICA;ABNORMAL CLINICAL;ACCESS PROGRAM;ACUTE CORONARY;ACUTE DECOMPENSATED;ACUTE LYMPHOBLASTIC;ADULT PATIENTS;ADULT PROSTATIC;ADVANCED NON-SQUAMOUS;AIR KERMA","2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","ADVERSE EVENTS;REFILL TIME;CAPILLARY REFILL;COMPUTED TOMOGRAPHIC;CORONARY COMPUTED;DM TYPE;INVASIVE CORONARY;CORONARY ANGIOGRAPHY;EMISSION COMPUTED;FNB NEEDLES;PHOTON EMISSION;SINGLE PHOTON;TOMOGRAPHIC ANGIOGRAPHY;COMPUTED TOMOGRAPHY;CONSECUTIVE PATIENTS;HSBA TITRES;MEDIAN OS;NOVARA PROVINCE;PFS PATIENTS;PROGRESSION-FREE SURVIVAL;TYPE VERSUS;ALS INCIDENCE;ASBESTOS EXPOSURE;BRAIN INJURY;CELLULAR MATERIAL;DRUG COMBINATION;EFFECTIVE DOSE;EMERGENCY DEPARTMENT;KRAS MUTATION;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML","8;8;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,17,3.59,400.12,14.41,8,0.47,50.53,0,0,3,1,4,0,0,9,0,13,4,0,0,0,0,0,0,17,0,0,15,0,0,1,1,0,0,0,0,0,"Italy;United States;Switzerland","18;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;3215 REPRODUCTIVE MEDICINE;52 PSYCHOLOGY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4204 MIDWIFERY;4206 PUBLIC HEALTH;5202 BIOLOGICAL PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","17;9;3;3;2;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PEDIATRIC;PREVENTION;RARE DISEASES;HEMATOLOGY;CANCER;CARDIOVASCULAR;PATIENT SAFETY;BIOENGINEERING;BRAIN DISORDERS;LUNG;NEURODEGENERATIVE;NEUROSCIENCES;NUTRITION;ALS;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEART DISEASE;ORPHAN DRUG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD","16;11;6;6;6;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2","CARDIOVASCULAR;NEUROLOGICAL;METABOLIC AND ENDOCRINE;REPRODUCTIVE HEALTH AND CHILDBIRTH;CANCER;INFLAMMATORY AND IMMUNE SYSTEM;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;RESPIRATORY;STROKE","4;3;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;6.7 PHYSICAL","9;2;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;MYELOMA","2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","4;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2018,117,13.7692307692308,3.15384615384615,0.41025641025641,0.358974358974359,0.615384615384615,1.71627906976744,1.41176470588235,2,1.38461538461538,0.512820512820513,2,72,24,11,4,0.62,0.21,0.09,0.03,16.04,0.525849001300388,5.23798076923077,0.401709401709402,1,0.505,0.413,0.449,0.424,"GIUSEPPE DE LUCA;MARCO BRAMBILLA;MONICA VERDOIA;ROBERTA MATHEOUD;ALESSANDRO CARRIERO;SANDRA D’ALFONSO;LUCIA BARBIERI;PAOLO MARINO;STELA VUJOSEVIC;G. LOI;MARCO KRENGLI;ROBERTA ROLLA;LETIZIA MAZZINI;STEFANO DE CILLÀ;BARBARA CANNILLO;CARLO CISARI;MATTEO NARDIN;ALESSANDRO DE SIRE;PATRIZIA PERGOLINI;GIAN MAURO SACCHETTI","13;11;9;8;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;5","MARCO BRAMBILLA;GIUSEPPE DE LUCA;ROBERTA MATHEOUD;MONICA VERDOIA;CHIARA SAGGIA;GIAN MAURO SACCHETTI;ALESSANDRO CARRIERO;LUCIA BARBIERI;BARBARA CANNILLO;MARCO KRENGLI;ROBERTA ROLLA;STEFANO DE CILLÀ;MATTEO NARDIN;G. LOI;STELA VUJOSEVIC;CARLO CISARI;ALESSANDRO DE SIRE;PAOLO MARINO;HARRY SURYAPRANATA;PATRIZIA PERGOLINI","2.65;1.82;1.56;1.44;1.02;0.98;0.96;0.95;0.92;0.88;0.82;0.79;0.78;0.77;0.77;0.72;0.72;0.69;0.63;0.62","GIUSEPPE DE LUCA;MARCO BRAMBILLA;MONICA VERDOIA;ROBERTA MATHEOUD;ALESSANDRO CARRIERO;SANDRA D’ALFONSO;LUCIA BARBIERI;PAOLO MARINO;STELA VUJOSEVIC;G. LOI;MARCO KRENGLI;ROBERTA ROLLA;LETIZIA MAZZINI;STEFANO DE CILLÀ;BARBARA CANNILLO;CARLO CISARI;MATTEO NARDIN;PATRIZIA PERGOLINI;GIAN MAURO SACCHETTI;RENZO BOLDORINI","13;11;9;8;7;6;6;6;6;6;6;6;6;6;5;5;5;5;5;4","MARCO BRAMBILLA;GIUSEPPE DE LUCA;ROBERTA MATHEOUD;MONICA VERDOIA;CHIARA SAGGIA;GIAN MAURO SACCHETTI;ALESSANDRO CARRIERO;LUCIA BARBIERI;BARBARA CANNILLO;MARCO KRENGLI;ROBERTA ROLLA;STEFANO DE CILLÀ;MATTEO NARDIN;G. LOI;STELA VUJOSEVIC;CARLO CISARI;PAOLO MARINO;PATRIZIA PERGOLINI;SANDRA D’ALFONSO;LETIZIA DEANTONIO","2.65;1.82;1.56;1.44;1.02;0.98;0.96;0.95;0.92;0.88;0.82;0.79;0.78;0.77;0.77;0.72;0.69;0.62;0.57;0.55","GIUSEPPE DE LUCA;FRANCESCO BOVENZI;LEONARDO BOLOGNESE;STELA VUJOSEVIC;PAOLO SGANZERLA;LETIZIA MAZZINI;SANDRA D’ALFONSO;LUCIA CORRADO;ANDREA CALVO;STEFANO DE CILLÀ;GABRIELE MORA;ANNA SONIA PETRONIO;MAURIZIO FERRARIO;ADRIANO CHIÒ;ANTONIO CANOSA;CRISTINA MOGLIA;ENRICA BERSANO;UMBERTO MANERA;MARCO BRAMBILLA;ALICE VAJDA","266;258;258;237;218;213;205;204;202;199;193;187;187;178;178;178;178;178;174;169","GIUSEPPE DE LUCA;STELA VUJOSEVIC;LETIZIA MAZZINI;STEFANO DE CILLÀ;GABRIELE MORA;MARCO BRAMBILLA;ADRIANO CHIÒ;ALICE VAJDA;AMMAR AL‐CHALABI;ANDREA CALVO;ANTONIO CANOSA;CRISTINA MOGLIA;ENRICA BERSANO;JAMES ROONEY;JAN H. VELDINK;LEONARD H. VAN DEN BERG;LUCIA CORRADO;MARCO BARBERIS;MAURA BRUNETTI;NEIL PEARCE","266;237;204;199;193;174;169;169;169;169;169;169;169;169;169;169;169;169;169;169","GIUSEPPE DE LUCA;MARCO BRAMBILLA;MONICA VERDOIA;ALESSANDRO CARRIERO;STELA VUJOSEVIC;PAOLO MARINO;STEFANO DE CILLÀ;G. LOI;GIAN MAURO SACCHETTI;LETIZIA MAZZINI;MARCO KRENGLI;ROBERTA MATHEOUD;LUCIA BARBIERI;PATRIZIA PERGOLINI;ROBERTA ROLLA;ALESSANDRA MOSCA;LETIZIA DEANTONIO;MARIO PIRISI;MATTEO NARDIN;E. MONÈS","13;11;9;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;3","MEDICINE;BIOLOGY;PHYSICS;MATHEMATICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;POLITICAL SCIENCE;PSYCHOLOGY;MATERIALS SCIENCE;SOCIOLOGY;ECONOMICS;GEOLOGY;ENVIRONMENTAL SCIENCE;GEOGRAPHY;HISTORY","115;17;17;11;10;9;8;6;6;4;4;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;NUCLEAR MEDICINE;ENDOCRINOLOGY;GASTROENTEROLOGY;RADIOLOGY;ONCOLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;ANESTHESIA;MECHANICAL ENGINEERING;MEDICAL PHYSICS;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;GENETICS;IMMUNOLOGY;LAW;NURSING;OPHTHALMOLOGY;OPTICS;PHYSICAL THERAPY;STATISTICS;UROLOGY","79;28;26;20;15;15;15;14;13;11;9;8;8;6;6;6;6;6;6;6;6;6;6;6","MYOCARDIAL INFARCTION;CANCER;DIABETES MELLITUS;RANDOMIZED CONTROLLED TRIAL;POPULATION;ADVERSE EFFECT;CONFIDENCE INTERVAL;RADIATION THERAPY;DISEASE;GENE;HEPATOCELLULAR CARCINOMA;ANGIOGRAPHY;COHORT;DOSIMETRY;HEART FAILURE;IMAGING PHANTOM;INTENSIVE CARE;PERFUSION;PLATELET;PROSPECTIVE COHORT STUDY;RETINAL;RETROSPECTIVE COHORT STUDY","16;12;12;11;8;6;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;4","ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;AMYOTROPHIC LATERAL SCLEROSIS;BREAST CANCER;CLINICAL ENDPOINT;DIABETIC RETINOPATHY;EJECTION FRACTION;IMMUNOTHERAPY;MULTICENTER STUDY;CLOPIDOGREL;DOSIMETER;ENDOVASCULAR TREATMENT;INSULIN RESISTANCE;METASTASIS;MUTATION;QUALITY ASSURANCE;REVASCULARIZATION;VITAMIN D DEFICIENCY;ALLELE;AORTIC VALVE REPLACEMENT;COLORECTAL CANCER;CONVENTIONAL PCI;CORONARY ANGIOGRAPHY;DOCETAXEL;DOSE PROFILE;FLUORESCEIN ANGIOGRAPHY;HAZARD RATIO;IMAGE QUALITY;MYELODYSPLASTIC SYNDROMES;NEPHRECTOMY;NEPHROPATHY;OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY;PERFUSION SCANNING;PHENOTYPE;PROSTATE CANCER;SORAFENIB;TISSUE MICROARRAY;TRANSISTOR","9;7;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PRASUGREL;TICAGRELOR;CARDIAC RESYNCHRONIZATION THERAPY;CONTRAST-INDUCED NEPHROPATHY;GATED SPECT;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;METASTATIC BREAST CANCER;SUBTHRESHOLD CONDUCTION;TRINUCLEOTIDE REPEAT EXPANSION;ABCIXIMAB;ANDROGEN DEPRIVATION THERAPY;AROMATASE;BIVALIRUDIN;BRAIN METASTASIS;CATHODIC PROTECTION;CIRCULATING TUMOR CELL;COMPOUND HETEROZYGOSITY;CORONARY STENT;DIABETIC MACULAR EDEMA;DNA METHYLATION;DOPPLER ECHOCARDIOGRAPHY;ELTROMBOPAG;FRACTIONAL FLOW RESERVE;GLUCOSE HOMEOSTASIS;GRANULOMATOSIS WITH POLYANGIITIS;HEREDITARY SPASTIC PARAPLEGIA;HOMEOSTATIC MODEL ASSESSMENT;INEFFECTIVE ERYTHROPOIESIS;INSULIN SENSITIVITY;KNEE PAIN;KRAS;LIPOPROTEIN(A);LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;LOSS FUNCTION;LYMPHEDEMA;METASTASECTOMY;MICROSCOPIC POLYANGIITIS;MISSENSE MUTATION;MODIFIED RANKIN SCALE;NEOADJUVANT THERAPY;NEUROPSYCHOLOGICAL ASSESSMENT;NIVOLUMAB;OSWESTRY DISABILITY INDEX;P2Y12;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PAZOPANIB;PD-L1;PRIMARY TUMOR;PROSTATE CARCINOMA;PROSTATECTOMY;PULMONARY ARTERY CATHETER;RADIOLUMINESCENCE;RIVAROXABAN;RUXOLITINIB;SOD1;TBARS;THROMBIN TIME;THROMBOPOIETIN;TIMI;TIROFIBAN;TRASTUZUMAB","5;4;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;AGED;MIDDLE AGED;ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;ADULT;AGED, 80 AND OVER;PLATELET AGGREGATION INHIBITORS;CORONARY ARTERY DISEASE;MYOCARDIAL INFARCTION;PRASUGREL HYDROCHLORIDE;ITALY;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;FOLLOW-UP STUDIES;PROSPECTIVE STUDIES;BIOMARKERS","60;55;47;43;39;34;21;20;18;16;16;15;15;14;13;13;11;10;10;9","ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;RADIOMICS IN MEDICAL IMAGING ANALYSIS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;RENAL CELL CARCINOMA;VITAMIN D AND HEALTH OUTCOMES;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;CANCER IMMUNOTHERAPY;COLORECTAL CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLIOMAS;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;MORAL DISTRESS IN HEALTHCARE PROFESSIONALS","8;6;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","CANCER IMAGING;TREATMENT;CARDIAC IMAGING;CLINICAL ENDPOINT;PLATELET REACTIVITY;DIABETIC RETINOPATHY;IMAGING;INTRAOCULAR PRESSURE;MYOCARDIAL PERFUSION;OCULAR HYPERTENSION;PET/CT;RADIOTHERAPY;STROKE (ENGINE);VITAMIN D;BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;C9ORF72;CANCER;CANCER IMMUNOEDITING;CARDIAC OUTPUT","5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","ACUTE CORONARY;LEFT VENTRICULAR;PATIENTS UNDERGOING;PLATELET REACTIVITY;SUBTHRESHOLD MICROPULSE;BREAST CANCER;CANCER PATIENTS;COHERENCE TOMOGRAPHY;CORONARY SYNDROMES;DIABETIC MACULAR;LONG-TERM FOLLOW-UP;MACULAR EDEMA;MYOCARDIAL INFARCTION;OPTICAL COHERENCE;PATIENTS TREATED;PERCUTANEOUS CORONARY;PHASE II;PROSPECTIVE STUDY;ACQUISITION PARAMETERS;ANTIPLATELET THERAPY;AORTIC VALVE;BLUEPRINT-HCC STUDY;BODY RADIOTHERAPY;CARCINOMA MRCC;CELL CARCINOMA;CHRONIC HEPATITIS;CORONARY INTERVENTIONS;CORONARY SYNDROME;DIABETIC PATIENTS;DUAL ANTIPLATELET","5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","RESEARCH FUNDING;COHERENCE TOMOGRAPHY;OPTICAL COHERENCE;INTENSIVE CARE;CARE UNIT;TRANSTHORACIC ECHOCARDIOGRAPHY;CARDIAC OUTPUT;ADVISORY COMMITTEES;COMPUTED TOMOGRAPHY;ENTITYS BOARD;PATIENTS TREATED;TOMOGRAPHY ANGIOGRAPHY;URIC ACID;ADVERSE EVENTS;HR CI;PLATELET COUNT;GC-RICH REGION;MECHANICALLY VENTILATED;SPEAKERS BUREAU;ACUTE CORONARY;CONFIDENCE INTERVAL;CONTRAST RESOLUTION;DAYS NA;DÉBITO CARDÍACO;EORTC QLQ-C;HONORARIA MEMBERSHIP;LEFT VENTRICULAR;LOW CONTRAST;MEDIAN AGE;MYOCARDIAL INFARCTION","14;13;13;12;11;10;9;8;8;8;8;8;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5",3,0.03,1.68,4,1,0,0,0,0,0,0,4,0,0,4.75,0,0,0,0,3.25,2,0,0,26,26,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,22,3.05,589.45,10.78,7,0.32,55.09,0,0,1,0,5,0,1,15,0,13,9,0,0,0,0,0,0,22,0,0,20,0,0,0,2,0,0,0,0,0,"Italy;United States;Germany;China;Finland;United Kingdom","12;6;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3208 MEDICAL PHYSIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;3213 PAEDIATRICS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","21;9;5;3;3;2;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;LUNG;PATIENT SAFETY;HEMATOLOGY;PREVENTION;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;ACUTE RESPIRATORY DISTRESS SYNDROME;ASSISTIVE TECHNOLOGY;HEART DISEASE;KIDNEY DISEASE;LYMPHOMA;NEUROSCIENCES;NUTRITION;OBESITY;PEDIATRIC","21;13;9;7;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;RESPIRATORY;METABOLIC AND ENDOCRINE;RENAL AND UROGENITAL","5;2;2;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS","9;4;1;1;1;1","LEUKEMIA / LEUKAEMIA;BLADDER CANCER;KIDNEY CANCER;NON-HODGKIN'S LYMPHOMA;ESOPHAGEAL / OESOPHAGEAL CANCER","3;2;2;2;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS","4;2;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","3;1;1;1;1","CANCER;KIDNEY DISEASE;RARE DISEASES","1;1;1","CANCER","1","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY","1;1;1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","2","KIDNEY CANCER","1",NA,NA
"AOU_NOVARAGALLIATE",2019,117,16.2820512820513,2.63247863247863,0.273504273504274,0.256410256410256,0.35042735042735,1.74011299435028,1.28,1.5,1.20588235294118,0.487179487179487,0,56,25,10,8,0.48,0.21,0.09,0.07,15.05,0.618964174668232,5.23602484472049,0.290598290598291,1,0.424,0.362,0.325,0.365,"LUCA NASSI;ROBERTA ROLLA;MATTIA BELLAN;STELA VUJOSEVIC;MARIO PIRISI;STEFANO DE CILLÀ;SIMONE FERRERO;UMBERTO DIANZANI;MARCO BRAMBILLA;ANDREA ROGNONI;GIORGIO QUADRI;ALESSANDRA IURLO;UMBERTO MORBIDUCCI;DIEGO GALLO;GUIDO GINI;FRANCESCO GROSSI;FABRIZIO D’ASCENZO;MARIO IANNACCONE;GIACOMO BOCCUZZI;GIUSEPPE DE LUCA","8;8;7;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5;5;5","STELA VUJOSEVIC;ROBERTA ROLLA;STEFANO DE CILLÀ;MARCO BRAMBILLA;MARIO PIRISI;VINCENZO CANTALUPPI;MATTIA BELLAN;CATERINA TOMA;DORIANA CHIARINOTTI;ANDREANA DE MAURI;GIULIA GENONI;UMBERTO DIANZANI;ANDREA MURACA;ROSANNA VASCHETTO;GIUSEPPE DE LUCA;PIER LUIGI INGRASSIA;LETIZIA MAZZINI;ELENA GROSSINI;MATTEO NARDIN;MONICA VERDOIA","1.12;1.02;0.91;0.78;0.74;0.71;0.69;0.64;0.63;0.63;0.62;0.62;0.59;0.58;0.56;0.54;0.53;0.52;0.5;0.5","LUCA NASSI;ROBERTA ROLLA;MATTIA BELLAN;STELA VUJOSEVIC;MARIO PIRISI;STEFANO DE CILLÀ;UMBERTO DIANZANI;MARCO BRAMBILLA;ANDREA ROGNONI;GIUSEPPE DE LUCA;ROSANNA VASCHETTO;DORIANA CHIARINOTTI;CATERINA TOMA;ANDREA MURACA;GIULIA GENONI;ANDREANA DE MAURI;LETIZIA MAZZINI;VINCENZO CANTALUPPI;SERGIO GENTILLI;PIETRO OCCHIPINTI","8;8;7;7;7;7;6;6;5;5;5;5;5;5;5;5;5;5;5;4","STELA VUJOSEVIC;ROBERTA ROLLA;STEFANO DE CILLÀ;MARCO BRAMBILLA;MARIO PIRISI;VINCENZO CANTALUPPI;MATTIA BELLAN;CATERINA TOMA;DORIANA CHIARINOTTI;ANDREANA DE MAURI;GIULIA GENONI;UMBERTO DIANZANI;ANDREA MURACA;ROSANNA VASCHETTO;GIUSEPPE DE LUCA;LETIZIA MAZZINI;MATTEO NARDIN;MONICA VERDOIA;GIANMARIA CAMMAROTA;SERGIO GENTILLI","1.12;1.02;0.91;0.78;0.74;0.71;0.69;0.64;0.63;0.63;0.62;0.62;0.59;0.58;0.56;0.53;0.5;0.5;0.5;0.49","MARCO BRAMBILLA;STEFANO DE CILLÀ;STELA VUJOSEVIC;ANDREA MURACA;CATERINA TOMA;EDOARDO VILLANI;PAOLO NUCCI;LETIZIA MAZZINI;PAOLO NAVALESI;ALESSANDRA IURLO;DAVIDE RAPEZZI;FRANCESCA LUNGHI;MASSIMILIANO BONIFACIO;EMANUELE TORTI;GIORDANA FLORIMBI;CARLO GENOVA;ERIKA RIJAVEC;FRANCESCO GROSSI;MARCO TAGLIAMENTO;FEDERICA BIELLO","240;184;182;168;168;168;168;152;134;127;125;125;125;114;114;112;112;112;112;110","MARCO BRAMBILLA;STELA VUJOSEVIC;ANDREA MURACA;CATERINA TOMA;LETIZIA MAZZINI;FEDERICA BIELLO;GIANMARIA CAMMAROTA;LUCA NASSI;ANDREA ROGNONI;MONIA LUNGHI;GIUSEPPE DE LUCA;ENRICA BERSANO;GLORIA BORRA;LAURA CANCELLIERE;RAMONA LUNGU;VINCENZO CANTALUPPI;ROBERTA ROLLA;ANDREA PATRIARCA;CARLA RIGO;ALESSANDRO NUZZO","240;182;168;168;147;110;109;100;99;97;92;85;78;78;78;68;56;55;55;54","LUCA NASSI;STELA VUJOSEVIC;MARCO BRAMBILLA;GIUSEPPE DE LUCA;ROBERTA ROLLA;ANDREA MURACA;ANDREA ROGNONI;CATERINA TOMA;LETIZIA MAZZINI;ANDREA PATRIARCA;GIANMARIA CAMMAROTA;PIETRO OCCHIPINTI;ROSANNA VASCHETTO;SERGIO RISO;STEFANO DE CILLÀ;FEDERICA BIELLO;MARIO PIRISI;MONICA VERDOIA;GIAN MAURO SACCHETTI;ROBERTA MATHEOUD","8;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;PSYCHOLOGY;ECONOMICS;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","115;18;14;7;7;7;7;6;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;ONCOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;RADIOLOGY;INTENSIVE CARE MEDICINE;PATHOLOGY;ANESTHESIA;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PSYCHIATRY;OPHTHALMOLOGY;GENETICS;OPTICS;PEDIATRICS;CANCER RESEARCH;EMERGENCY MEDICINE;NUCLEAR MEDICINE;PHYSICAL THERAPY","89;33;20;18;17;16;15;13;12;11;11;11;10;9;8;7;7;7;6;6;6;6","CANCER;DISEASE;DIABETES MELLITUS;ADVERSE EFFECT;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;POPULATION;CLINICAL TRIAL;LYMPHOMA;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;COHORT;PLATELET;BIOMARKER;CHEMOTHERAPY;GENE;LUNG CANCER;RETROSPECTIVE COHORT STUDY;BLOOD PRESSURE;INCIDENCE (GEOMETRY);KIDNEY;MECHANICAL VENTILATION;OBESITY;OBSERVATIONAL STUDY;PREGNANCY;RENAL FUNCTION;THROMBOSIS;TRAINING (METEOROLOGY);VENTILATION (ARCHITECTURE)","16;15;10;9;9;9;9;7;7;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4","CLINICAL ENDPOINT;ACUTE CORONARY SYNDROME;AMYOTROPHIC LATERAL SCLEROSIS;HAZARD RATIO;IMMUNOTHERAPY;RITUXIMAB;CLOPIDOGREL;DIABETIC RETINOPATHY;PERCUTANEOUS CORONARY INTERVENTION;BREAST CANCER;DIFFUSE LARGE B-CELL LYMPHOMA;HEART RATE;IMATINIB;MACULAR EDEMA;TOLERABILITY;WEIGHT LOSS;ARTERIAL DISEASE;CHRONIC LYMPHOCYTIC LEUKEMIA;COLORECTAL CANCER;CONVENTIONAL PCI;DBC;FATTY LIVER;FETUS;FOLLICULAR LYMPHOMA;FRACTION OF INSPIRED OXYGEN;GERIATRIC ONCOLOGY;IMAGE QUALITY;INTERIM ANALYSIS;LIPOPROTEIN;LUNG ULTRASOUND;MEAN PLATELET VOLUME;MYELOFIBROSIS;NEONATAL RESUSCITATION;NEPHRECTOMY;PAIN MEDICINE;PERFORMANCE STATUS;PERIPHERALLY INSERTED CENTRAL CATHETER;PLATELET ACTIVATION;PLATELET-RICH PLASMA;PREECLAMPSIA;PRESSURE SUPPORT VENTILATION;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;RETINOPATHY;SUNITINIB","9;6;6;6;5;5;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","NIVOLUMAB;TICAGRELOR;PRASUGREL;ANTHRACYCLINE;BENDAMUSTINE;CRITICAL LIMB ISCHEMIA;MACE;MYELOPROLIFERATIVE NEOPLASM;NILOTINIB;NONALCOHOLIC FATTY LIVER DISEASE;SOD1;TARGET LESION;ADIPOKINE;ADIPONECTIN;ANAPLASTIC LYMPHOMA KINASE;BARE METAL;CARDIAC INDEX;CIRCULATING TUMOR CELL;COLONOSCOPY;CORONAVIRUS DISEASE 2019 (COVID-19);CORTICOSPINAL TRACT;COTTON WOOL SPOTS;CROSSOVER STUDY;DASATINIB;DIABETIC MACULAR EDEMA;DRUG-ELUTING STENT;ELTROMBOPAG;ERLOTINIB;EXCESS WEIGHT;FOCUSED ASSESSMENT WITH SONOGRAPHY FOR TRAUMA;GASTRIC BYPASS;GEFITINIB;GIANT CELL ARTERITIS;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;IBRUTINIB;INTERNATIONAL PROGNOSTIC INDEX;INTRAUTERINE GROWTH RESTRICTION;LACUNARITY;LDL RECEPTOR;LIPOPROTEIN(A);LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;MULTICENTER TRIAL;NEOADJUVANT THERAPY;OBESTATIN;OBINUTUZUMAB;PAZOPANIB;PEAK INSPIRATORY PRESSURE;PLACENTA;PODOCYTE;PRENATAL DIAGNOSIS;RESPIRATORY RATE;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RETICULOCYTE;RUXOLITINIB;SILENT PERIOD;STROKE VOLUME;THROMBOPOIETIN;TRANSIENT ELASTOGRAPHY;UMBILICAL ARTERY;UPPER MOTOR NEURON;VENETOCLAX;VINORELBINE","5;4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;FEMALE;MALE;AGED;MIDDLE AGED;AMYOTROPHIC LATERAL SCLEROSIS;ACUTE CORONARY SYNDROME;CARCINOMA, NON-SMALL-CELL LUNG;LUNG NEOPLASMS;TREATMENT OUTCOME;ADULT;AGED, 80 AND OVER;ITALY;PLATELET AGGREGATION INHIBITORS;BIOMARKERS;RETROSPECTIVE STUDIES;CORONARY ARTERY DISEASE;PERCUTANEOUS CORONARY INTERVENTION;RISK FACTORS","59;58;44;41;35;31;18;17;16;16;16;14;14;14;14;13;13;12;11;11","ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;LYMPHOID NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;AGE-RELATED MACULAR DEGENERATION RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFICACY AND RESISTANCE IN CML TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;MANAGEMENT OF VASCULAR ACCESS IN HEALTHCARE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CANCER IMMUNOTHERAPY;CLASSIFICATION AND MANAGEMENT OF VASCULITIDES;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;NEONATAL LUNG DEVELOPMENT AND RESPIRATORY MORBIDITY;PATHOPHYSIOLOGY AND MANAGEMENT OF PREECLAMPSIA;RENAL CELL CARCINOMA;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;ROLE OF OSTEOPONTIN IN BIOMINERALIZATION AND INFLAMMATION;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS","7;7;6;5;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;1","CLINICAL ENDPOINT;MANTLE CELL LYMPHOMA;CORONARY STENTS;INTRAOCULAR PRESSURE;BLEEDING RISK;DIABETIC RETINOPATHY;DRUG-ELUTING STENTS;IMAGING IN VASCULITIS;MOTOR NEURON;MYELOPROLIFERATIVE NEOPLASM;NEONATAL RESUSCITATION;OCULAR HYPERTENSION;OPTICAL COHERENCE TOMOGRAPHY;OSTEOPONTIN;PLATELET REACTIVITY;TOLERABILITY;ANIMAL MODEL;ANTICOAGULANT THERAPY;BENDAMUSTINE;CARDIAC ULTRASOUND","9;6;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2","FONDAZIONE ITALIANA;ITALIANA LINFOMI;AMYOTROPHIC LATERAL;LATERAL SCLEROSIS;ELDERLY PATIENTS;LEFT MAIN;LUNG CANCER;PATIENTS TREATED;ANTIPLATELET THERAPY;CELL LUNG;CORONARY ARTERY;DUAL ANTIPLATELET;MULTICENTER STUDY;NON-SMALL CELL;PILOT STUDY;PLATELET REACTIVITY;RED CELL;RETROSPECTIVE STUDY;THIN STENTS;UNPROTECTED LEFT;WEIGHT LOSS;ACUTE CORONARY;ADJUSTED VENTILATORY;ADVANCED RENAL;ANIMAL BENCH-MODEL;ARTERY DISEASE;B-CELL LYMPHOMA;BILIARY CANNULATION;BILIARY OBSTRUCTION;CELL DISTRIBUTION","6;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","ADVISORY COMMITTEES;ENTITYS BOARD;SPEAKERS BUREAU;RESEARCH FUNDING;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;HONORARIA MEMBERSHIP;MG OAD;GRANT FUNDING;RESEARCH GRANT;FUNDING INSTITUTION;CONSULTANCY HONORARIA;NOVARTIS HONORARIA;HONORARIA INCYTE;CLINICAL TRIAL;COMMITTEES SPEAKERS;INCYTE HONORARIA;PATIENTS TREATED;ADVERSE EVENTS;CONTENT HTTPSLINKSLWWCOMHSA;DIGITAL CONTENT;LECTURE FEE;PFIZER HONORARIA;SUPPLEMENTAL DIGITAL;ARTERIAL THROMBOSIS;MPN DIAGNOSIS;BONE MARROW;ELDERLY PATIENTS;HONORARIA NOVARTIS;HONORARIA PFIZER;MEDIAN AGE","60;60;44;42;33;21;19;18;18;16;15;14;13;12;12;12;12;11;11;11;11;11;11;10;10;9;9;9;9;9",4,0.03,12.36,18.5,0,0,0,0,0,0,1,19,1,0,26.5,0,0,4,5.5,19.75,5.75,0,0,45.25,45.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,4.14,567.05,12.88,11,0.52,49.81,0,2,5,0,4,0,0,10,0,14,7,0,0,0,0,0,0,21,0,0,21,0,0,0,0,0,0,0,0,0,"Italy;United States;Finland","11;6;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3208 MEDICAL PHYSIOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4015 MARITIME ENGINEERING;4206 PUBLIC HEALTH;4207 SPORTS SCIENCE AND EXERCISE;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","17;9;7;3;3;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;NEUROSCIENCES;DIGESTIVE DISEASES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;PATIENT SAFETY;BIOENGINEERING;CHILDHOOD LEUKEMIA;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;LUNG;NEURODEGENERATIVE;PEDIATRIC;PEDIATRIC CANCER;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;STROKE","18;11;9;8;6;5;4;3;3;3;2;2;2;2;2;2;2;2;2;2","CANCER;ORAL AND GASTROINTESTINAL;NEUROLOGICAL;STROKE;CARDIOVASCULAR","8;3;2;2;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS","15;3;2;1;1;1;1;1","LEUKEMIA / LEUKAEMIA;MYELOMA;LIVER CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA","3;3;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.3 CHEMOPREVENTION;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","6;2;2;1;1;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,6,"PUBLIC LIBRARY OF SCIENCE","6","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","12;4;2;2;1;1;1;1","BREAST CANCER;CANCER;PREVENTION","3;3;1","CANCER","4",NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","5","BREAST CANCER;NOT SITE-SPECIFIC CANCER","4;1",NA,NA
"AOU_NOVARAGALLIATE",2020,146,16.2945205479452,3.18493150684931,0.335616438356164,0.321917808219178,0.404109589041096,2.01298701298701,1.48484848484848,1.95833333333333,1.96666666666667,0.643835616438356,0,66,39,20,4,0.45,0.27,0.14,0.03,25.99,1.03153291048646,5.39833333333333,0.308219178082192,1,0.532,0.39,0.385,0.374,"GIUSEPPE DE LUCA;MONICA VERDOIA;ALESSANDRO CARRIERO;MATTEO NARDIN;MATTIA BELLAN;LUIGI MARIO CASTELLO;MARIO PIRISI;FEDERICA NEGRO;PIER PAOLO SAINAGHI;FILIPPO PATRUCCO;FRANCESCO GAVELLI;ROBERTA ROLLA;GIUSEPPE PATTI;STELA VUJOSEVIC;STEFANO DE CILLÀ;MARCO BRAMBILLA;FRANÇESCO DELLA CORTE;PIERO EMILIO BALBO;ROCCO GIOSCIA;ANDREA ROGNONI","17;16;14;12;11;11;11;11;10;9;9;9;8;8;8;8;8;7;7;6","GIUSEPPE DE LUCA;MONICA VERDOIA;MATTEO NARDIN;FEDERICA NEGRO;ALESSANDRO CARRIERO;MARCO BRAMBILLA;STELA VUJOSEVIC;STEFANO DE CILLÀ;MATTIA BELLAN;ROBERTA ROLLA;ROCCO GIOSCIA;MARIO PIRISI;MARCO KRENGLI;LUIGI MARIO CASTELLO;FILIPPO PATRUCCO;FRANCESCO GAVELLI;PAOLO NUCCI;CATERINA TOMA;RENZO BOLDORINI;ALESSANDRO DE SIRE","1.79;1.72;1.6;1.48;1.46;1.37;1.27;1.27;0.99;0.89;0.83;0.8;0.8;0.8;0.78;0.74;0.73;0.73;0.71;0.7","GIUSEPPE DE LUCA;MONICA VERDOIA;ALESSANDRO CARRIERO;MATTEO NARDIN;MATTIA BELLAN;LUIGI MARIO CASTELLO;MARIO PIRISI;FEDERICA NEGRO;PIER PAOLO SAINAGHI;FILIPPO PATRUCCO;FRANCESCO GAVELLI;ROBERTA ROLLA;GIUSEPPE PATTI;STELA VUJOSEVIC;STEFANO DE CILLÀ;MARCO BRAMBILLA;FRANÇESCO DELLA CORTE;PIERO EMILIO BALBO;ROCCO GIOSCIA;ANDREA ROGNONI","17;16;14;12;11;11;11;11;10;9;9;9;8;8;8;8;8;7;7;6","GIUSEPPE DE LUCA;MONICA VERDOIA;MATTEO NARDIN;FEDERICA NEGRO;ALESSANDRO CARRIERO;MARCO BRAMBILLA;STELA VUJOSEVIC;STEFANO DE CILLÀ;MATTIA BELLAN;ROBERTA ROLLA;ROCCO GIOSCIA;MARIO PIRISI;MARCO KRENGLI;LUIGI MARIO CASTELLO;FILIPPO PATRUCCO;FRANCESCO GAVELLI;CATERINA TOMA;RENZO BOLDORINI;PIER PAOLO SAINAGHI;PAOLA SAVOIA","1.79;1.72;1.6;1.48;1.46;1.37;1.27;1.27;0.99;0.89;0.83;0.8;0.8;0.8;0.78;0.74;0.73;0.71;0.7;0.7","ADAM TORBICKI;ALEXANDER COHEN;ANDREA FONTANELLA;ANDRÉS J. MUÑOZ MARTÍN;BENJAMIN BRENNER;CATHERINE LAMBERT;CECILIA BECATTINI;GIANCARLO AGNELLI;GIORGIO VESCOVO;GUALBERTO GUSSONI;GUY MEYER;JEAN M. CONNORS;MARIA R. SUEIRO;MAURO CAMPANINI;MELINA VERSO;MENNO V. HUISMAN;RUPERT BAUERSACHS;LUIGI MARIO CASTELLO;PIER PAOLO SAINAGHI;ALESSANDRO CARRIERO","786;786;786;786;786;786;786;786;786;786;786;786;786;786;786;786;786;398;395;388","MAURO CAMPANINI;PIER PAOLO SAINAGHI;GIUSEPPE DE LUCA;ANDREA ROGNONI;PIERO EMILIO BALBO;ALESSANDRO CARRIERO;ALESSIO PASCHÈ;MICHELA BARINI;ELEONORA RIZZI;GIUSEPPE FRANCESCO CASCIARO;MICOL GIULIA CITTONE;VERONICA VASSIA;MARCO KRENGLI;ALESSANDRA GALBIATI;ANITA REBECCA PEDRINELLI;EYAL HAYDEN;ILARIA NERICI;SIMONA PRIORA;LUIGI MARIO CASTELLO;GIUSEPPE CIRRINCIONE","786;363;344;282;261;259;254;243;233;226;226;212;210;205;205;205;205;205;204;181","GIUSEPPE DE LUCA;ALESSANDRO CARRIERO;MARCO BRAMBILLA;MONICA VERDOIA;ROCCO GIOSCIA;MATTIA BELLAN;PIER PAOLO SAINAGHI;MARIO PIRISI;FRANCESCO GAVELLI;LUIGI MARIO CASTELLO;ANDREA ROGNONI;FEDERICA NEGRO;MATTEO NARDIN;ROBERTA ROLLA;CATERINA TOMA;CRISTINA RIGAMONTI;GIANMARIA CAMMAROTA;PIERO EMILIO BALBO;STELA VUJOSEVIC;ZENO FALASCHI","16;12;10;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;ENGINEERING;POLITICAL SCIENCE;PSYCHOLOGY;ECONOMICS;GEOGRAPHY;SOCIOLOGY;HISTORY;MATERIALS SCIENCE;ART;PHILOSOPHY","143;26;13;12;8;6;5;5;5;4;3;3;2;2;1;1","INTERNAL MEDICINE;PATHOLOGY;SURGERY;CARDIOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;PEDIATRICS;ENDOCRINOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;EMERGENCY MEDICINE;INTENSIVE CARE MEDICINE;PSYCHIATRY;VIROLOGY;NUCLEAR MEDICINE;GENETICS;BIOCHEMISTRY;ANESTHESIA;OPTICS","111;30;30;24;21;21;18;17;16;16;16;15;15;13;13;11;10;9;8;8","DISEASE;CANCER;MYOCARDIAL INFARCTION;POPULATION;OUTBREAK;CONFIDENCE INTERVAL;DIABETES MELLITUS;COHORT;CHEMOTHERAPY;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;COHORT STUDY;GENE;PROSPECTIVE COHORT STUDY;VITAMIN D AND NEUROLOGY;ADVERSE EFFECT;CONTEXT (ARCHAEOLOGY);CORONARY ARTERY DISEASE;HEART FAILURE;LYMPHOMA;PNEUMONIA;RADIATION THERAPY","51;22;19;19;16;13;13;12;10;9;8;7;7;7;7;6;6;6;6;6;6;6","INFECTIOUS DISEASE (MEDICAL SPECIALTY);2019-20 CORONAVIRUS OUTBREAK;ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;CONVENTIONAL PCI;BREAST CANCER;AMYOTROPHIC LATERAL SCLEROSIS;HAZARD RATIO;PROSTATE CANCER;CLOPIDOGREL;COLORECTAL CANCER;PROSTATE;BRONCHOALVEOLAR LAVAGE;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;DIABETIC RETINOPATHY;EJECTION FRACTION;IMMUNOTHERAPY;METASTASIS;REVASCULARIZATION;TYPE 1 DIABETES;VITAMIN D DEFICIENCY","33;14;11;11;8;7;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);PRASUGREL;TICAGRELOR;BIFIDOBACTERIUM;COLONOSCOPY;DIABETIC MACULAR EDEMA;ESTROGEN RECEPTOR;IBRUTINIB;LYMPHEDEMA;LYMPHOVASCULAR INVASION;NIVOLUMAB;P2Y12;VENETOCLAX;ACUTE CHEST SYNDROME;ADIPOKINE;AFLIBERCEPT;AL AMYLOIDOSIS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ANTIVIRAL THERAPY;ANTIVIRAL TREATMENT;BECK HOPELESSNESS SCALE;BENDAMUSTINE;BILATERAL NEPHRECTOMY;BRADYCARDIA;CASPASE;CASPASE 3;CENTRAL RETINAL VEIN OCCLUSION;CEREBRAL VASCULITIS;CETUXIMAB;CHEMOIMMUNOTHERAPY;CHILD ABUSE;CIRCULATING TUMOR CELL;COGNITIVE DECLINE;COMPOUND HETEROZYGOSITY;COPD EXACERBATION;COTTON WOOL SPOTS;CYP24A1;DIASTOLIC HEART FAILURE;DRUG-ELUTING STENT;EPIRETINAL MEMBRANE;FOURNIER GANGRENE;FRACTIONAL FLOW RESERVE;FRAMESHIFT MUTATION;FRONTOTEMPORAL DEMENTIA;GENE POLYMORPHISM;GENOTYPING;HEART FAILURE WITH PRESERVED EJECTION FRACTION;HYSTEROSALPINGOGRAPHY;IMMUNE CHECKPOINT;INFERIOR VENA CAVA FILTER;INTRA ARTICULAR;INTRAEPITHELIAL NEOPLASIA;ISG15;KETOACIDOSIS;KRAS;LACTOBACILLUS REUTERI;MACE;MACULOPATHY;METASTATIC BREAST CANCER;MULTIPARAMETRIC MRI;NEOADJUVANT THERAPY;NONALCOHOLIC FATTY LIVER DISEASE;ONCOGENE;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PD-L1;PEMBROLIZUMAB;PHARMACOGENETICS;PHOSPHATIDYLCHOLINE;PROSTATE BIOPSY;PROSTATECTOMY;RANIBIZUMAB;RESTRICTIVE CARDIOMYOPATHY;RIVAROXABAN;STEATOHEPATITIS;SUBTHRESHOLD CONDUCTION;TARGET LESION;TAXANE;VINORELBINE","33;4;4;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;ITALY;COVID-19;RETROSPECTIVE STUDIES;PERCUTANEOUS CORONARY INTERVENTION;ADULT;ACUTE CORONARY SYNDROME;RISK FACTORS;AGED, 80 AND OVER;BIOMARKERS;PROSPECTIVE STUDIES;CORONARY ARTERY DISEASE;ST ELEVATION MYOCARDIAL INFARCTION;VITAMIN D;DIABETES MELLITUS, TYPE 1","78;67;46;42;34;33;28;20;20;18;17;14;13;12;12;11;10;10;10;9","IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CORONAVIRUS DISEASE 2019;VITAMIN D AND HEALTH OUTCOMES;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIVERSITY AND FUNCTION OF GUT MICROBIOME;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;RADIOTHERAPY PHYSICS AND TECHNOLOGY;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CANCER IMMUNOTHERAPY;CANCER SURVIVORSHIP AND QUALITY OF LIFE;LYMPHANGIOGENESIS IN CANCER METASTASIS AND DISEASE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;PATHOGENESIS AND TREATMENT OF SYSTEMIC SCLEROSIS;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS","12;7;6;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2","2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;TREATMENT;CLINICAL CHARACTERISTICS;VITAMIN D;CANCER;CLINICAL ENDPOINT;CORONAVIRUS;PLATELET REACTIVITY;CORONAVIRUS INFECTIONS;CT SCAN;DIABETIC RETINOPATHY;DOSE REDUCTION;NEURODEGENERATION;NONINVASIVE VENTILATION;OPTICAL COHERENCE TOMOGRAPHY;TYPE 1 DIABETES;ANTIVIRAL TREATMENT;AUTOIMMUNE HEPATITIS;BETACORONAVIRUS","11;10;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2","ACUTE CORONARY;AMYOTROPHIC LATERAL;CORONARY INTERVENTION;LATERAL SCLEROSIS;LUNG CANCER;PATIENTS TREATED;PERCUTANEOUS CORONARY;UNDERGOING PERCUTANEOUS;ANTIPLATELET THERAPY;BREAST CANCER;CELL LUNG;CORONARY SYNDROME;CORONAVIRUS DISEASE;COVID- OUTBREAK;PROSTATE CANCER;ARTERY DISEASE;BRONCHOALVEOLAR LAVAGE;CANCER RELATED;CORONARY ARTERY;CORONARY SYNDROMES;COVID- PANDEMIC;COVID- PATIENT;DUAL ANTIPLATELET;ELDERLY PATIENTS;HEART FAILURE;ITALIAN EXPERIENCE;NON-SMALL CELL;PATIENTS UNDERGOING;RISK FACTORS;TYPE DIABETES","7;5;5;5;5;5;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ENTITYS BOARD;PATIENTS TREATED;COVID- PANDEMIC;SARS-COV- INFECTION;BREAST CANCER;LUNG CANCER;COVID- PATIENTS;PERCUTANEOUS CORONARY;MMLMATH XMLNSMMLHTTPWWWWORGMATHMATHML;SCIENCEGOOGLE SCHOLAR;ACUTE CORONARY;ARRIGO ALESSANDRIA;AZIENDA OSPEDALIERA;CESARE ARRIGO;CORONAVIRUS DISEASE;IN-HOSPITAL MORTALITY;OSPEDALIERA SS;SS ANTONIO;CANCER PATIENTS;CORONARY INTERVENTION;INCREASED RISK;INTENSIVE CARE;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;PATIENTS UNDERGOING;CARDIOLOGY AZIENDA;ACUTE RESPIRATORY;CARE UNIT;CONFIDENCE INTERVAL;CORONARY SYNDROME","22;22;17;17;16;15;12;12;11;11;10;10;10;10;10;10;10;10;9;9;9;9;9;9;9;8;7;7;7;7",2,0.01,3.67,6.75,0,0,0,0,0,0,0,7.5,0,0,6.75,0,0,0,3,4.5,0,0,0,45.25,45.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,3.17,392,9.42,12,0.67,58.11,0,1,3,1,5,0,0,8,0,13,5,0,0,0,0,0,0,17,1,0,18,0,0,0,0,0,0,0,0,0,"Italy;United States;Denmark;Netherlands;Spain;United Kingdom","6;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3205 MEDICAL BIOCHEMISTRY AND METABOLOMICS;3212 OPHTHALMOLOGY AND OPTOMETRY","18;11;8;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;CANCER;HEMATOLOGY;DIGESTIVE DISEASES;PATIENT SAFETY;AGING;LUNG;LYMPHOMA;PREVENTION;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BIOTECHNOLOGY;BRAIN DISORDERS;BREAST CANCER;CARDIOVASCULAR;COMPLEMENTARY AND INTEGRATIVE HEALTH;DEMENTIA","15;11;8;6;5;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;EYE;METABOLIC AND ENDOCRINE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL","5;1;1;1;1","6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.1 PHARMACEUTICALS","12;2;2;2;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;OVARIAN CANCER","3;2;2;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.2 SURVEILLANCE","4;1;1;1",1,5998273,272648.77,5,22,9,1,11,54529.7545454545,2.67743732237596,"ACADEMIC MEDICAL CENTER;ALZHEIMER EUROPE;ANAXOMICS (SPAIN);ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE;AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITA;EUROPEAN ADVANCED TRANSLATIONAL RESEARCH INFRASTRUCTURE - ERIC;FONDAZIONE G.B. BIETTI;INSTITUT CATALÀ DE LA SALUT;INSTITUT D'INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL;INTERNATIONAL DIABETES FEDERATION;IRCCS OSPEDALE SAN RAFFAELE;KLINIČKI CENTAR CRNE GORE;MULTIMEDICA;OXURION (BELGIUM);QUEEN'S UNIVERSITY BELFAST;UNIVERSITY MEDICAL CENTER UTRECHT;UNIVERSITY OF CÁDIZ;UNIVERSITY OF MILAN;UNIVERSITY OF MONTENEGRO;UNIVERSITY OF ROME TOR VERGATA","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);RIA - RESEARCH AND INNOVATION ACTION (FUNDING SCHEME)","1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BRAIN DISORDERS;CLINICAL RESEARCH;DEMENTIA;DIABETES;EYE DISEASE AND DISORDERS OF VISION;NEURODEGENERATIVE;NEUROSCIENCES","1;1;1;1;1;1;1;1;1;1;1","EYE;METABOLIC AND ENDOCRINE;NEUROLOGICAL","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_NOVARAGALLIATE",2021,197,21.2893401015228,3.60406091370558,0.274111675126904,0.269035532994924,0.390862944162437,2.17791411042945,1.25581395348837,2.12,1.26229508196721,0.609137055837564,0,81,52,25,9,0.41,0.26,0.13,0.05,16.08,1.04250327043116,6.45949720670391,0.32994923857868,1,0.555,0.414,0.339,0.453,"GIUSEPPE PATTI;MATTIA BELLAN;PIER PAOLO SAINAGHI;ANDREA PATRIARCA;GIUSEPPE DE LUCA;ALESSANDRO CARRIERO;MARIO PIRISI;ROBERTO CANTELLO;PAOLA SAVOIA;LUIGI MARIO CASTELLO;MONICA VERDOIA;DANILA AZZOLINA;ANDREA ROGNONI;PIERO EMILIO BALBO;ROBERTA ROLLA;LETIZIA MAZZINI;FILIPPO PATRUCCO;GIAN CARLO AVANZI;FRANCESCA PALANDRI;UMBERTO DIANZANI","27;17;17;15;14;13;13;13;12;12;11;11;10;10;10;10;9;9;8;8","GIUSEPPE PATTI;PAOLA SAVOIA;GIUSEPPE DE LUCA;ROBERTO CANTELLO;MONICA VERDOIA;MATTIA BELLAN;ALESSANDRO CARRIERO;PIER PAOLO SAINAGHI;LETIZIA MAZZINI;DOMIZIA VECCHIO;PIERO EMILIO BALBO;MARIO PIRISI;ANDREA PATRIARCA;EDOARDO CAMMARATA;LUIGI MARIO CASTELLO;ROBERTA ROLLA;CHIARA AIROLDI;ROCCO GIOSCIA;MARCO BRAMBILLA;LAURA CRISTINA GIRONI","2.29;1.76;1.55;1.52;1.28;1.2;1.17;1.12;0.95;0.93;0.84;0.83;0.82;0.8;0.79;0.78;0.76;0.76;0.74;0.74","GIUSEPPE PATTI;MATTIA BELLAN;PIER PAOLO SAINAGHI;ANDREA PATRIARCA;GIUSEPPE DE LUCA;ALESSANDRO CARRIERO;MARIO PIRISI;ROBERTO CANTELLO;PAOLA SAVOIA;LUIGI MARIO CASTELLO;MONICA VERDOIA;DANILA AZZOLINA;ANDREA ROGNONI;PIERO EMILIO BALBO;ROBERTA ROLLA;LETIZIA MAZZINI;FILIPPO PATRUCCO;GIAN CARLO AVANZI;UMBERTO DIANZANI;GIANLUCA GAÏDANO","27;17;17;15;14;13;13;13;12;12;11;11;10;10;10;10;9;9;8;8","GIUSEPPE PATTI;PAOLA SAVOIA;GIUSEPPE DE LUCA;ROBERTO CANTELLO;MONICA VERDOIA;MATTIA BELLAN;ALESSANDRO CARRIERO;PIER PAOLO SAINAGHI;LETIZIA MAZZINI;DOMIZIA VECCHIO;PIERO EMILIO BALBO;MARIO PIRISI;ANDREA PATRIARCA;EDOARDO CAMMARATA;LUIGI MARIO CASTELLO;ROBERTA ROLLA;ROCCO GIOSCIA;MARCO BRAMBILLA;LAURA CRISTINA GIRONI;FABIOLA DE MARCHI","2.29;1.76;1.55;1.52;1.28;1.2;1.17;1.12;0.95;0.93;0.84;0.83;0.82;0.8;0.79;0.78;0.76;0.74;0.74;0.7","PIER PAOLO SAINAGHI;VINCENZO CANTALUPPI;MATTIA BELLAN;PIERO EMILIO BALBO;MARIO PIRISI;GIUSEPPE PATTI;ALESSIO BARICICH;LUIGI MARIO CASTELLO;PATRIZIA ZEPPEGNO;FILIPPO PATRUCCO;GIAN CARLO AVANZI;DARIA CUNEO;CARLA GRAMAGLIA;CRISTINA RIGAMONTI;CARLO CISARI;E. GATTONI;ELEONORA GAMBARO;ELISA CLIVATI;MARCO BATTAGLIA;EYAL HAYDEN","957;862;777;711;704;689;666;656;645;623;620;594;585;572;561;556;553;531;531;501","PIER PAOLO SAINAGHI;MARIO PIRISI;PIERO EMILIO BALBO;MATTIA BELLAN;LUIGI MARIO CASTELLO;GIUSEPPE PATTI;E. GATTONI;PATRIZIA ZEPPEGNO;ELISA CLIVATI;CRISTINA RIGAMONTI;GIAN CARLO AVANZI;ALESSIO BARICICH;FILIPPO PATRUCCO;LEONARDO GRISAFI;CARLA GRAMAGLIA;EYAL HAYDEN;LUCA LORENZINI;VINCENZO CANTALUPPI;CARLO CISARI;MARCO INVERNIZZI","827;686;645;626;625;576;556;538;531;524;513;496;495;481;478;478;478;478;474;474","GIUSEPPE PATTI;ANDREA PATRIARCA;PIER PAOLO SAINAGHI;GIUSEPPE DE LUCA;ROBERTO CANTELLO;ALESSANDRO CARRIERO;MARIO PIRISI;MATTIA BELLAN;LUIGI MARIO CASTELLO;LETIZIA MAZZINI;ANDREA ROGNONI;PIERO EMILIO BALBO;GIAN CARLO AVANZI;MARCO MENNUNI;ROBERTA ROLLA;GIANLUCA GAÏDANO;FILIPPO PATRUCCO;LAURA CRISTINA GIRONI;MARCO BRAMBILLA;PATRIZIA ZEPPEGNO","24;14;13;12;12;11;11;11;10;10;10;8;8;7;7;7;6;6;6;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;MATHEMATICS;ECONOMICS;PSYCHOLOGY;SOCIOLOGY;ENGINEERING;BUSINESS;GEOGRAPHY;GEOLOGY;PHILOSOPHY;POLITICAL SCIENCE;ART;HISTORY","190;42;24;13;9;9;8;5;5;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;CARDIOLOGY;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;EMERGENCY MEDICINE;ENVIRONMENTAL HEALTH;GENETICS;PSYCHIATRY;BIOCHEMISTRY;OPTICS;PEDIATRICS;INTENSIVE CARE MEDICINE;VIROLOGY;NUCLEAR MEDICINE;DERMATOLOGY;ANESTHESIA;CANCER RESEARCH;PHYSICAL THERAPY","154;48;38;38;28;23;23;23;18;17;17;17;16;16;15;14;13;12;10;9;9;9","DISEASE;MYOCARDIAL INFARCTION;COHORT;CANCER;POPULATION;RANDOMIZED CONTROLLED TRIAL;OUTBREAK;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;CONFIDENCE INTERVAL;GENE;INCIDENCE (GEOMETRY);HEART FAILURE;LUNG;PROSPECTIVE COHORT STUDY;BONE MARROW;CHEMOTHERAPY;CORONARY ARTERY DISEASE;EPIDEMIOLOGY;LYMPHOMA","66;26;20;19;17;17;15;15;14;13;13;13;12;10;10;9;9;9;8;8","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;ACUTE CORONARY SYNDROME;PERCUTANEOUS CORONARY INTERVENTION;AMYOTROPHIC LATERAL SCLEROSIS;CONVENTIONAL PCI;HAZARD RATIO;MYELOFIBROSIS;EJECTION FRACTION;MULTICENTER STUDY;CLOPIDOGREL;COLORECTAL CANCER;BREAST CANCER;PHASES OF CLINICAL RESEARCH;UNIVARIATE ANALYSIS;ADENOCARCINOMA;AORTIC VALVE REPLACEMENT;CASE FATALITY RATE;CHRONIC LYMPHOCYTIC LEUKEMIA;COGNITIVE IMPAIRMENT;CORONARY ANGIOGRAPHY;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;ESSENTIAL THROMBOCYTHEMIA;IMMUNOTHERAPY;ISCHEMIC STROKE;MANTLE CELL LYMPHOMA;MUTATION;PHENOTYPE;RITUXIMAB;T CELL;TYPE 2 DIABETES;VASCULITIS","39;18;13;11;11;8;8;8;8;7;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);MACE;RUXOLITINIB;TICAGRELOR;FRACTIONAL FLOW RESERVE;MODIFIED RANKIN SCALE;ANAPLASTIC LYMPHOMA KINASE;CARDIAC RESYNCHRONIZATION THERAPY;COLONOSCOPY;DIFFUSING CAPACITY;EXOME SEQUENCING;GIANT CELL ARTERITIS;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;HEART FAILURE WITH PRESERVED EJECTION FRACTION;METASTATIC BREAST CANCER;MICROVESICLES;P2Y12;PRASUGREL;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;STROKE VOLUME;TRANSIENT ELASTOGRAPHY;VINCRISTINE","39;5;4;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;COVID-19;MALE;FEMALE;MIDDLE AGED;AGED;RETROSPECTIVE STUDIES;ITALY;PERCUTANEOUS CORONARY INTERVENTION;ACUTE CORONARY SYNDROME;SARS-COV-2;ST ELEVATION MYOCARDIAL INFARCTION;ADULT;TREATMENT OUTCOME;AGED, 80 AND OVER;PROSPECTIVE STUDIES;LUNG NEOPLASMS;PLATELET AGGREGATION INHIBITORS;PROGNOSIS","101;96;60;44;43;35;34;29;25;24;23;20;20;19;15;13;13;11;11;10","IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CORONAVIRUS DISEASE 2019;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;LYMPHOID NEOPLASMS;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;ADVANCEMENTS IN LUNG CANCER RESEARCH;APPLICATIONS OF DEEP LEARNING IN MEDICAL IMAGING;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY","11;7;7;7;7;7;6;5;5;4;4;3;3;3;3;3;3;3;3;3","CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;DISCONTINUATION;MYELOFIBROSIS;CARDIAC IMAGING;MACE;MANTLE CELL LYMPHOMA;TREATMENT;BETACORONAVIRUS;CLINICAL CHARACTERISTICS;CROSS-SECTIONAL STUDY;POSTINFARCTION VENTRICULAR SEPTAL DEFECT;RUXOLITINIB;RUXOLITINIB THERAPY;SPINAL MUSCULAR ATROPHY;UNIVARIATE ANALYSIS;BLEEDING RISK;CASE FATALITY RATE;CORONARY STENTS","18;12;11;6;6;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3","ACUTE CORONARY;CORONARY SYNDROME;AMYOTROPHIC LATERAL;LATERAL SCLEROSIS;PATIENTS UNDERGOING;COVID- PATIENTS;COVID- PANDEMIC;PATIENTS TREATED;PELABRESIB CPI-;PHASE STUDY;CLINICAL OUTCOME;ELDERLY PATIENTS;MANIFEST PHASE;MULTICENTER STUDY;MULTIPLE SCLEROSIS;STEMI PATIENTS;ANTIPLATELET THERAPY;BREAST CANCER;CANCER PATIENTS;CELL LYMPHOMA;CORONARY BIFURCATION;CORONARY INTERVENTION;CROSS-SECTIONAL STUDY;DUAL ANTIPLATELET;HOSPITALIZED PATIENTS;IN-HOSPITAL MORTALITY;ITALIAN COHORT;LUNG CANCER;MANTLE CELL;MECHANICAL REPERFUSION","10;9;8;8;7;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","ADVISORY COMMITTEES;ENTITYS BOARD;CORONAVIRUS DISEASE;PATIENTS TREATED;SARS-COV- INFECTION;COVID- PANDEMIC;SPEAKERS BUREAU;CHEST CT;COVID- PATIENTS;CONSULTANCY HONORARIA;DISEASE COVID-;RISK FACTORS;HR CI;ACUTE RESPIRATORY;MATH XMLNSHTTPWWWWORGMATHMATHML;XMLNSHTTPWWWWORGMATHMATHML IDM;DOSE INTENSITY;HONORARIA MEMBERSHIP;LEFT VENTRICULAR;PRIMARY ENDPOINT;RESEARCH FUNDING;TRAVEL SUPPORT;BRONCHOALVEOLAR LAVAGE;COMMITTEES SPEAKERS;HEART FAILURE;INTENSIVE CARE;MYOCARDIAL INFARCTION;PATIENTS UNDERGOING;COVID- PNEUMONIA;IN-HOSPITAL MORTALITY","51;51;25;23;23;21;21;20;19;18;18;18;17;16;16;16;15;15;15;15;15;15;13;13;12;12;12;12;11;11",1,0.01,0.75,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,1,1,0,0,0,17,17,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,4.29,596.86,7.02,13,0.62,101.1,0,0,2,0,10,0,0,9,0,16,5,0,0,0,0,0,0,20,0,1,21,0,0,0,0,0,0,0,0,0,"Italy;United States","5;5","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY","21;11;7;3;3;3;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;LYMPHOMA;PATIENT SAFETY;BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;NEUROSCIENCES;AGING;BIOTECHNOLOGY;NEURODEGENERATIVE;ORPHAN DRUG;PREVENTION;ALS;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BIOENGINEERING","21;19;10;10;9;6;4;3;3;3;3;2;2;2;2;2;1;1;1;1","CANCER;CARDIOVASCULAR;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM;ORAL AND GASTROINTESTINAL;RESPIRATORY;SKIN","7;3;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.4 SURGERY","16;5;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BLADDER CANCER;MYELOMA;PROSTATE CANCER","6;3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING","7;2;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO;FUTURE SCIENCE GROUP;KARGER PUBLISHERS","9;5;4;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;3105 GENETICS;3101 BIOCHEMISTRY AND CELL BIOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS","32;11;5;5;3;3;3;3;2;1;1;1;1","RARE DISEASES;CLINICAL RESEARCH;BIODEFENSE;BRAIN DISORDERS;EMERGING INFECTIOUS DISEASES;GENETICS;INFECTIOUS DISEASES;LUNG;PNEUMONIA;PNEUMONIA & INFLUENZA;PREVENTION;VACCINE RELATED;ALS;NEURODEGENERATIVE;NEUROSCIENCES;BEHAVIORAL AND SOCIAL SCIENCE;CANCER;COMPLEMENTARY AND INTEGRATIVE HEALTH;DEPRESSION;GENETIC TESTING","5;4;3;3;3;3;3;3;3;3;3;3;2;2;2;1;1;1;1;1","INFECTION;NEUROLOGICAL;MENTAL HEALTH","3;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","5;3;2","BIOMEDICAL;CLINICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","4;1;1;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH","4;4;1","NOT SITE-SPECIFIC CANCER;LEUKEMIA / LEUKAEMIA","2;1",NA,NA
"AOU_NOVARAGALLIATE",2022,167,19.2874251497006,3.03592814371258,0.25748502994012,0.269461077844311,0.263473053892216,1.96511627906977,1.16216216216216,1.875,1.22222222222222,0.70059880239521,0,59,36,23,9,0.35,0.22,0.14,0.05,6.25,0.6996351502706,6.55627425614489,0.323353293413174,1,0.466,0.462,0.401,0.49,"MATTIA BELLAN;PIER PAOLO SAINAGHI;GIUSEPPE PATTI;MARIO PIRISI;PAOLA SAVOIA;LUIGI MARIO CASTELLO;ROSALBA MINISINI;CRISTINA RIGAMONTI;MARCO KRENGLI;CARLA GRAMAGLIA;FILIPPO PATRUCCO;RENZO BOLDORINI;PATRIZIA ZEPPEGNO;STELVIO TONELLO;GIULIA FRANCESCA MANFREDI;DANIELA FERRANTE;LETIZIA MAZZINI;FABIOLA DE MARCHI;ROBERTO CANTELLO;FEDERICA VERONESE","16;16;16;15;11;10;9;9;9;9;8;8;8;8;8;8;8;7;7;7","GIUSEPPE PATTI;PAOLA SAVOIA;MATTIA BELLAN;PIER PAOLO SAINAGHI;MARIO PIRISI;FEDERICA VERONESE;MARCO KRENGLI;FILIPPO PATRUCCO;ELISA ZAVATTARO;CRISTINA RIGAMONTI;PATRIZIA ZEPPEGNO;LUIGI MARIO CASTELLO;RENZO BOLDORINI;CARLA GRAMAGLIA;ROBERTO CANTELLO;GIULIA FRANCESCA MANFREDI;ALESSANDRO CARRIERO;ROSALBA MINISINI;LETIZIA MAZZINI;LORENZA SCOTTI","1.67;1.39;1.32;1.29;1.14;0.97;0.91;0.86;0.83;0.78;0.76;0.75;0.72;0.72;0.71;0.7;0.64;0.58;0.57;0.56","MATTIA BELLAN;PIER PAOLO SAINAGHI;GIUSEPPE PATTI;MARIO PIRISI;PAOLA SAVOIA;LUIGI MARIO CASTELLO;CRISTINA RIGAMONTI;MARCO KRENGLI;CARLA GRAMAGLIA;FILIPPO PATRUCCO;RENZO BOLDORINI;PATRIZIA ZEPPEGNO;GIULIA FRANCESCA MANFREDI;LETIZIA MAZZINI;FABIOLA DE MARCHI;ROBERTO CANTELLO;FEDERICA VERONESE;GIAN CARLO AVANZI;CHIARA AIROLDI;ELISA ZAVATTARO","16;16;16;15;11;10;9;9;9;8;8;8;8;8;7;7;7;7;6;6","GIUSEPPE PATTI;PAOLA SAVOIA;MATTIA BELLAN;PIER PAOLO SAINAGHI;MARIO PIRISI;FEDERICA VERONESE;MARCO KRENGLI;FILIPPO PATRUCCO;ELISA ZAVATTARO;CRISTINA RIGAMONTI;PATRIZIA ZEPPEGNO;LUIGI MARIO CASTELLO;RENZO BOLDORINI;CARLA GRAMAGLIA;ROBERTO CANTELLO;GIULIA FRANCESCA MANFREDI;ALESSANDRO CARRIERO;LETIZIA MAZZINI;FRANCESCO GAVELLI;LAURA CRISTINA GIRONI","1.67;1.39;1.32;1.29;1.14;0.97;0.91;0.86;0.83;0.78;0.76;0.75;0.72;0.72;0.71;0.7;0.64;0.57;0.56;0.55","MARIO PIRISI;MATTIA BELLAN;PIER PAOLO SAINAGHI;CARLA GRAMAGLIA;ENDRE CZEITER;ROSALBA MINISINI;STELVIO TONELLO;FRANCESCA GROSSI;FRANÇESCO DELLA CORTE;PATRIZIA ZEPPEGNO;DAVID J. PINATO;LUIGI MARIO CASTELLO;ANDREA PATRIARCA;GIAN CARLO AVANZI;CRISTINA RIGAMONTI;ABHISHEK DIXIT;ALESSIO CACCIOPPOLA;ALEX FURMANOV;ALEXANDRA BRAŽINOVÁ;ALEXANDRE GHUYSEN","154;144;141;133;122;102;102;99;99;87;82;82;73;70;69;68;68;68;68;68","MARIO PIRISI;PIER PAOLO SAINAGHI;MATTIA BELLAN;CARLA GRAMAGLIA;PATRIZIA ZEPPEGNO;ANDREA PATRIARCA;GIAN CARLO AVANZI;CRISTINA RIGAMONTI;ELEONORA RIZZI;ERICA MATINO;ERIKA ZECCA;GIUSEPPE FRANCESCO CASCIARO;MARTINA COSTANZO;FRANCESCA GROSSI;FRANÇESCO DELLA CORTE;LETIZIA MAZZINI;FILIPPO PATRUCCO;PIERO EMILIO BALBO;ALESSIO BARICICH;G. DONATO","152;136;130;127;84;73;70;66;64;64;64;64;64;62;62;56;55;55;52;52","MARIO PIRISI;PIER PAOLO SAINAGHI;MATTIA BELLAN;GIUSEPPE PATTI;CARLA GRAMAGLIA;CRISTINA RIGAMONTI;PATRIZIA ZEPPEGNO;ANDREA PATRIARCA;GIAN CARLO AVANZI;GIULIA FRANCESCA MANFREDI;FEDERICA VERONESE;LETIZIA MAZZINI;FRANCESCO GAVELLI;RENZO BOLDORINI;ALESSANDRO CARRIERO;FABIOLA DE MARCHI;FILIPPO PATRUCCO;ROBERTO CANTELLO;MARCO KRENGLI;ANTONIO ACQUAVIVA","14;14;14;13;8;8;7;7;7;7;7;6;6;6;5;5;5;5;5;4","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;PHYSICS;ENGINEERING;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;BUSINESS;PHILOSOPHY;GEOGRAPHY;ART;MATERIALS SCIENCE","163;40;18;17;15;14;14;10;5;5;5;3;3;2;1;1","INTERNAL MEDICINE;PATHOLOGY;ONCOLOGY;PSYCHIATRY;SURGERY;IMMUNOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;PEDIATRICS;BIOCHEMISTRY;GASTROENTEROLOGY;GENETICS;EMERGENCY MEDICINE;CANCER RESEARCH;PALEONTOLOGY;CLINICAL PSYCHOLOGY;NURSING;ARTIFICIAL INTELLIGENCE;ECONOMIC GROWTH;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;MEDICAL EMERGENCY","131;35;27;26;24;20;20;19;18;18;17;15;15;14;13;11;10;10;9;9;9;9;9","DISEASE;CANCER;GENE;POPULATION;COHORT;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;CONFIDENCE INTERVAL;OUTBREAK;RANDOMIZED CONTROLLED TRIAL;MYOCARDIAL INFARCTION;PROSPECTIVE COHORT STUDY;CONTEXT (ARCHAEOLOGY);HEALTH CARE;POISON CONTROL;ADVERSE EFFECT;NEUROLOGY;ODDS RATIO;VACCINATION;BONE MARROW;CHEMOTHERAPY;DEPRESSION (ECONOMICS);INCIDENCE (GEOMETRY);LYMPHOMA;MULTIVARIATE ANALYSIS;RADIATION THERAPY","47;24;19;17;16;13;12;10;10;10;9;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6","INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;GENE EXPRESSION;BREAST CANCER;AMYOTROPHIC LATERAL SCLEROSIS;AUTOIMMUNE HEPATITIS;EJECTION FRACTION;HAZARD RATIO;IMMUNOTHERAPY;SUICIDE PREVENTION;DEMENTIA;INJURY PREVENTION;MYELOFIBROSIS;NEURORADIOLOGY;PERCUTANEOUS CORONARY INTERVENTION;PROSTATE CANCER;TELEMEDICINE;UNIVARIATE ANALYSIS;GERMLINE;HEAD AND NECK CANCER;MULTICENTER STUDY;MUTATION;NICOTINAMIDE;PROSTATE;PROTOCOL (SCIENCE);RITUXIMAB","27;10;9;8;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;HEAD AND NECK SQUAMOUS-CELL CARCINOMA;NIVOLUMAB;SUICIDE ATTEMPT;AXITINIB;BECK ANXIETY INVENTORY;CHEMOIMMUNOTHERAPY;FRONTOTEMPORAL DEMENTIA;GAS6;GERMLINE MUTATION;HEPATITIS A VACCINE;RUXOLITINIB;SUICIDAL IDEATION;TAXANE;TELEDERMATOLOGY;TRANSIENT ELASTOGRAPHY;ABATACEPT;ALTERNATIVE COMPLEMENT PATHWAY;ANDROGEN RECEPTOR;ANTHRACYCLINE;BECK HOPELESSNESS SCALE;BOOSTER DOSE;BROTH MICRODILUTION;CALCITONIN GENE-RELATED PEPTIDE;CANCER CACHEXIA;CARDIAC RESYNCHRONIZATION THERAPY;CARDIOTOCOGRAPHY;CAREGIVER BURDEN;CASPOFUNGIN;CETUXIMAB;CHRONIC MYELOMONOCYTIC LEUKEMIA;CLASSICAL COMPLEMENT PATHWAY;CLINICAL PHENOTYPE;COGNITIVE DECLINE;CONTRAST-INDUCED NEPHROPATHY;CONVERGENT VALIDITY;CRIZOTINIB;DASATINIB;DIFFUSING CAPACITY;DIROFILARIA;DIROFILARIA REPENS;DISCRIMINANT VALIDITY;EVANS SYNDROME;EXTRAMEDULLARY HEMATOPOIESIS;FALL PREVENTION;FRACTIONAL FLOW RESERVE;GENE SIGNATURE;GLYCATED HEMOGLOBIN;HORMONAL THERAPY;HORMONE THERAPY;IMMUNE CHECKPOINT;INJURY SEVERITY SCORE;INTERNATIONAL PROGNOSTIC INDEX;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;LOWER URINARY TRACT SYMPTOMS;METHYLTRANSFERASE;MODIFIED RANKIN SCALE;MYELOPROLIFERATIVE NEOPLASM;NIACINAMIDE;NILOTINIB;NUCLEOTIDE EXCISION REPAIR;OBINUTUZUMAB;PANCREATIC DUCTAL ADENOCARCINOMA;PAZOPANIB;PEMBROLIZUMAB;PERIPARTUM CARDIOMYOPATHY;PHENOCOPY;PLACENTA;PLEOMORPHIC XANTHOASTROCYTOMA;POSACONAZOLE;PROBAND;PROSTATE BIOPSY;REPRESSOR;RIBAVIRIN;RIGHT CORONARY ARTERY;ROS1;SACUBITRIL;SACUBITRIL, VALSARTAN;SEED DORMANCY;SOD1;STROKE VOLUME;SYNTHETIC LETHALITY;SØRENSEN–DICE COEFFICIENT;TAU PROTEIN;TELEHEALTH;TIMI;TNF INHIBITOR;TRANSCRIPTOME;TRANSLATION (BIOLOGY);TRINUCLEOTIDE REPEAT EXPANSION;USUAL INTERSTITIAL PNEUMONIA","27;6;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;FEMALE;RETROSPECTIVE STUDIES;MALE;SARS-COV-2;ADULT;PANDEMICS;AGED;ITALY;AMYOTROPHIC LATERAL SCLEROSIS;PROSPECTIVE STUDIES;DERMATITIS, ATOPIC;HEAD AND NECK NEOPLASMS;MIDDLE AGED;POSITRON-EMISSION TOMOGRAPHY;TOMOGRAPHY, X-RAY COMPUTED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;BIOMARKERS","85;80;37;18;17;16;16;13;12;11;11;10;9;7;7;7;7;7;6;6","IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;SUICIDAL BEHAVIOR AND PREVENTION STRATEGIES;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;CORONAVIRUS DISEASE 2019 RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;ACUTE MYELOID LEUKEMIA;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;MECHANISMS OF APOPTOTIC CELL CLEARANCE AND IMMUNE REGULATION;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;ADVANCEMENTS IN LUNG CANCER RESEARCH;ATOPIC DERMATITIS AND SKIN MICROBIOME;CANCER IMMUNOTHERAPY;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF BILIARY TRACT DISORDERS;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;DISEASES RELATED TO BLOOD GROUP VARIANTS","6;6;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","PANDEMIC;CLINICAL ENDPOINT;2019-20 CORONAVIRUS OUTBREAK;AUTOIMMUNE HEPATITIS;DEPRESSION (ECONOMICS);INTERQUARTILE RANGE;NEURORADIOLOGY;PET/CT;UNIVARIATE ANALYSIS;C9ORF72;CLINICAL CHARACTERISTICS;DECITABINE;DIAGNOSIS;EMERGENCY DEPARTMENT VISITS;LIVER BIOPSY;LIVER FIBROSIS;MYOCARDIAL REVASCULARIZATION;PSYCHOLOGICAL AUTOPSY;STEATOSIS;AXITINIB","12;10;9;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;2","COVID- PANDEMIC;COVID- PATIENTS;CORONARY INTERVENTION;OBSERVATIONAL STUDY;PATIENTS AFFECTED;PERCUTANEOUS CORONARY;PROSTATE CANCER;AML PATIENTS;AUTOIMMUNE HEPATITIS;CELL CARCINOMA;METASTATIC RENAL;MULTICENTER STUDY;NECK CANCER;PATIENTS UNDERGOING;PHASE II;PHASE III;POPULATION-BASED STUDY;RANDOMIZED PHASE;RENAL CELL;ACUTE CORONARY;ALS PATIENTS;AMYOTROPHIC LATERAL;ARTERIAL HYPERTENSION;ATOPIC DERMATITIS;BILIO-PANCREATIC DISEASES;BRAIN INJURY;BREAST CANCER;BRONCHOALVEOLAR LAVAGE;CANCER PATIENTS;CARE UNIT","7;6;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MENTAL PAIN;RISK FACTORS;HR CI;PATIENTS UNDERGOING;CHEST CT;MYOCARDIAL DAMAGE;PATIENTS TREATED;STAGE III;COVID- PANDEMIC;DEPRESSIVE SYMPTOMS;III NSCLC;INTENSIVE CARE;MEDIAN AGE;STATISTICALLY SIGNIFICANT;CD CD;COHORT STUDY;INDEPENDENT PREDICTORS;MULTIVARIATE ANALYSIS;OBSERVATIONAL STUDY;PRIMARY ENDPOINT;RELATIONSHIP RECIPROCITY;ADVERSE EVENTS;ALL-CAUSE MORTALITY;ALS PATIENTS;CLINICAL PRACTICE;COVID- PATIENTS;LOGISTIC REGRESSION;MEDIAN FOLLOW-UP;MOLECULAR CLUSTERS;ODDS RATIO","19;16;12;12;11;11;11;10;9;9;9;9;9;9;8;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7",4,0.02,12.72,5.5,0,1,0,2,0,1,0,6.5,0,0,5,0,0,0,1,4.75,0,0,0,13.25,13.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,16,3.25,3186.06,6.87,7,0.44,118,0,0,1,1,4,0,0,9,1,10,6,0,0,0,0,0,0,15,1,0,15,0,1,0,0,0,0,0,0,0,"Italy;United States;Portugal;United Kingdom","16;6;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3215 REPRODUCTIVE MEDICINE","16;9;5;2;2;2;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;CHRONIC LIVER DISEASE AND CIRRHOSIS;LIVER DISEASE;PREVENTION;BREAST CANCER;CARDIOVASCULAR;DIABETES;HEMATOLOGY;LUNG;NEUROSCIENCES;NUTRITION;OBESITY;AGING;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS","16;6;6;5;4;4;3;3;3;2;2;2;2;2;2;2;2;1;1;1","CANCER;ORAL AND GASTROINTESTINAL;METABOLIC AND ENDOCRINE;CARDIOVASCULAR;INJURIES AND ACCIDENTS;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","6;4;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;8.1 ORGANISATION AND DELIVERY OF SERVICES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.3 NUTRITION AND CHEMOPREVENTION;5.1 PHARMACEUTICALS","6;2;2;1;1;1;1","LIVER CANCER;BREAST CANCER;NON-HODGKIN'S LYMPHOMA;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;RESPIRATORY SYSTEM;SARCOMA","3;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;3.2 NUTRITIONAL SCIENCE IN CANCER PREVENTION","6;1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,"FRONTIERS;SPRINGER NATURE;ZENODO","14;2;2","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;4202 EPIDEMIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3210 NUTRITION AND DIETETICS;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;44 HUMAN SOCIETY;4410 SOCIOLOGY;52 PSYCHOLOGY","27;19;13;3;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;BRAIN DISORDERS;GENETICS;AUTOIMMUNE DISEASE;HUMAN GENOME;MULTIPLE SCLEROSIS;NEURODEGENERATIVE;NEUROSCIENCES;MENTAL HEALTH;PEDIATRIC;AUTISM;BIOTECHNOLOGY;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);PREVENTION;BEHAVIORAL AND SOCIAL SCIENCE;DEPRESSION;DIABETES;NUTRITION;SERIOUS MENTAL ILLNESS;SUICIDE","13;12;11;8;7;7;7;7;5;5;4;4;4;3;2;1;1;1;1;1","NEUROLOGICAL;METABOLIC AND ENDOCRINE","11;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","7;4;1","BIOMEDICAL;CLINICAL","7;6","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","6;1","NOT SITE-SPECIFIC CANCER","7",NA,NA
"AOU_NOVARAGALLIATE",2023,135,20.162962962963,2.61481481481482,0.237037037037037,0.22962962962963,0.296296296296296,1.75,1.23076923076923,1.34782608695652,1.33333333333333,0.711111111111111,0,56,33,9,5,0.41,0.24,0.07,0.04,3.52,0.802748511978381,5.67259786476868,0.355555555555556,1,0.451,0.338,0.345,0.342,"MARIO PIRISI;LETIZIA MAZZINI;ELISA ZAVATTARO;PAOLA SAVOIA;PATRIZIA ZEPPEGNO;ANDREA CALVO;CARLA GRAMAGLIA;ADRIANO CHIÒ;ROSALBA MINISINI;ALESSANDRO LIBRETTI;MATTIA BELLAN;GIUSEPPE PATTI;GIANLUCA GAÏDANO;CARLO CATTRINI;VALENTINO REMORGIDA;MARCO BRAMBILLA;ALESSANDRO CARRIERO;ANTONIO CANOSA;ORAZIO CAFFO;PIER PAOLO SAINAGHI","9;8;7;7;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5","ALESSANDRO LIBRETTI;VALENTINO REMORGIDA;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;ELISA ZAVATTARO;PAOLA SAVOIA;FEDERICA VERONESE;FILIPPO PATRUCCO;MARIO PIRISI;MARCO BRAMBILLA;PAOLO SOLIDORO;DANIELA SURICO;ALESSANDRO CARRIERO;LIBERA TROÌA;CHIARA AIROLDI;CARMELA RINALDI;ELIA ESPOSTO;LETIZIA MAZZINI;RAFFAELLA CALATI;FABIO MADEDDU","1.16;1.16;0.96;0.96;0.81;0.81;0.6;0.59;0.57;0.57;0.55;0.5;0.49;0.49;0.48;0.47;0.46;0.46;0.45;0.45","MARIO PIRISI;LETIZIA MAZZINI;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;ROSALBA MINISINI;ALESSANDRO LIBRETTI;MATTIA BELLAN;GIUSEPPE PATTI;GIANLUCA GAÏDANO;CARLO CATTRINI;VALENTINO REMORGIDA;MARCO BRAMBILLA;ALESSANDRO CARRIERO;PIER PAOLO SAINAGHI;FABIOLA DE MARCHI;FEDERICA VERONESE;DANIELA SURICO;ALESSIA MENNITTO;FILIPPO PATRUCCO;ELIA ESPOSTO","9;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;4;4","ALESSANDRO LIBRETTI;VALENTINO REMORGIDA;PATRIZIA ZEPPEGNO;CARLA GRAMAGLIA;FEDERICA VERONESE;FILIPPO PATRUCCO;MARIO PIRISI;MARCO BRAMBILLA;DANIELA SURICO;ALESSANDRO CARRIERO;LIBERA TROÌA;CHIARA AIROLDI;CARMELA RINALDI;ELIA ESPOSTO;LETIZIA MAZZINI;FRANCESCO GAVELLI;STELA VUJOSEVIC;GIUSEPPE PATTI;FABIOLA DE MARCHI;ALBERTO DE PEDRINI","1.16;1.16;0.96;0.96;0.6;0.59;0.57;0.57;0.5;0.49;0.49;0.48;0.47;0.46;0.46;0.45;0.41;0.41;0.4;0.4","MARIO PIRISI;ANDREA PATRIARCA;ROSALBA MINISINI;ALESSANDRA RICCO;NICOLA CASCAVILLA;MATTIA BELLAN;GIUSEPPE PATTI;PIER PAOLO SAINAGHI;VALENTINA ARCANGELI;DAVIDE D’ONGHIA;LUIGI MARIO CASTELLO;STELVIO TONELLO;UGO DE GIORGI;ADRIANO CHIÒ;ANDREA CALVO;FABRIZIO PANE;ALESSANDRA BOLOGNA;ANDREA DECENSI;ANGIOLO GADDUCCI;CLAUDIO ZAMAGNI","66;51;47;46;46;44;43;41;40;38;38;38;38;37;37;33;32;32;32;32","MARIO PIRISI;ANDREA PATRIARCA;MATTIA BELLAN;PIER PAOLO SAINAGHI;GIUSEPPE PATTI;ELEONORA RIZZI;ERICA MATINO;ERIKA ZECCA;GIUSEPPE FRANCESCO CASCIARO;LETIZIA MAZZINI;DANIELA SURICO;ALESSANDRO CROCE;ANITA REBECCA PEDRINELLI;MARTINA COSTANZO;RAFFAELLA LANDI;VERONICA VASSIA;GIUSEPPE GUZZARDI;DANIELE SOLA;MARCO BRAMBILLA;CARLO CATTRINI","66;51;44;41;39;29;29;29;29;29;27;26;26;26;26;26;24;23;21;18","MARIO PIRISI;LETIZIA MAZZINI;ALESSANDRO LIBRETTI;CARLO CATTRINI;ANDREA PATRIARCA;MARCO BRAMBILLA;MATTIA BELLAN;CARLA GRAMAGLIA;GIUSEPPE PATTI;PATRIZIA ZEPPEGNO;PIER PAOLO SAINAGHI;ALESSANDRO CARRIERO;ALESSIA MENNITTO;GIANLUCA GAÏDANO;VALENTINO REMORGIDA;FEDERICA VERONESE;DANIELA SURICO;ELIA ESPOSTO;FABIOLA DE MARCHI;GABRIELE DELL’ERA","9;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;ENGINEERING;MATHEMATICS;SOCIOLOGY;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY","133;24;15;11;10;7;7;6;6;6;4;4;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GASTROENTEROLOGY;ENVIRONMENTAL HEALTH;GENETICS;PEDIATRICS;PSYCHIATRY;IMMUNOLOGY;CARDIOLOGY;RADIOLOGY;FAMILY MEDICINE;NURSING;ANESTHESIA;OPTICS;OPHTHALMOLOGY;ENDOCRINOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;OBSTETRICS","107;30;26;26;19;15;15;14;13;12;10;10;9;9;8;8;7;6;6;6;6","DISEASE;CANCER;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;RETROSPECTIVE COHORT STUDY;POPULATION;COHORT;ADVERSE EFFECT;CLINICAL TRIAL;CHEMOTHERAPY;ALTERNATIVE MEDICINE;GENE;LYMPHOMA;HEART FAILURE;INCIDENCE (GEOMETRY);ANTIBODY;DIABETES MELLITUS;EPILEPSY;IMMUNE SYSTEM;MULTIVARIATE ANALYSIS;OBSERVATIONAL STUDY;PREGNANCY;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;QUALITY OF LIFE (HEALTHCARE);TRANSPLANTATION","22;20;16;15;14;13;12;11;11;10;9;9;7;6;6;5;5;5;5;5;5;5;5;5;5;5","HAZARD RATIO;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;TOLERABILITY;PLACEBO;BREAST CANCER;COLORECTAL CANCER;PROSTATE CANCER;RITUXIMAB;AMYOTROPHIC LATERAL SCLEROSIS;DEMENTIA;UNIVARIATE ANALYSIS;2019-20 CORONAVIRUS OUTBREAK;CABOZANTINIB;CHRONIC LYMPHOCYTIC LEUKEMIA;DIABETIC RETINOPATHY;DOCETAXEL;EJECTION FRACTION;FETUS;HEART RATE;SUICIDE PREVENTION","11;11;7;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","CORONAVIRUS DISEASE 2019 (COVID-19);ANDROGEN DEPRIVATION THERAPY;SUICIDAL IDEATION;BECK HOPELESSNESS SCALE;COGNITIVE DECLINE;COLONOSCOPY;DIFFUSING CAPACITY;FRONTOTEMPORAL DEMENTIA;LEWY BODY;METASTATIC BREAST CANCER;PAZOPANIB;RADIOIMMUNOTHERAPY;STRUCTURAL VARIATION;ABATACEPT;ANDROGEN RECEPTOR;ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY;APREMILAST;AQUAPORIN 1;BENDAMUSTINE;BIVALIRUDIN;BONE HEALTH;BRCA MUTATION;CAPECITABINE;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CENTRAL VENOUS PRESSURE;CHEMOIMMUNOTHERAPY;CHROMOPHOBE CELL;DABIGATRAN;DEMENTIA WITH LEWY BODIES;DIABETIC MACULAR EDEMA;DNA METHYLATION;DOUBLE BLIND;EARLY PREGNANCY FACTOR;ELTROMBOPAG;ESOPHAGEAL VARICES;ESTROGEN RECEPTOR;EVANS SYNDROME;FOLINIC ACID;FUNDUS PHOTOGRAPHY;GAS6;GERMLINE MUTATION;HAND ECZEMA;HAPLOINSUFFICIENCY;HERPESVIRIDAE;HYPERTRIGLYCERIDEMIA;IBRUTINIB;IGHV@;INJURY SEVERITY SCORE;INTERNATIONAL PROGNOSTIC SCORING SYSTEM;INTRAUTERINE GROWTH RESTRICTION;IRINOTECAN;KIR6.2;LENVATINIB;LIPOPROTEIN(A);LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2;MEASUREMENT INVARIANCE;MODIFIED RANKIN SCALE;MYCOBACTERIUM ABSCESSUS;NIVOLUMAB;OXALIPLATIN;PATIENT HEALTH QUESTIONNAIRE;PEAK INSPIRATORY PRESSURE;PEDIATRIC TRAUMA;PLACENTA;POLYMORPHISM (COMPUTER SCIENCE);PR INTERVAL;PREMATURE RUPTURE OF MEMBRANES;RESPIRATORY RATE;SENTINEL LYMPH NODE;STROKE VOLUME;SUICIDE ATTEMPT;SUICIDE RISK;TAXANE;TERM PREGNANCY;TIMI;TRABECTEDIN;TRANSCRIPTOME;TRIPLE-NEGATIVE BREAST CANCER;TWIN PREGNANCY;UROTHELIAL CARCINOMA;VENETOCLAX;VINCRISTINE;VITREOUS HEMORRHAGE;WEIGHT MANAGEMENT","11;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;;COVID-19;FEMALE;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADULT;SKIN NEOPLASMS;AMYOTROPHIC LATERAL SCLEROSIS;MALE;PROSPECTIVE STUDIES;DIABETES MELLITUS;DIABETIC RETINOPATHY;NEOPLASM RECURRENCE, LOCAL;AORTIC VALVE;AORTIC VALVE STENOSIS;HEMORRHAGE;MELANOMA;MIDDLE AGED;RISK FACTORS","73;62;15;14;14;13;12;10;9;9;9;7;7;7;6;6;6;6;6;6","AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;HEALTH RISKS OF MEDICAL IMAGING RADIATION EXPOSURE;MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE DISORDERS;SUICIDAL BEHAVIOR AND PREVENTION STRATEGIES;ACUTE MYELOID LEUKEMIA;AGE-RELATED MACULAR DEGENERATION RESEARCH;ATOPIC DERMATITIS AND SKIN MICROBIOME;DETECTION AND MANAGEMENT OF RETINAL DISEASES;DIAGNOSIS AND MANAGEMENT OF PANCREATITIS;EPILEPSY AND SEIZURES;GENDER BIAS IN ACADEMIC MEDICINE AND SCIENCE;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;LYMPHOID NEOPLASMS;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;POSITRON EMISSION TOMOGRAPHY IMAGING IN ONCOLOGY;RENAL CELL CARCINOMA","8;5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","CLINICAL ENDPOINT;TOLERABILITY;PANDEMIC;TREATMENT;HELP-SEEKING BEHAVIORS;UNIVARIATE ANALYSIS;CABOZANTINIB;DIABETIC RETINOPATHY;INTERPERSONAL THEORY;INTERQUARTILE RANGE;METASTATIC PROSTATE CANCER;OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY;PHLEBOTOMY;PSYCHOLOGICAL AUTOPSY;STROKE (ENGINE);SUICIDAL BEHAVIOR;ANTIEPILEPTIC DRUGS;ATRIAL FIBRILLATION;BECK HOPELESSNESS SCALE;C9ORF72","7;7;5;5;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2","OBSERVATIONAL STUDY;PROSTATE CANCER;RETROSPECTIVE STUDY;PATIENTS PTS;POLYETHYLENE GLYCOL;CANCER PATIENTS;CELL CARCINOMA;CHRONIC LYMPHOCYTIC;CLINICAL OUTCOMES;CLINICAL TRIAL;COVID- PANDEMIC;HEART FAILURE;LYMPHOCYTIC LEUKEMIA;METASTATIC RENAL;PATIENTS TREATED;RENAL CELL;VENTRICULAR PACING;AMYOTROPHIC LATERAL;AORTIC STENOSIS;ASCORBATE VERSUS;B-CELL LYMPHOMA;BLOOD PRESSURE;BREAST CANCER;CANCER MCRPC;CANCER MCSPC;CASTRATION-RESISTANT PROSTATE;CASTRATION-SENSITIVE PROSTATE;COGNITIVE IMPAIRMENT;COLONOSCOPY CLEANSING;COLORECTAL LIVER","5;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","HR CI;SSM KPA;PATIENTS TREATED;LIVER DECOMPENSATION;LSM KPA;MONTHS CI;OESOPHAGEAL VARICES;PATIENTS UNDERGOING;STRUCTURAL VARIANTS;CLINICAL PRACTICE;CT SCAN;FEMALE SURGEONS;MEDIAN FOLLOW-UP;PRIMARY ENDPOINT;TRANSPLANT SURGEONS;ADVERSE EVENTS;HIGH-RISK OESOPHAGEAL;LI DROP;MEDIAN AGE;STIFFNESS MEASUREMENT;ACUTE KIDNEY;COVID- PANDEMIC;KBG SYNDROME;KIDNEY INJURY;PROGRESSION-FREE SURVIVAL;RISK FACTORS;SURVIVAL PFS;VIRAL ETIOLOGY;CDD EXPRESSION;DISEASE PROGRESSION","21;18;15;13;11;10;10;10;10;9;9;9;9;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,3.29,856.71,7.22,4,0.29,60.93,0,0,2,0,5,0,0,7,0,11,3,0,0,0,0,0,0,14,0,0,14,0,0,0,0,0,0,0,0,0,"United States;Italy","6;4","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;4206 PUBLIC HEALTH;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;4203 HEALTH SERVICES AND SYSTEMS","13;7;4;3;3;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NUTRITION;OBESITY;PREVENTION;BIOMEDICAL IMAGING;CANCER;CARDIOVASCULAR;DIABETES;HEART DISEASE;HEMATOLOGY;BIOENGINEERING;DIGESTIVE DISEASES;LYMPHOMA;PATIENT SAFETY;PEDIATRIC;RARE DISEASES;AGING;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE","12;9;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;1;1;1","CARDIOVASCULAR;CANCER;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE;EYE","6;5;5;3;2;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.3 MEDICAL DEVICES","8;3;2;1;1;1","NON-HODGKIN'S LYMPHOMA;BLOOD CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;MELANOMA","2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","3",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,19,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;ZENODO;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","8;7;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;3106 INDUSTRIAL BIOTECHNOLOGY;3107 MICROBIOLOGY;3208 MEDICAL PHYSIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3212 OPHTHALMOLOGY AND OPTOMETRY;38 ECONOMICS;3803 ECONOMIC THEORY;46 INFORMATION AND COMPUTING SCIENCES;4609 INFORMATION SYSTEMS;51 PHYSICAL SCIENCES;5107 PARTICLE AND HIGH ENERGY PHYSICS;52 PSYCHOLOGY","26;10;5;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;DIGESTIVE DISEASES;CANCER;CARDIOVASCULAR;HEART DISEASE;RARE DISEASES;DIABETES;GENETICS;KIDNEY DISEASE;LUNG;PANCREATIC CANCER;PREVENTION;AGING;ARTHRITIS;ATHEROSCLEROSIS;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;BRAIN DISORDERS;CHRONIC LIVER DISEASE AND CIRRHOSIS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES","9;5;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","CARDIOVASCULAR;METABOLIC AND ENDOCRINE;EYE;INFLAMMATORY AND IMMUNE SYSTEM;INJURIES AND ACCIDENTS","2;2;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","2;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","7;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","12;2","PANCREATIC CANCER;KIDNEY CANCER","2;1","3 GOOD HEALTH AND WELL BEING","1"
"AOU_NOVARAGALLIATE",2024,128,19.7734375,2.7265625,0.2578125,0.2265625,0.2734375,1.45454545454545,1.06451612903226,1.20833333333333,1.12903225806452,0.515625,1,63,26,9,9,0.49,0.2,0.07,0.07,0.71,0.743888385833229,4.13708690330477,0.4375,1,0.485,0.328,0.422,0.362,"GIUSEPPE PATTI;GABRIELE DELL’ERA;ALESSANDRO LIBRETTI;VALERIA TERRUSO;CINZIA ROBERTI;RUGGIERO LEONE;ROBERTO TARLETTI;GIOVANNI FRISULLO;ANTONELLA BONI;ANDREA ZINI;DANIELE ORSUCCI;GIAMPIETRO RUZZA;PAOLO CANDELARESI;SILVIA CENCIARELLI;GINO VOLPI;FRANCESCA PISTOIA;MARIA GUARINO;EMANUELE ALESSANDRO CAGGIA;MAURIZIO PACIARONI;ANNA CAVALLINI","12;7;6;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5;5","GIUSEPPE PATTI;ALESSANDRO LIBRETTI;CRISTINA RIGAMONTI;MARCELLO DI MARTINO;PAOLA SAVOIA;VALENTINO REMORGIDA;GIANLUCA GAÏDANO;PAOLO BOFFANO;ELIA ESPOSTO;EDOARDO CAMMARATA;MATTEO DONADON;LUIGI MARIO CASTELLO;LIBERA TROÌA;ALESSANDRO RABIOLO;LUDOVICA VENEZIA;LIVIO LEO;FRANCESCO GAVELLI;PAOLO BAROFFIO;FORNARO RICCARDO;I GIORGIO","1.13;1.03;1.01;0.92;0.73;0.72;0.7;0.59;0.58;0.58;0.58;0.56;0.55;0.53;0.52;0.51;0.5;0.5;0.5;0.5","GIUSEPPE PATTI;GABRIELE DELL’ERA;ALESSANDRO LIBRETTI;ROBERTO TARLETTI;ALESSANDRO RABIOLO;MATTIA BELLAN;GIANLUCA GAÏDANO;CARLO CATTRINI;STEFANO DE CILLÀ;PAOLO BOFFANO;ROBERTA MATHEOUD;PAOLA SAVOIA;ALESSANDRA GENNARI;MARIO PIRISI;LETIZIA MAZZINI;CARLA GRAMAGLIA;VALENTINO REMORGIDA;MARCELLO DI MARTINO;ANNA DEGIOVANNI;ELIA ESPOSTO","12;7;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3","GIUSEPPE PATTI;ALESSANDRO LIBRETTI;CRISTINA RIGAMONTI;MARCELLO DI MARTINO;PAOLA SAVOIA;VALENTINO REMORGIDA;GIANLUCA GAÏDANO;PAOLO BOFFANO;ELIA ESPOSTO;EDOARDO CAMMARATA;MATTEO DONADON;LIBERA TROÌA;ALESSANDRO RABIOLO;LUDOVICA VENEZIA;FRANCESCO GAVELLI;PAOLO BAROFFIO;FORNARO RICCARDO;GABRIELE DELL’ERA;SAMIR MOUHSSINE;ROBERTA MATHEOUD","1.13;1.03;1.01;0.92;0.73;0.72;0.7;0.59;0.58;0.58;0.58;0.55;0.53;0.52;0.5;0.5;0.5;0.49;0.46;0.42","CARLO CATTRINI;A JÜRGENS;A. JAMBRINA;A.M. VANDEN BROECKE;BERNARDO HERRERA‐IMBRODA;C. CAPONE;DANIEL ALAMEDA;DAVID LORENTE;DAVID OLMOS;ELENA CASTRO;MARCO TREVISAN;NURIA ROMERO-LAORDEN;PEDRO P. LÓPEZ‐CASAS;ROSA M. LOZANO;SUZY VAN SANDEN;DAVID F. GARWAY‐HEATH;DAVID P. CRABB;GIANLUCA GAÏDANO;NAWAR MAHER;SAMIR MOUHSSINE","14;9;9;9;9;9;9;9;9;9;9;9;9;9;9;7;7;7;7;7","CARLO CATTRINI;GIANLUCA GAÏDANO;NAWAR MAHER;SAMIR MOUHSSINE;ALESSANDRO RABIOLO;SERGIO RISO;FABIOLA DE MARCHI;LETIZIA MAZZINI;DANIELA ROSALBA;EDUARDO ROCCA;MARCELLO DI MARTINO;ALESSANDRO VOLPE;AMEET SHAH;ANDREA PATRIARCA;ANDREW MCNAUGHT;ANIL NEGI;AUGUSTO AZUARA‐BLANCO;CARLOTTA PALUMBO;CARMELA RINALDI;DAVID C. BROADWAY","14;7;7;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3","GIUSEPPE PATTI;ALESSANDRO LIBRETTI;ALESSANDRO RABIOLO;CARLO CATTRINI;GIANLUCA GAÏDANO;MARCO BRAMBILLA;MARIO PIRISI;MATTIA BELLAN;PAOLO BOFFANO;ROBERTA MATHEOUD;VALENTINO REMORGIDA;LETIZIA MAZZINI;GIONATA STRIGARO;MARCELLO DI MARTINO;STEFANO DE CILLÀ;ALESSIA MENNITTO;ANNA DEGIOVANNI;LIBERA TROÌA;LUDOVICA VENEZIA;SAMIR MOUHSSINE","9;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;MATHEMATICS;MATERIALS SCIENCE;PHILOSOPHY;ECONOMICS;ART;POLITICAL SCIENCE;SOCIOLOGY;HISTORY","125;23;14;13;11;10;9;5;4;4;3;2;2;2;1","INTERNAL MEDICINE;CARDIOLOGY;SURGERY;PATHOLOGY;ONCOLOGY;PSYCHIATRY;GENETICS;INTENSIVE CARE MEDICINE;RADIOLOGY;GASTROENTEROLOGY;OPHTHALMOLOGY;BIOCHEMISTRY;IMMUNOLOGY;PHYSICAL THERAPY;QUANTUM MECHANICS;DERMATOLOGY;GENERAL SURGERY;GERONTOLOGY;MECHANICAL ENGINEERING;PEDIATRICS","88;27;27;21;20;14;12;12;12;10;9;8;8;8;8;7;7;7;7;7","CANCER;DISEASE;RANDOMIZED CONTROLLED TRIAL;COHORT;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;GENE;ISCHEMIA;TERM (TIME);ABLATION;ATRIAL FIBRILLATION;CHEMOTHERAPY;DIABETES MELLITUS;MYOCARDIAL INFARCTION;OBSERVATIONAL STUDY;PREGNANCY;STROKE (ENGINE);ALTERNATIVE MEDICINE;COHORT STUDY;ENZYME;EPILEPSY;LUNG;PROPORTIONAL HAZARDS MODEL;RESECTION;RETINAL;STENOSIS","19;15;12;11;8;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4","IMMUNOTHERAPY;CATHETER ABLATION;COLORECTAL CANCER;ISCHEMIC STROKE;AMYOTROPHIC LATERAL SCLEROSIS;BLADDER CANCER;BREAST CANCER;DIABETIC RETINOPATHY;MINOR STROKE;PROSTATE CANCER;RETINOPATHY;ACUTE CORONARY SYNDROME;CHRONIC LYMPHOCYTIC LEUKEMIA;CLINICAL ENDPOINT;DOCETAXEL;FLUORESCEIN ANGIOGRAPHY;GENE EXPRESSION;GLAUCOMA SURGERY;IDIOPATHIC GENERALIZED EPILEPSY;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTERNAL CONSISTENCY;LEVETIRACETAM;MANTLE CELL LYMPHOMA;MULTICENTER STUDY;PLACEBO;PULMONARY VEIN;UNIVARIATE ANALYSIS;VITRECTOMY","7;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PEMBROLIZUMAB;UROTHELIAL CARCINOMA;COLONOSCOPY;CONVERGENT VALIDITY;CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;ADENOSQUAMOUS CARCINOMA;ANDROGEN DEPRIVATION THERAPY;ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY;B-CELL RECEPTOR;BRUTON'S TYROSINE KINASE;CARDIOTOCOGRAPHY;CARFILZOMIB;CROSSOVER STUDY;DABIGATRAN;DIFFUSING CAPACITY;DIRECT BILIRUBIN;DNA METHYLATION;EXECUTIVE DYSFUNCTION;EXTERNAL LIMITING MEMBRANE;FERTILITY PRESERVATION;FLUORESCENCE IN SITU HYBRIDIZATION;GAS6;GENE EXPRESSION PROFILING;GERMLINE MUTATION;GESTATIONAL DIABETES;GLUCAGONOMA;GLUTAMINE SYNTHETASE;GRANULOMATOSIS WITH POLYANGIITIS;HEME OXYGENASE;IBRUTINIB;INTERVERTEBRAL DISC DISPLACEMENT;LENVATINIB;LOSS OF HETEROZYGOSITY;MACULAR HOLE;MAMMOGRAPHY;MEN1;METASTATIC BREAST CANCER;MICROSCOPIC POLYANGIITIS;MODIFIED RANKIN SCALE;NORMAL TENSION GLAUCOMA;OBETICHOLIC ACID;OSTEONECROSIS OF THE JAW;P2Y12;PARS PLANA;PRIMARY MOTOR CORTEX;SEVERE SEPSIS;SINGLE-NUCLEOTIDE POLYMORPHISM;SUICIDAL IDEATION;TBARS;THIOBARBITURIC ACID;UMBILICAL ARTERY;UPPER MOTOR NEURON;UROTHELIAL CANCER;VINCRISTINE","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ITALY;TREATMENT OUTCOME;PROSPECTIVE STUDIES;PROGNOSIS;SEVERITY OF ILLNESS INDEX;REGISTRIES;SURVEYS AND QUESTIONNAIRES;VISUAL ACUITY;ADOLESCENT;ANTIBODIES, MONOCLONAL, HUMANIZED;ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL","73;54;36;33;29;28;25;14;12;11;8;7;6;6;4;4;4;3;3;3","DIAGNOSIS AND TREATMENT OF BLADDER CANCER;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANTIPLATELET THERAPY IN CARDIOVASCULAR DISEASE;DIAGNOSIS AND TREATMENT OF HEART FAILURE;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;ACUTE MYELOID LEUKEMIA;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CHOLESTEROL-LOWERING TREATMENT;CUTANEOUS ADNEXAL NEOPLASMS AND RELATED SYNDROMES;DETECTION AND MANAGEMENT OF RETINAL DISEASES;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DUAL-ENERGY COMPUTED TOMOGRAPHY","4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","STROKE (ENGINE);INFARCTION TREATMENT;INTRAOCULAR PRESSURE;PRIMARY OPEN-ANGLE GLAUCOMA;TREATMENT;ATRIAL FIBRILLATION;BIOMARKERS FOR IMMUNOTHERAPY;CARDIOTHORACIC SURGERY;CATHETER ABLATION;CLINICAL PRACTICE;DIABETIC RETINOPATHY;MACULAR DEGENERATION;METASTATIC UROTHELIAL CARCINOMA;MINOR STROKE;NEURODEGENERATION;PROSTHETIC VALVES EVALUATION;RADIOFREQUENCY ABLATION;ANTIEPILEPTIC DRUGS;AVELUMAB;BOWEL PREPARATION","5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2","CLINICAL TRIAL;ISCHEMIC STROKE;AMYOTROPHIC LATERAL;ANTIPLATELET TREATMENT;ATRIAL FIBRILLATION;CELL CARCINOMA;DIABETIC RETINOPATHY;DUAL ANTIPLATELET;ITALIAN STUDY;LATERAL SCLEROSIS;LUNG CANCER;MACHINE LEARNING;OBSERVATIONAL STUDY;PROSTATE CANCER;READAPT STUDY;UROTHELIAL CARCINOMA;ACUTE CORONARY;ACUTE MYELOID;ADVANCED UROTHELIAL;BREAST CANCER;CANCER MCSPC;CANCER PATIENTS;CARDIOPULMONARY EXERCISE;CASTRATION-SENSITIVE PROSTATE;CHRONIC LYMPHOCYTIC;CLINICAL FEATURES;CLINICAL PRACTICE;COMBINED LIFESTYLE;CORONARY SYNDROME;DEVELOPING PROSTHESIS-PATIENT","4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PSYCHOLOGICAL PAIN;PATIENTS TREATED;ISCHEMIC STROKE;HEART FAILURE;HR CI;HRR NON-BRCA;PATIENTS AFFECTED;SURVIVAL OS;SURVIVAL PFS;PROGRESSION-FREE SURVIVAL;AF RECURRENCE;ANCA-ASSOCIATED VASCULITIS;CELL MALIGNANCIES;CENTRAL NERVOUS;CLINICAL PRACTICE;CLL PATIENTS;COHORT STUDY;DISEASE PROGRESSION;DUAL ANTIPLATELET;EJECTION FRACTION;EQUIVALENT SOFT-TISSUE;INCLUDED PATIENTS;IOP MMHG;MEDIAN PFS;MONTHS CI;NERVOUS SYSTEM;OPTIPHARMHF REGISTRY;ORAL VV;RATIO CI;TRANSCATHETER EDGE-TO-EDGE","9;8;7;6;6;6;6;6;6;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,4.5,101,0.87,0,0,25,0,0,0,0,1,0,0,1,0,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Italy;Switzerland","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS","2;1;1;1;1","CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;LYMPHOMA;NUTRITION;RARE DISEASES","1;1;1;1;1;1;1","CANCER;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL","1;1;1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1","NON-HODGKIN'S LYMPHOMA","1","5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
